Compound as well as pharmaceutical composition and application thereof
The new EGFR degrading agent developed through PROTAC technology solves the problem of insufficient resistance and selectivity of existing EGFR inhibitors, and achieves efficient degradation and safety improvement of EGFR mutant proteins. It is suitable for EGFR activity such as non-small cell lung cancer. Abnormal related cancer.
Patent Information
- Application Number
- CN202310582734.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2023-05-23
- Publication Date
- 2024-11-26
AI Technical Summary
Existing EGFR inhibitors are prone to drug resistance problems when treating non-small cell lung cancer, and are less selective to wild-type EGFR, resulting in adverse reactions and lack effective fourth-generation treatment methods.
A novel compound, based on PROTAC technology, is designed as a highly selective EGFR degrader, which can efficiently degrade EGFR mutant protein without affecting the wild type, and promotes its degradation by combining E3 ubiquitin ligase and EGFR protein.
It has achieved efficient degradation of EGFR mutant proteins, improved treatment selectivity and safety, overcome drug resistance problems, and is suitable for a variety of cancers related to abnormal EGFR activity, especially non-small cell lung cancer.
Smart Images

Figure CN119019401A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to a compound and a pharmaceutical composition and application thereof, and in particular to a compound which can be prepared as a drug for treating and / or preventing cancer and a pharmaceutical composition and application thereof. Background Art
[0002] EGFR (Epidermal Growth Factor Receptor) is a transmembrane protein, also known as ErbB-1 or HER1, belonging to the epidermal growth factor receptor family (ErbBs). So far, there are 4 subtypes of the ErbB family discovered by humans, namely ErbB1 (EGFR), ErbB2 (HER2 / neu), ErbB3 (HER3) and ErbB4 (HER4). Like all tyrosine kinases, it contains three regional structures: extracellular region, transmembrane region and intracellular region. EGFR overexpression, mutation or gene amplification promotes the occurrence and development of a variety of malignant tumors, such as breast cancer, colon cancer, ovarian cancer, glioblastoma, esophageal cancer, head and neck epithelial cancer, especially non-small cell lung cancer. When the extracellular domain binds to specific ligands (such as epidermal growth factor (EGF), transforming growth factor α (TGF-α), cytokines and epiregulin), EGFR will self-aggregate to form homodimers or form heterodimers with other ErbB family members, resulting in phosphorylation of key tyrosine residues in the cytoplasmic domain, which in turn activates downstream signaling pathways, thereby regulating cell growth, proliferation, migration and other processes. Dysregulation of EGFR signal transduction will promote tumor cell proliferation, angiogenesis, invasion, migration and metastasis.
[0003] The first generation of EGFR inhibitors represented by gefitinib and erlotinib have good efficacy in patients with non-small cell lung cancer carrying EGFR activating mutations L858R and Del 19, but the vast majority of patients will show varying degrees of drug resistance after about a year of treatment due to the appearance of EGFR T790M mutations in the body. In order to solve this drug resistance problem, researchers have developed second-generation irreversible EGFR inhibitors represented by afatinib, but this type of EGFR inhibitor has low selectivity for wild-type EGFR, leading to serious adverse reactions. The third generation of highly selective irreversible EGFR inhibitors represented by osimertinib and omotinib, after a period of use, develop drug resistance due to the induced EGFR T797S mutation. Although efforts are being made to develop fourth-generation EGFR inhibitors for the EGFR T797S mutation, there is no mature treatment method, so the clinical demand is imminent. Summary of the invention
[0004] Objectives of the invention: The first objective of the present invention is to provide a compound, the second objective is to provide a pharmaceutical composition comprising the compound, and the third objective is to provide applications of the compound and its pharmaceutical composition.
[0005] Technical solution: The compound of formula I of the present invention or its enantiomer, diastereomer, racemate, cis-trans isomer, deuterated substance, metabolite, prodrug, solvate, hydrate, pharmaceutically acceptable salt or cocrystal,
[0006] B-L-E
[0007] I,
[0008] Its structure:
[0009] B is
[0010] Z is selected from C 1-4 Alkyl, deuterated (C 1-4 Alkyl) or halogenated (C 1-4 alkyl);
[0011] R1 is selected from hydrogen, halogen, C 1-4 Alkyl, deuterated (C 1-4 Alkyl) or halogenated (C 1-4 alkyl);
[0012] R2 is selected from C 1-6 Alkyl, deuterated (C 1-6 Alkyl) or halogenated (C 1-6 alkyl);
[0013] X is selected from a single bond, C 1-4 Alkylene, C 2-4 Alkyne or C 2-4 alkenylene;
[0014] V is selected from -NR x1 (C 1-10 Alkylene)R x2 - or a 4-10 membered monocyclic heterocycloalkylene group containing 1 or 2 N atoms, a 6-11 membered spirocyclic heterocycloalkylene group containing 1 or 2 N atoms, a 6-10 membered cyclic heterocycloalkylene group containing 1 or 2 N atoms, or a 7-10 membered bridged heterocycloalkylene group containing 1 or 2 N atoms; and -NR x1 (C 1-10 Alkylene)R x2 -The left end is connected to X and the right end is connected to L;
[0015] R x1 Selected from hydrogen or C 1-3 alkyl;
[0016] R x2Selected from -O-, -N(C 1-3 -alkyl)- or -NH-;
[0017] R4 is selected from deuterium, halogen, C 1-6 Alkyl, halogenated (C 1-6 Alkyl), C 1-6 Alkoxy, halogenated (C 1-6 Alkoxy) or deuterated (C 1-6 Alkoxy);
[0018] a is selected from 0, 1, 2, 3 or 4;
[0019] E is
[0020] R5 is selected from the group consisting of deuterium, halogen, cyano, C 1-3 Alkyl, halogenated (C 1-3 alkyl) or deuterated (C 1-3 alkyl);
[0021] b is selected from 0, 1, 2 or 3;
[0022] W is selected from -C(=O)- or -CH2-;
[0023] L is
[0024] L1 is connected to E, L4 is connected to B;
[0025] L1 is selected from a single bond, -O-, -NR g -, -NH(C=O)-, -C≡C-, 4-10 membered monocyclic heterocycloalkylene containing 1 or 2 N atoms, 6-20 membered spirocyclic heterocycloalkylene containing 1 or 2 N atoms, 6-18 membered cyclic heterocycloalkylene containing 1 or 2 N atoms, or 7-10 membered bridged heterocycloalkylene containing 1 or 2 N atoms;
[0026] L2 is selected from a single bond, -(CH2) r2 -、-(CH2) r2 -(C=O)-, -(CH2) r2 -NRg-, 4-10 membered monocyclic heterocycloalkylene containing 1 or 2 N atoms, 6-20 membered spirocyclic heterocycloalkylene containing 1 or 2 N atoms, 6-18 membered cycloheterocycloalkylene containing 1 or 2 N atoms, or 7-10 membered bridged heterocycloalkylene containing 1 or 2 N atoms; -(CH2) r2 -(C=O)-, -(CH2) r2 The left end of -NRg- is connected to L1, and the right end is connected to L3;
[0027] L3 is a single bond, -(CH2)r3 -, a 4-10 membered monocyclic heterocycloalkylene containing 1 or 2 N atoms, a 6-20 membered spirocyclic heterocycloalkylene containing 1 or 2 N atoms, a 6-18 membered cyclic heterocycloalkylene containing 1 or 2 N atoms, or a 7-10 membered bridged heterocycloalkylene containing 1 or 2 N atoms;
[0028] L4 is selected from a single bond, -(CH2) r4 -, a 4-10 membered monocyclic heterocycloalkylene containing 1 or 2 N atoms, a 6-20 membered spirocyclic heterocycloalkylene containing 1 or 2 N atoms, a 6-18 membered cyclic heterocycloalkylene containing 1 or 2 N atoms, or a 7-10 membered bridged heterocycloalkylene containing 1 or 2 N atoms;
[0029] R g Selected from hydrogen or C 1-3 alkyl;
[0030] r2 is selected from 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12;
[0031] r3 is selected from 1, 2, 3, 4, 5, 6, 7 or 8;
[0032] r4 is selected from 1, 2, 3, 4, 5, 6, 7 or 8.
[0033] In some embodiments,
[0034] Z is selected from methyl, ethyl, propyl, isopropyl, -CD3 or trifluoromethyl;
[0035] R1 is selected from hydrogen, methyl, ethyl, propyl, -CD3 or trifluoromethyl;
[0036] R2 is selected from methyl, ethyl, propyl, isopropyl, isobutyl or sec-butyl;
[0037] X is selected from a single bond, -CH2-, -CH2CH2- or -C≡C-;
[0038] V is selected from -NR x1 (C 1-8 Alkylene)R x2 -, a 4-6 membered monocyclic heterocycloalkylene group containing 1 or 2 N atoms, a 6-11 membered spirocyclic heterocycloalkylene group containing 1 or 2 N atoms, a 6-10 membered cyclic heterocycloalkylene group containing 1 or 2 N atoms, or a 7-8 membered bridged heterocycloalkylene group containing 1 or 2 N atoms; -NR x1 (C 1-8 Alkylene)R x2 -'s left end is connected to X, and its right end is connected to L;
[0039] R x1 is selected from hydrogen or methyl;
[0040] R x2 Selected from -O-, -NCH3- or -NH-;
[0041] R4 is selected from deuterium, fluorine, chlorine, bromine, -CF3, methyl, methoxy, ethoxy, propoxy, isopropoxy, trifluoromethoxy or -OCD3;
[0042] a is selected from 0, 1, 2 or 3.
[0043] In some embodiments,
[0044] R1 is selected from hydrogen, methyl or -CD3;
[0045] R2 is selected from isopropyl, isobutyl or sec-butyl;
[0046] X is selected from a single bond, -CH2- or -C≡C-;
[0047] V is selected from -NR x1 (C 1-6 Alkylene)R x2 -, aziridinyl, tetrahydropyrrolidinyl, piperazinyl, piperidinyl, cyclopropylidene azetidinyl, cyclopropylidene azetidine, cyclopropylidene azetidine, cyclopropylidene azetidine, cyclobutylidene azetidine, cyclobutylidene azetidine, cyclobutylidene azetidine, cyclobutylidene azetidine, cyclobutylidene azetidine, cyclopentylidene azetidine, cyclopentylidene azetidine, cyclopentylidene azetidine, cyclopentylidene azetidine, cyclohexylidene azetidine, cyclohexylidene azetidine, cyclohexylidene azetidine, azetidinyl, azetidine, azetidine, azetidine, azetidine, azetidine, azetidine, azetidine, azetidine, azetidine, azetidine, azetidine, azetidine, azetidine, azetidine, azetidine, azetidine, azetidine, azetidine, azetidine, azetidine, azetidine Cyclobutyl, cyclohexylidene azetyl, cyclohexylidene azetyl, cyclobutylidene spiroazetyl, cyclobutylidene spiroazetyl, cyclobutylidene spiroazetyl, cyclobutylidene spiroazetyl, cyclopentylidene spiroazetyl, cyclopentylidene spiroazetyl, cyclopentylidene spiroazetyl, cyclopentylidene spiroazetyl, cyclohexylidene spiroazetyl, cyclohexylidene spiroazetyl azetidinyl, azetidinyl spiroazetidinyl, azetidinyl spiroazepentyl, azetidinyl spiroazetidinyl, azetidinyl spiroazetidinyl, azetidinyl spiroazetidinyl, azetidinyl spiroazetidinyl, azetidinyl spiroazetidinyl, azetidinyl spiroazetidinyl, azetidinyl spiroazetidinyl, azetidinyl spiroazetidinyl;
[0048] R x1 is selected from hydrogen or methyl;
[0049] R x2Selected from -O-, -NCH3- or -NH-;
[0050] R4 is selected from fluorine, methoxy, trifluoromethoxy or -OCD3;
[0051] R5 is selected from fluoro, cyano, methyl, trifluoromethyl or -CD3;
[0052] b is selected from 0, 1 or 2;
[0053] W is selected from -C(=O)- or -CH2-.
[0054] In some embodiments,
[0055] V is selected from -N(CH3)-(C 1-6 Alkylene)-NH-, -NH-(C 1-6 Alkylene)-NH-, -NH-(C 1-6 Alkylene)-N(CH3)-, -NH-(C 1-6 Alkylene)-C(=O)-, -NH-(C 1-6 Alkylene)-O-,
[0056] The left side of the V structure fragment is connected to X, and the right side is connected to L;
[0057] E is selected from
[0058] R5 is selected from fluoro, methyl, trifluoromethyl or -CD3;
[0059] b is selected from 0 or 1.
[0060] In some embodiments, B is selected from
[0061]
[0062] R1 is selected from hydrogen or methyl;
[0063] R2 is selected from isopropyl, sec-butyl or isobutyl;
[0064] R 41 is selected from methoxy, deuterated methoxy or trifluoromethoxy;
[0065] Z is selected from methyl, ethyl, propyl or isopropyl;
[0066] c is selected from 0, 1, 2, 3, 4, 5 or 6;
[0067] E is selected from
[0068]
[0069] In some embodiments,
[0070] L1 is selected from a single bond, -O-, -NH, -N(CH3)-, -C≡C-, and The left side is connected to E, and the right side is connected to L2;
[0071] L2 is selected from a single bond, -(CH2)r2-, -(CH2) r2 -(C=O)-, -(CH2) r2 -NH-, -(CH2) r2 -N(CH3)-, And -(CH2) r2 -(C=O)-, -(CH2) r2 -NH-, -(CH2) r2 -N(CH3)-, The left side is connected to L1, and the right side is connected to L3;
[0072] L3 is selected from a single bond, -(CH2) r3 -、 and The left side is connected to L2, and the right side is connected to L4;
[0073] L4 is selected from a single bond, -(CH2) r4 -、 and The left side is connected to L3, and the right side is connected to B;
[0074] n1 is 1, 2, 3 or 4;
[0075] n2 is 1, 2, 3 or 4;
[0076] n3 is 1, 2, 3 or 4;
[0077] n4 is 1, 2, 3 or 4;
[0078] n5 is 1, 2, 3 or 4;
[0079] n6 is 1, 2, 3 or 4;
[0080] n7 is 0, 1, 2 or 3;
[0081] n8 is 0, 1, 2, or 3;
[0082] n9 is 0, 1, 2 or 3;
[0083] n10 is 0, 1, 2 or 3;
[0084] Q1 is CH or N;
[0085] Q 2 is CH or N;
[0086] Q 3 is CH or N;
[0087] Y is hydrogen, halogen, -(C=O) or C 1-3 alkyl;
[0088] n11 is 1, 2, 3 or 4;
[0089] r2 is selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10;
[0090] r3 is selected from 1, 2, 3, 4, 5 or 6;
[0091] r4 is selected from 1, 2, 3, 4, 5 or 6.
[0092] In some embodiments,
[0093] L1 is selected from a single bond, -O-, -NH, -N(CH3)-, -C≡C-, and The left side is connected to E, and the right side is connected to L2;
[0094] L2 is selected from a single bond, -(CH2) r2 -、-(CH2) r2 -(C=O)-, -(CH2) r2 -NH-, -(CH2) r2 -N(CH3)-, And -(CH2) r2 -(C=O)-, -(CH2) r2 -NH-, -(CH2) r2 -N(CH3)-, The left side is connected to L1, and the right side is connected to L3;
[0095] L3 is selected from a single bond, -(CH2) r3 -、 and The left side is connected to L2, and the right side is connected to L4;
[0096] L4 is selected from a single bond, -(CH2) r4 -、 and The left side is connected to L3, and the right side is connected to B;
[0097] n1 is 1, 2 or 3;
[0098] n2 is 1, 2 or 3;
[0099] n3 is 1 or 2;
[0100] n4 is 1 or 2;
[0101] n5 is 1 or 2;
[0102] n6 is 1 or 2;
[0103] n7 is 1 or 2;
[0104] n8 is 1 or 2;
[0105] n9 is 0, 1 or 2;
[0106] n10 is 0, 1 or 2;
[0107] Q 1 is CH or N;
[0108] Q 2 For CH, Q 3 is N;
[0109] Or, Q 2 N, Q 3 for CH;
[0110] Y is hydrogen;
[0111] r2 is selected from 1, 2, 3, 4, 5, 6, 7, 8, or 9;
[0112] r3 is selected from 1, 2, 3 or 4;
[0113] r4 is selected from 1, 2, 3 or 4.
[0114] In some embodiments,
[0115] L1 is selected from a single bond, -O-, -NH, -N(CH3)-, -(C=O)NH-, -NH(C=O)-, -C≡C-, The left side of the L1 structural fragment is connected to E, and the right side is connected to L2;
[0116] L2 is selected from a single bond, -(CH2) r2 -、-(CH2) r2 -(C=O)-, -(CH2) r2 -NH-, -(CH2) r2 -N(CH3)-,
[0117] The left side of the L2 structural fragment is connected to L1, and the right side is connected to L3;
[0118] L3 is selected from a single bond, -(CH2) r3 -、
[0119] The left side of the L3 structural fragment is connected to L2, and the right side is connected to L4;
[0120] L4 is selected from a single bond, -(CH2) r4 -、
[0121] The left side of the L4 structural fragment is connected to L3, and the right side is connected to V;
[0122] r2 is selected from 1, 2, 3, 4, 5, 6, 7 or 8;
[0123] r3 is selected from 1 or 2;
[0124] r4 is selected from 1 or 2.
[0125] In some embodiments,
[0126] L is selected from a single bond,
[0127]
[0128] The left side of the L structural fragment is connected to E, and the right side is connected to B;
[0129] d is selected from 0, 1, 2, 3, 4, 5, 6, 7 or 8;
[0130] t is selected from 0, 1, 2, 3, 4, 5, 6, 7 or 8;
[0131] n is selected from 1, 2 or 3;
[0132] q is selected from 1, 2 or 3;
[0133] m is selected from 0, 1, 2, 3 or 4.
[0134] In some embodiments, the compound is selected from any of the following compounds:
[0135]
[0136]
[0137]
[0138]
[0139]
[0140]
[0141]
[0142]
[0143]
[0144]
[0145]
[0146]
[0147] Compared with traditional drugs, PROTAC has significant advantages: wider range of action, higher activity, can target "undruggable" targets; improve selectivity, activity and safety; overcome tumor drug resistance, etc. Based on PROTAC technology, the present invention develops a new EGFR degrader to solve the problems of drug resistance and safety currently faced by EGFR inhibitors.
[0148] The compound described in the present invention or its enantiomer, diastereomer, cis-trans isomer, racemate, deuterated product, metabolite, prodrug, solvate, hydrate, pharmaceutically acceptable salt or cocrystal is used to prepare EGFR degrader drugs, and is also used to prepare drugs for treating and / or preventing cancer.
[0149] In some embodiments, the cancer is a cancer associated with abnormal EGFR activity or expression.
[0150] In some embodiments, the cancer is lung cancer.
[0151] In some embodiments, the cancer is non-small cell lung cancer.
[0152] The pharmaceutical composition of the present invention contains the compound as shown in Formula I, or its enantiomers, diastereomers, racemates, cis-trans isomers, deuterated substances, metabolites, prodrugs, solvates, hydrates, pharmaceutically acceptable salts or cocrystals and pharmaceutically acceptable carriers or excipients.
[0153] In some embodiments, in the pharmaceutical composition, the compound or its enantiomer, diastereomer, racemate, cis-trans isomer, deuterated substance, metabolite, prodrug, solvate, hydrate, pharmaceutically acceptable salt or cocrystal is in a therapeutically effective amount.
[0154] The pharmaceutical composition of the present invention is used for preparing EGFR degrader drugs, and is also used for preparing drugs for treating and / or preventing cancer.
[0155] In some embodiments, the cancer is a cancer associated with abnormal EGFR activity or expression.
[0156] In some embodiments, the cancer is lung cancer.
[0157] In some embodiments, the cancer is non-small cell lung cancer.
[0158] The pharmaceutical excipients can be those widely used in the field of drug production. Excipients are mainly used to provide a safe, stable and functional pharmaceutical composition, and can also provide methods to dissolve the active ingredient at a desired rate after the subject receives the administration, or promote the effective absorption of the active ingredient after the subject receives the composition. The pharmaceutical excipients can be inert fillers, or provide a certain function, such as stabilizing the overall pH value of the composition or preventing the degradation of the active ingredient of the composition. The pharmaceutical excipients can include one or more of the following excipients: adhesives, suspending agents, emulsifiers, diluents, fillers, granulating agents, adhesives, disintegrants, lubricants, anti-adhesive agents, glidants, wetting agents, gelling agents, absorption delay agents, dissolution inhibitors, enhancers, adsorbents, buffers, chelating agents, preservatives, colorants, flavoring agents and sweeteners.
[0159] The pharmaceutical composition of the present invention can be prepared according to the disclosed content using any method known to those skilled in the art, such as conventional mixing, dissolving, granulating, emulsifying, grinding, encapsulating, embedding or lyophilizing processes.
[0160] The pharmaceutical composition of the present invention can be administered in any form, including injection (intravenous), mucosal, oral (solid and liquid preparations), inhalation, ocular, rectal, topical or parenteral (infusion, injection, implantation, subcutaneous, intravenous, intraarterial, intramuscular) administration. The pharmaceutical composition of the present invention can also be a controlled release or delayed release dosage form (e.g., liposomes or microspheres). Examples of solid oral preparations include, but are not limited to, powders, capsules, caplets, soft capsules, and tablets. Examples of liquid preparations for oral or mucosal administration include, but are not limited to, suspensions, emulsions, elixirs, and solutions. Examples of topical preparations include, but are not limited to, emulsions, gels, ointments, creams, patches, pastes, foams, lotions, drops, or serum preparations. Examples of preparations for parenteral administration include, but are not limited to, solutions for injection, dry preparations that can be dissolved or suspended in a pharmaceutically acceptable carrier, suspensions for injection, and emulsions for injection. Examples of other suitable formulations of the pharmaceutical composition include, but are not limited to, eye drops and other ophthalmic preparations; aerosols such as nasal sprays or inhalers; liquid dosage forms suitable for parenteral administration; suppositories and lozenges.
[0161] The term "pharmaceutically acceptable salt" refers to salts of the compounds of the present invention, prepared from compounds having specific substituents discovered by the present invention with relatively nontoxic acids or bases. When the compounds of the present invention contain relatively acidic functional groups, base addition salts can be obtained by contacting the free form of such compounds with a sufficient amount of base in a pure solution or a suitable inert solvent. Pharmaceutically acceptable base addition salts include sodium, potassium, calcium, ammonium, organic amino or magnesium salts or similar salts. When the compounds of the present invention contain relatively basic functional groups, acid addition salts can be obtained by contacting the free form of such compounds with a sufficient amount of acid in a pure solution or a suitable inert solvent. Examples of pharmaceutically acceptable acid addition salts include inorganic acid salts such as hydrochloric acid, hydrobromic acid, nitric acid, carbonic acid (forming carbonate or bicarbonate), phosphoric acid (forming phosphate, monohydrogen phosphate, dihydrogen phosphate, sulfuric acid (forming sulfate or bisulfate), hydroiodic acid, phosphorous acid, and the like; and organic acid salts such as acetic acid, propionic acid, isobutyric acid, maleic acid, malonic acid, benzoic acid, succinic acid, suberic acid, fumaric acid, lactic acid, mandelic acid, phthalic acid, benzenesulfonic acid, p-toluenesulfonic acid, citric acid. Acids such as tartaric acid and methanesulfonic acid; organic acid salts also include salts of amino acids (such as arginine, etc.), and salts of organic acids such as glucuronic acid. Certain specific compounds of the present invention contain basic and acidic functional groups, and can be converted into any base or acid addition salt. Preferably, the salt is contacted with a base or acid in a conventional manner, and the parent compound is separated, thereby regenerating the free form of the compound. The free form of the compound differs from its various salt forms in certain physical properties, such as different solubility in polar solvents.
[0162] The "pharmaceutically acceptable salts" of the present invention can be synthesized from parent compounds containing acid radicals or bases by conventional chemical methods. In general, such salts are prepared by reacting these compounds in free acid or base form with a stoichiometric amount of an appropriate base or acid in water or an organic solvent or a mixture of the two. In general, non-aqueous media such as ether, ethyl acetate, ethanol, isopropanol or acetonitrile are preferred.
[0163] The term "enantiomer" refers to stereoisomers that are non-superimposable mirror images of each other. Examples of enantiomers include, but are not limited to
[0164]
[0165] The term "racemate" is a mixture of enantiomers. Examples of racemates include, but are not limited to
[0166] yes
[0167] of the racemate.
[0168] The term "diastereoisomers" refers to stereoisomers that have identical atomic composition but different arrangements in space and are not mirror images of each other.
[0169] The term "cis-trans isomers" refers to isomers caused by the inability of a double bond or a single bond of a ring-forming carbon atom to rotate freely.
[0170] The term "metabolite" refers to a pharmaceutically active product produced by the in vivo metabolism of a compound of Formula I or a salt thereof. Such a product may be produced, for example, by oxidation, reduction, hydrolysis, amidation, deamidation, esterification, deesterification, glucuronidation, enzymatic cleavage, etc. of the administered compound. Therefore, the present invention includes metabolites of the compounds of the present invention, including compounds produced by a process of contacting a compound of the present invention with a mammal for a period of time sufficient to obtain a metabolite thereof.
[0171] Metabolites are typically identified by preparing radiolabeled isotopes of the compounds of the invention, administering them parenterally to animals, such as rats, mice, guinea pigs, monkeys, or humans, at detectable doses (e.g., greater than about 0.5 mg / kg), allowing sufficient time for metabolism to occur (typically about 30 seconds to 30 hours), and isolating the conversion products from urine, blood, or other biological samples. These products are easily isolated because they are labeled (others are isolated by using antibodies that can bind to antigenic epitopes present in the metabolites). The metabolite structure is determined in a conventional manner, for example, by MS, LC / MS or NMR analysis. Generally, the analysis of metabolites is performed in the same manner as conventional drug metabolism studies known to those skilled in the art. As long as the metabolite products are not otherwise not found in vivo, they can be used in assays for therapeutic dosing of the compounds of the invention. The compounds of the invention may contain non-natural proportions of atomic isotopes on one or more of the atoms that make up the compound. For example, compounds may be labeled with radioisotopes, such as tritium ( 3 H), iodine-125( 125 I) or C-14( 14 C) All isotopic variations of the compounds of the present invention, whether radioactive or not, are included within the scope of the present invention.
[0172] In addition to the form of salts, the compounds provided by the present invention also exist in the form of prodrugs. The prodrugs of the compounds described herein are easily chemically changed under physiological conditions to be converted into the compounds of the present invention. Any compound that can be converted in vivo to provide a bioactive substance (i.e., a compound shown in Formula I) is a prodrug within the scope and spirit of the present invention. For example, a carboxyl-containing compound can form a physiologically hydrolyzable ester, which acts as a prodrug by being hydrolyzed in vivo to obtain the compound shown in Formula I itself. The prodrug is preferably administered orally, because hydrolysis occurs mainly under the influence of digestive enzymes in many cases. When the ester itself is active or hydrolysis occurs in the blood, parenteral administration can be used.
[0173] Those skilled in the art will appreciate that, according to the conventions used in the art, the structural formulas used in this application to describe groups It means that the corresponding group is connected to other fragments and groups in the compound shown in Formula I through this site.
[0174] The term "degrader" refers to a compound of Formula I or its enantiomers, diastereomers, cis-trans isomers, racemates, deuterated products, metabolites, prodrugs, solvates, hydrates, pharmaceutically acceptable salts or cocrystals that simultaneously bind to E3 ubiquitin ligase and EGFR protein, and bring the EGFR protein and E3 ubiquitin ligase into proximity with each other, thereby degrading the EGFR protein under the action of E3 ubiquitin ligase.
[0175] The term "halogen" refers to fluorine, chlorine, bromine or iodine.
[0176] The term "alkyl" refers to a straight or branched chain alkyl group having a specified number of carbon atoms. Examples of alkyl groups include methyl, ethyl, n-propyl, isopropyl, n-butyl, tert-butyl, isobutyl, sec-butyl, n-pentyl, n-hexyl, and the like.
[0177] The term "alkoxy" refers to the group -O-alkyl, wherein alkyl is as defined above.
[0178] The term "alkylene" refers to a divalent group formed by removing another hydrogen atom from an "alkyl" group. Examples of alkylene groups include, but are not limited to, ethylene, propylene, butylene, pentylene, hexylene, and the like.
[0179] The term "alkenyl" refers to an alkyl group as defined above consisting of at least two carbon atoms and at least one carbon-carbon double bond. "Alkenylene" is a divalent group formed by removing another hydrogen atom from an alkenyl group. Examples of alkenylene include, but are not limited to, -CH=CH- and -CH=CH-CH2-.
[0180] The term "alkynyl" is an alkyl group as defined above consisting of at least two carbon atoms and at least one carbon-carbon triple bond. "Alkynylidene" refers to a divalent group formed by removing another hydrogen atom from an "alkynyl" group. Examples of alkynylidene include, but are not limited to -C≡C-.
[0181] The term "heterocycloalkyl" refers to a saturated or partially saturated monocyclic or polycyclic group with heteroatoms, which contains 3-20 ring atoms, one or more of which are independently selected from heteroatoms N, O or S, and the remaining ring atoms are carbon. Preferably 3 to 20 ring atoms, 1-3 of which are heteroatoms. More preferably 4-16 ring atoms, 1-2 of which are N, including 4-10-membered monocyclic heterocycloalkyl, 6-20-membered spirocyclic heterocycloalkyl, 6-18-membered ring heterocycloalkyl, 7-10-membered bridged heterocycloalkyl. The term "heterocycloalkylene" refers to a divalent group formed by removing another hydrogen atom on the basis of the above-mentioned "heterocycloalkyl", including 4-10-membered monocyclic heterocycloalkylene, 6-20-membered spirocyclic heterocycloalkylene, 6-18-membered ring heterocycloalkylene, 7-10-membered bridged heterocycloalkylene. Examples include but are not limited to
[0182]
[0183] The term "haloalkyl" refers to an alkyl group substituted with one or more halogens, as defined above. Examples of haloalkyl groups include, but are not limited to, trifluoromethyl.
[0184] The term "haloalkoxy" refers to an alkoxy group substituted with one or more halogens, as defined above. Examples of haloalkoxy include, but are not limited to, trifluoromethoxy.
[0185] The term "deuterated alkyl" refers to an alkyl group substituted with one or more deuterium groups, as defined above. Examples of deuterated alkyl groups include, but are not limited to, -CD3.
[0186] The term "deuterated alkoxy" refers to an alkoxy group substituted with one or more deuterium groups, as defined above. Examples of deuterated alkoxy groups include, but are not limited to -OCD3.
[0187] The hydrogen atoms described in the present invention can be replaced by their isotope deuterium, and any hydrogen atom in the compounds involved in the present invention can also be replaced by a deuterium atom.
[0188] Beneficial effects: Compared with the prior art, the present invention has the following significant advantages:
[0189] 1. The compound can efficiently and selectively degrade various EGFR mutant proteins (DC 50 <10nM), but no degradation activity on wild-type protein, with high selectivity and low toxicity;
[0190] 2. The compound has a good therapeutic effect on cancer and has low toxicity. It can be used to prepare drugs for treating and / or preventing a variety of cancers associated with abnormal EGFR activity or expression, especially non-small cell lung cancer. DETAILED DESCRIPTION
[0191] The technical solution of the present invention is further described below in conjunction with embodiments.
[0192] Example 1: Synthesis of Intermediate 6
[0193]
[0194] a) At -20°C, add a solution of R(+)-alpha-methylbenzylamine trifluoroacetate (1.95mmol) in THF (10mL) to a solution of N-fluorobisbenzenesulfonamide (3.07g, 9.75mmol) and sodium bicarbonate (1.55g, 14.63mmol) in THF (20mL). After reacting at -20°C for 10 minutes, slowly add compound 1 (3.88g, 19.50mmol), continue the reaction for 24 hours, add water (10mL) to quench the reaction, and extract with ether three times. Combine the organic phases, dry them over anhydrous sodium sulfate, filter, concentrate, and separate by column chromatography to obtain compound 2 (2.5g, 75%). MS (ESI, m / z): 218 (M + +1).
[0195] b) Tetramethylammonium borohydride (491 mg, 5.52 mmol) was added to a solution of compound 2 (1.0 g, 4.60 mmol) in methanol (20 mL) at 0°C. The reaction was continued at 0°C for 4 hours until the reaction was complete. Saturated ammonium chloride was added to quench the reaction and the mixture was extracted three times with ethyl acetate. The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain compound 3 (856 mg, 85%). MS (ESI, m / z): 220 (M + +1).
[0196] c) At 0°C, NaH (52 mg, 1.3 mmol, 60%) was added to a solution of compound 3 (219 mg, 1.0 mmol) in anhydrous THF (3 mL). After reacting for 1 hour, iodomethane (184 mg, 1.3 mmol) was added thereto. After the reaction was completed at 0°C for 1 hour, saturated ammonium chloride was added to quench the reaction, and the mixture was extracted three times with ethyl acetate. The organic phases were combined, dried over anhydrous sodium sulfate, filtered, concentrated, and subjected to column chromatography to obtain compound 4 (210 mg, 90%). MS (ESI, m / z): 234 (M + +1).
[0197] d) At room temperature, trifluoroacetic acid (380 μL, 5.0 mmol) was added to a DCM (2 mL) solution of compound 4 (233 mg, 1.0 mmol). The reaction was complete after 3 hours. Compound 5 (172 mg, 75%) was obtained after distillation under reduced pressure. MS (ESI, m / z): 134 (M + +1).
[0198] e) Add triethylamine (416 μL, 3.0 mmol) to a solution of compound 5 (230 mg, 1.0 mmol) and 4-amino-2-chloropyrimidine (130 mg, 1.0 mmol) in isopropanol (5 mL). The reaction was completed after 4 hours at 90°C. After cooling to room temperature, the mixture was extracted three times with ethyl acetate. The organic phases were combined, dried over anhydrous sodium sulfate, filtered, concentrated, and purified by column chromatography to obtain compound 6 (154 mg, 68%). MS (ESI, m / z): 227 (M + +1).
[0199] Example 2: Synthesis of Intermediate 14
[0200]
[0201] a) Pd2(dba)3 (45.6 mg, 0.05 mmol), Xantphos (57.8 mg, 0.1 mmol) and Cs2CO3 (977 mg, 3.0 mmol) were added to a solution of (2R, 3S)-2-methyl-3-((methylsulfonyl)methyl)azetidine (12) (163 mg, 1.0 mmol) and compound 10 (285 mg, 1.0 mmol) in 1,4-dioxane (5 mL). The mixture was heated to 100°C for 4 hours until the reaction was complete. After cooling to room temperature, the mixture was extracted three times with EA. The organic phases were combined, dried over anhydrous sodium sulfate, filtered, concentrated, and separated by column chromatography to obtain compound 13 (275 mg, 75%). MS (ESI, m / z): 367 (M + +1).
[0202] b) At 0°C, N-bromosuccinimide (NBS) (178 mg, 1.0 mmol) was added to a DMF (6 mL) solution of compound 13 (367 mg, 1.0 mmol) and the reaction was completed after 1 hour. The reaction solution was extracted three times with EA. The organic phases were combined, dried over anhydrous sodium sulfate, filtered, concentrated, and separated by column chromatography to obtain compound 14 (423 mg, 95%). MS (ESI, m / z): 445 (M + +1).
[0203] Example 3: Synthesis of Intermediate 17
[0204]
[0205] a) Pd2(dba)3 (45.6 mg, 0.05 mmol), Xantphos (57.8 mg, 0.1 mmol) and Cs2CO3 (977 mg, 3.0 mmol) were added to a solution of compound 15 (149 mg, 1.0 mmol) and compound 11 (285 mg, 1.0 mmol) in 1,4-dioxane (5 mL). The mixture was heated to 100°C for 4 hours until the reaction was complete. After cooling to room temperature, the mixture was extracted three times with EA. The organic phases were combined, dried over anhydrous sodium sulfate, filtered, concentrated, and separated by column chromatography to obtain compound 4 (275 mg, 77%). MS (ESI, m / z): 367 (M + +1).
[0206] b) At 0°C, N-bromosuccinimide (178 mg, 1.0 mmol) was added to a DMF (6 mL) solution of compound 16 (367 mg, 1.0 mmol) and the reaction was completed after 1 hour. The reaction solution was extracted three times with EA. The organic phases were combined, dried over anhydrous sodium sulfate, filtered, concentrated, and separated by column chromatography to obtain compound 17 (409 mg, 95%). MS (ESI, m / z): 445 (M + +1).
[0207] Example 4: Synthesis of Intermediate 21
[0208]
[0209] a) Pd2(dba)3 (45.6 mg, 0.05 mmol), Xantphos (57.8 mg, 0.1 mmol) and Cs2CO3 (977 mg, 3.0 mmol) were added to a solution of compound 14 (446 mg, 1.0 mmol) and raw material 18 (198 mg, 1.0 mmol) in 1,4-dioxane (5 mL). The mixture was heated to 100°C for 4 hours until the reaction was complete. After cooling to room temperature, the mixture was extracted three times with EA. The organic phases were combined, dried over anhydrous sodium sulfate, filtered, concentrated, and separated by column chromatography to obtain compound 19 (197 mg, 35%). MS (ESI, m / z): 563 (M + +1).
[0210] b) At 0°C, Brettphos Pd G3 (181 mg, 0.2 mmol) and cesium carbonate (975 mg, 3.0 mmol) were added to a solution of compound 19 (563 mg, 1.0 mmol) and compound 6 (226 mg, 1.0 mmol) in 1,4-dioxane (5 mL). The temperature was raised to 100°C and the reaction was complete after 4 hours. After cooling to room temperature, the mixture was extracted three times with EA. The organic phases were combined, dried over anhydrous sodium sulfate, filtered, concentrated, and separated by column chromatography to obtain intermediate 20 (361 mg, 48%). MS (ESI, m / z): 753 (M + +1).
[0211] c) Trifluoroacetic acid (2 mL) was added to a solution of compound 20 (752 mg, 1.0 mmol) in dichloromethane (2 mL) at 0°C. The reaction was completed after 4 hours at 0°C. The mixture was concentrated under reduced pressure to obtain intermediate 21 (554 mg, 85%). MS (ESI, m / z): 753 (M + +1).
[0212] Example 5: Synthesis of Intermediates 22 to 33
[0213] The synthesis method is the same as the synthesis of intermediate 21 in Example 4, except that the corresponding raw materials need only be replaced.
[0214]
[0215] Example 6: Synthesis of Intermediate 37
[0216]
[0217] a) Pd2(dba)3 (45.6 mg, 0.05 mmol), CuI (19 mg, 0.1 mmol) and Cs2CO3 (977 mg, 3.0 mmol) were added to a solution of compound 14 (446 mg, 1.0 mmol) and raw material 34 (209 mg, 1.0 mmol) in 1,4-dioxane (5 mL). The mixture was heated to 100°C for 4 hours until the reaction was complete. After cooling to room temperature, the mixture was extracted three times with EA. The organic phases were combined, dried over anhydrous sodium sulfate, filtered, concentrated, and separated by column chromatography to obtain compound 19 (252 mg, 45%). MS (ESI, m / z): 560 (M + +1).
[0218] b) At 0°C, Brettphos Pd G3 (181 mg, 0.2 mmol) and Cs2CO3 (975 mg, 3.0 mmol) were added to a solution of compound 35 (560 mg, 1.0 mmol) and compound 6 (226 mg, 1.0 mmol) in 1,4-dioxane (5 mL). The temperature was raised to 100°C and the reaction was complete after 4 hours. After cooling to room temperature, the mixture was extracted three times with EA. The organic phases were combined, dried over anhydrous sodium sulfate, filtered, concentrated, and separated by column chromatography to obtain intermediate 36 (360 mg, 48%). MS (ESI, m / z): 750 (M + +1).
[0219] c) Trifluoroacetic acid (2 mL) was added to a solution of compound 36 (752 mg, 1.0 mmol) in dichloromethane (2 mL) at 0°C. The reaction was completed after 4 hours at 0°C. The mixture was concentrated under reduced pressure to obtain intermediate 37 (553 mg, 85%). MS (ESI, m / z): 650 (M + +1).
[0220] Example 7: Synthesis of Intermediate 38
[0221]
[0222] The synthesis method is the same as that of the intermediate 37 in Example 6, except that the corresponding raw materials are replaced. MS (ESI, m / z): 622 (M + +1).
[0223] Example 8: Synthesis of Intermediate 42
[0224]
[0225] a) Pd2(dba)3 (45.6 mg, 0.05 mmol), Xantphos (57.8 mg, 0.1 mmol) and Cs2CO3 (977 mg, 3.0 mmol) were added to a solution of compound 14 (446 mg, 1.0 mmol) and raw material 39 (103 mg, 1.0 mmol) in 1,4-dioxane (5 mL). The mixture was heated to 100°C for 4 hours until the reaction was complete. After cooling to room temperature, the mixture was extracted three times with EA. The organic phases were combined, dried over anhydrous sodium sulfate, filtered, concentrated, and separated by column chromatography to obtain compound 40 (163 mg, 36%). MS (ESI, m / z): 454 (M + +1).
[0226] b) At 0°C, Brettphos Pd G3 (181 mg, 0.2 mmol) and Cs2CO3 (975 mg, 3.0 mmol) were added to a solution of compound 40 (453 mg, 1.0 mmol) and compound 6 (226 mg, 1.0 mmol) in 1,4-dioxane (5 mL). The temperature was raised to 100°C and the reaction was complete after 4 hours. After cooling to room temperature, the mixture was extracted three times with EA. The organic phases were combined, dried over anhydrous sodium sulfate, filtered, concentrated, and separated by column chromatography to obtain intermediate 41 (302 mg, 47%). MS (ESI, m / z): 644 (M + +1).
[0227] c) 2M NaOH solution (1 mL) was added to a solution of compound 41 (752 mg, 1.0 mmol) in tetrahydrofuran (2 mL) at 0°C. The reaction was complete after 4 hours at 0°C. The pH was adjusted to 5, filtered and dried to obtain intermediate 42 (440 mg, 70%). MS (ESI, m / z): 630 (M + +1).
[0228] Example 9: Synthesis of Intermediate 45
[0229]
[0230] a) Pd2(dba)3 (45.6 mg, 0.05 mmol), Xantphos (57.8 mg, 0.1 mmol) and Cs2CO3 (977 mg, 3.0 mmol) were added to a solution of compound 14 (446 mg, 1.0 mmol) and raw material 43 (71 mg, 1.0 mmol) in 1,4-dioxane (5 mL). The mixture was heated to 100°C for 4 hours until the reaction was complete. After cooling to room temperature, the mixture was extracted with EA three times. The organic phases were combined, dried over anhydrous sodium sulfate, filtered, concentrated, and separated by column chromatography to obtain compound 44 (165 mg, 39%). MS (ESI, m / z): 422 (M + +1).
[0231] b) At 0°C, Brettphos Pd G3 (181 mg, 0.2 mmol) and Cs2CO3 (975 mg, 3.0 mmol) were added to a solution of compound 44 (421 mg, 1.0 mmol) and compound 6 (226 mg, 1.0 mmol) in 1,4-dioxane (5 mL). The temperature was raised to 100°C for 4 hours until the reaction was complete. After cooling to room temperature, the mixture was extracted three times with EA. The organic phases were combined, dried over anhydrous sodium sulfate, filtered, concentrated, and separated by column chromatography to obtain intermediate 45 (300 mg, 49%). MS (ESI, m / z): 612 (M ++1).
[0232] Example 10: Synthesis of Intermediates 46 to 54
[0233] The synthesis method is similar to that of the intermediate 45 in Example 9, except that only the corresponding raw materials need to be replaced.
[0234]
[0235]
[0236] Example 11: Synthesis of Intermediates 57a-b
[0237]
[0238] a) The raw material 55 (2.0 g, 7.25 mmol) was dissolved in DMF (10 mL), and glycine tert-butyl ester (1.14 g, 8.69 mmol) and DIPEA (2.84 mL, 9.43 mmol) were added to the reaction system. The reaction was carried out at 90°C for 5 hours. After the reaction was completed, the mixture was cooled to room temperature, diluted with water, extracted with dichloromethane (10 mL×3), and the organic phases were combined, washed with saturated NaCl solution, dried over anhydrous sodium sulfate, filtered, concentrated under reduced pressure, and purified by column chromatography to obtain intermediate 56a (1.58 g, 56%). MS (ESI, m / z): 410 (M + +1). Intermediate 56b can be obtained by simply replacing the corresponding raw materials and following the same preparation method.
[0239] b) Intermediate 56a (387.4 mg, 1 mmol) was dissolved in dichloromethane (2 mL), trifluoroacetic acid (148 μL) was added, and the mixture was reacted at 25° C. for 8 hours, and concentrated under reduced pressure to obtain intermediate 57a (291 mg, 88%). MS (ESI, m / z): 332 (M + +1). Intermediate 57b can be prepared by the same method by simply replacing the corresponding raw materials.
[0240] Example 12: Synthesis of Intermediates 59a-c
[0241]
[0242] a) The raw material 55 (2.0 g, 7.25 mmol) was dissolved in DMF (10 mL), aminoethanol (530 mg, 8.69 mmol) and DIPEA (2.84 mL, 9.43 mmol) were added to the reaction system, and the reaction was carried out at 90°C for 5 hours. After the reaction was completed, the mixture was cooled to room temperature, diluted with water, extracted with dichloromethane (10 mL×3), the organic phases were combined, washed with saturated NaCl solution, dried over anhydrous Na2SO4, filtered to remove salt, concentrated under reduced pressure, and purified by column chromatography to obtain intermediate 58a (1.59 g, 50%). MS (ESI, m / z): 318 (M + +1). Intermediates 58b-c can be obtained by simply replacing the corresponding raw materials and following the same preparation method.
[0243] b) Under nitrogen protection, the intermediate 58a (387.4 mg, 1 mmol) was dissolved in tetrahydrofuran (2 mL), triethylamine (207 μL, 1.5 mmol) and MsCl (172 mg, 1.5 mmol) were added at 0°C, reacted at 0°C for 3 hours, and directly spin-dried to obtain the intermediate 24 (348 mg, 88%). MS (ESI, m / z): 396 (M + +1). Intermediates 59b-c can be prepared in the same manner by simply replacing the corresponding starting materials.
[0244] Example 13: Synthesis of Intermediates 61a-c
[0245]
[0246] a) The raw material 60 (2.0 g, 7.25 mmol) was dissolved in DMF (10 mL), and 2-bromoethanol (1.1 g, 8.69 mmol), NaHCO3 (793 mg, 9.43 mmol) and NaI (109 mg, 0.73 mmol) were added to the reaction system, and the reaction was carried out at 90°C for 5 hours. After the reaction was completed, the mixture was cooled to room temperature, diluted with water, extracted with dichloromethane (10 mL×3), and the organic phases were combined, washed with saturated NaCl solution, dried over anhydrous Na2SO4, filtered, concentrated under reduced pressure, and purified by column chromatography to obtain intermediate 61a (1.59 g, 50%). MS (ESI, m / z): 319 (M + +1). Intermediates 61b-c can be obtained by simply replacing the corresponding raw materials and following the same preparation method.
[0247] b) Under nitrogen protection, the intermediate 61a (318 mg, 1 mmol) was dissolved in tetrahydrofuran (2 mL), triethylamine (207 μL, 1.5 mmol) and MsCl (172 mg, 1.5 mmol) were added at 0°C, and the reaction was completed at 0°C for 3 hours, and the reaction was concentrated under reduced pressure to obtain the intermediate 62a (348 mg, 88%). MS (ESI, m / z): 396 (M + +1). Intermediates 62b-c can be prepared in the same manner by simply replacing the corresponding raw materials.
[0248] Example 14: Synthesis of Intermediates 65a-f
[0249]
[0250] a) Under nitrogen protection, intermediate 79 (323 mg, 1 mmol), Pd(dppf)2Cl2 (70 mg, 0.1 mmol), 1-ethynol (84 mg, 1.5 mmol) and CuI (38 mg, 0.2 mmol) were dissolved in DMF (10 mL), triethylamine (0.33 mL) was added, and the mixture was stirred at 80°C overnight. After the reaction was complete, water was added to quench the mixture, and the mixture was extracted with ethyl acetate (10 mL×3). The organic phases were combined, washed with saturated NaCl solution, dried over anhydrous Na2SO4, filtered, concentrated under reduced pressure, and purified by column chromatography to obtain intermediate 64a (209 mg, 70%). MS (ESI, m / z): 299 (M++1). Intermediates 64b-f, 70a-b and 73a-b can be obtained by simply replacing the corresponding raw materials.
[0251] b) The same synthesis step b as intermediate 61a-c is carried out, except that the corresponding raw materials are replaced and the same preparation method is used to obtain intermediates 65a-f, 71a-b and 74a-b.
[0252] Example 15: Synthesis of Intermediates 77a-b, 79a-c, 81a-c
[0253]
[0254] a) The raw material 75 (2.0 g, 7.25 mmol) was dissolved in DMF (10 mL), and octahydrocyclopentane [c] pyrrol-5-ol (1.1 g, 8.69 mmol) and DIPEA (2.84 mL, 9.43 mmol) were added to the reaction system, and the reaction was carried out at 90°C for 5 hours. After the reaction was completed, the mixture was cooled to room temperature, diluted with water, extracted with dichloromethane (10 mL×3), and the organic phases were combined, washed with saturated NaCl solution, dried over anhydrous Na2SO4, filtered to remove salt, concentrated under reduced pressure, and purified by column chromatography to obtain intermediate 76a (1.91 g, 50%). MS (ESI, m / z): 384 (M ++1). Intermediates 76b, 78a-c and 80a-c can be obtained by the same preparation method by simply replacing the corresponding raw materials.
[0255] b) Under nitrogen protection, the intermediate 76a (383 mg, 1 mmol) was dissolved in tetrahydrofuran (2 mL), triethylamine (207 μL, 1.5 mmol) and MsCl (172 mg, 1.5 mmol) were added at 0°C, reacted for 3 hours at 0°C, and concentrated under reduced pressure to obtain the intermediate 77a (405 mg, 88%). MS (ESI, m / z): 462 (M++1). Intermediates 77b, 79a-c and 81a-c were prepared by the same method by simply replacing the corresponding raw materials.
[0256] Example 16: Synthesis of Intermediates 82-101
[0257] The synthesis method is the same as the synthesis of intermediate 77a in Example 15, except that the corresponding raw materials need only be replaced.
[0258]
[0259]
[0260] Example 17: Synthesis of Intermediate 103
[0261]
[0262] a) The raw material 75 (2.0 g, 7.25 mmol) was dissolved in DMF (10 mL), and tert-butyl 2,6-diazaspiro[3.3]heptane-2-carboxylate (1.72 g, 8.69 mmol) and DIPEA (2.84 mL, 9.43 mmol) were added to the reaction system, and the reaction was carried out at 90°C for 5 hours. After the reaction was completed, the mixture was cooled to room temperature, diluted with water, extracted with dichloromethane (10 mL×3), and the organic phases were combined, washed with saturated NaCl solution, dried over anhydrous Na2SO4, filtered to remove salt, concentrated under reduced pressure, and purified by column chromatography to obtain intermediate 102 (2.46 g, 54%). MS (ESI, m / z): 455 (M + +1).
[0263] b) The intermediate 102 (1 mmol) was dissolved in a solution of dichloromethane (1 mmol / 5 mL) and methanol (1 mmol / 1 mL), and a 4 M HCl solution in dioxane (0.5 mL) was added at 0°C. The mixture was reacted at room temperature for 4 hours. After the reaction was completed as monitored by TLC, the reaction solution was dried by spin drying, and isopropyl ether was added to make a slurry. The intermediate 103 was obtained by suction filtration. MS (ESI, m / z): 355 (M + +1).
[0264] Example 18: Synthesis of Intermediates 104-116
[0265] The synthesis method is the same as the synthesis of intermediate 103 in Example 17, except that only the corresponding raw materials need to be replaced.
[0266]
[0267]
[0268] Example 19: Synthesis of Intermediates 119a-b
[0269]
[0270] The synthesis method is the same as that of the intermediate 103 in Example 17, except that the corresponding raw materials are replaced. 119a, MS (ESI, m / z): 331 (M + +1);119b, MS(ESI,m / z):345(M + +1).
[0271] Example 20: Synthesis of Intermediates 121a-c
[0272]
[0273] The synthesis method is the same as that of the intermediate 103 in Example 17, except that the corresponding raw materials are replaced. 121a, MS (ESI, m / z): 317 (M + +1);121b, MS(ESI,m / z):331(M + +1); 121c, 359 (M + +1.
[0274] Example 21 Synthesis of Intermediate 123
[0275]
[0276] The synthesis method is the same as the synthesis of intermediate 103 in Example 17, except that the corresponding raw materials are replaced. MS (ESI, m / z): 374 (M + +1).
[0277] Example 22: Synthesis of Intermediate 125
[0278]
[0279] The synthesis method is the same as the synthesis of intermediate 57a-b in Example 11, except that the corresponding raw materials are replaced. MS (ESI, m / z): 332 (M + +1).
[0280] Example 23: Synthesis of Intermediate 127
[0281]
[0282] The synthesis method is the same as the synthesis of intermediates 59a-c in Example 12, except that the corresponding raw materials are replaced. MS (ESI, m / z): 382 (M + +1).
[0283] Example 24: Synthesis of Intermediate 129
[0284]
[0285] a) The raw material 117 (2.0 g, 7.25 mmol) was dissolved in DMF (10 mL), and tert-butyl (5-bromopentyl)carbamate (2.3 g, 8.69 mmol), NaHCO3 (793 mg, 9.43 mmol) and NaI (109 mg, 0.73 mmol) were added to the reaction system, and the reaction was carried out at 90°C for 5 hours. After the reaction was completed, the mixture was cooled to room temperature, diluted with water, extracted with dichloromethane (10 mL×3), and the organic phases were combined, washed with saturated NaCl solution, dried over anhydrous Na2SO4, filtered, concentrated under reduced pressure, and purified by column chromatography to obtain intermediate 128 (221 g, 48%). MS (ESI, m / z): 460 (M + +1).
[0286] b) The intermediate 128 (1 mmol) was dissolved in a solution of dichloromethane (1 mmol / 5 mL) and methanol (1 mmol / 1 mL), and a 4 M HCl solution in dioxane (0.5 mL) was added at 0°C. The mixture was reacted at room temperature for 4 hours. After the reaction was completed as monitored by TLC, the reaction solution was dried by spin drying, and isopropyl ether was added to make a slurry. The intermediate 129 was obtained by suction filtration. MS (ESI, m / z): 360 (M + +1).
[0287] Example 25: Synthesis of Intermediate 132
[0288]
[0289] The synthesis method is the same as the synthesis of intermediate 103 in Example 17, except that the corresponding raw materials are replaced. MS (ESI, m / z): 373 (M + +1).
[0290] Example 26: Synthesis of Intermediate 135
[0291]
[0292] The synthesis method is the same as the synthesis of intermediate 103 in Example 17, except that the corresponding raw materials are replaced. MS (ESI, m / z): 369 (M ++1).
[0293] Example 27: Synthesis of Intermediate 137
[0294]
[0295] The synthesis method is the same as the synthesis of intermediate 59a-c in Example 12, except that the corresponding raw materials are replaced. MS (ESI, m / z): 440 (M + +1).
[0296] Example 28: Synthesis of Intermediate 139
[0297]
[0298] The synthesis method is the same as the synthesis of intermediate 59a-c in Example 12, except that the corresponding raw materials are replaced. MS (ESI, m / z): 426 (M + +1).
[0299] Example 29: Synthesis of Compound S1
[0300]
[0301] The raw material 21 (638 mg, 1 mmol) was dissolved in DMF (5 mL), and 59a (593 mg, 1.5 mmol), DIPEA (0.53 mL, 3 mmol) and NaI (15 mg, 0.1 mmol) were added to the solution. The mixture was reacted at 60 °C for 5 hours. After the reaction was complete, the mixture was concentrated under reduced pressure and purified by column chromatography to obtain compound S1 (234 mg, 25%). 1H NMR(500MHz,DMSO-d6)δ11.02(s,1H),8.90(s,1H),8.29(d,J=7.5Hz,2H),8 .15(d,J=5.7Hz,1H),7.49(t,J=7.9Hz,1H),7.23(dd,J=7.9,1.1Hz,1H),7.1 4(dd,J=7.8,1.2Hz,1H),7.02(t,J=3.7Hz,1H),6.95(t,J=0.7Hz,1H),6.27( d,J=5.7Hz,1H),5.27(t,J=5.9Hz,1H),5.12(m,1H),5.03(m,1H),4.13–3.97 (m,2H),3.84(dd,J=9.1,5.5Hz,2H),3.77–3.67(m,3H),3.64(s,4H),3.67– 3.37(m,6H),3.33(dd,J=14.8,6.0Hz,1H),3.30(s,2H),3.07(d,J=5.5Hz,7H ),2.76(dt,J=11.5,5.8Hz,1H),2.75–2.64(m,3H),2.57(m,1H),2.21–2.04( m,2H),1.95(m,1H),1.87(m,1H),1.26(d,J=6.4Hz,6H).MS(ESI,m / z):938(M + +1).
[0302] Example 30: Synthesis of Compound S2
[0303]
[0304] According to the synthesis of compound S1, the corresponding intermediate was replaced to obtain compound S2. 1H NMR (500MHz, DMSO-d6) δ11.02 (s, 1H), 8.90 (s, 1H), 8.29 (d, J = 5.9Hz, 2H), 8. 15(d,J=5.7Hz,1H),7.49(t,J=7.9Hz,1H),7.13–7.07(m,2H),6.98–6.89(m, 2H),6.27(d,J=5.7Hz,1H),5.16–5.09(m,2H),5.03(td,J=3.6,1.7Hz,1H),3 .95(m,1H),3.87(dd,J=9.2,5.6Hz,2H),3.83–3.62(m,9H),3.63–3.53(m,1H) ,3.46(pd,J=6.5,0.9Hz,1H),3.39–3.27(m,6H),3.08(s,3H),2.96(s,2H),2 .82(p,J=5.8Hz,1H),2.69-2.65(m,1H),2.61–2.47(m,2H),2.40–2.31(m,1H ),2.17–2.02(m,2H),1.94-1.89(m,1H),1.84(m,1H),1.78–1.65(m,2H),1.6 9–1.58(m,1H),1.61–1.49(m,1H),1.26(d,J=6.4Hz,6H).MS(ESI,m / z):966(M + +1).
[0305] Example 31: Synthesis of Compound S3
[0306]
[0307] According to the synthesis of compound S1, the corresponding intermediate was replaced to obtain compound S3. 1H NMR (500MHz, DMSO-d6) δ11.02(s,1H),8.57(s,1H),8.11(d,J=4.9Hz,1H),7.96(dd,J=5.7,3.8Hz,1H),7.49–7.41(m,2H),7.33(s,1H),7.08(s,1H) ,7.02(t,J=3.7Hz,1H),6.88(s,1H),6.62(d,J=4.9Hz,1H),5.12(s,1H), 4.92(s,1H),4.11(d,J=14.5Hz,2H),3.96(s,1H),3.69(d,J=8.2Hz,6H),3 .63(d,J=4.7Hz,4H),3.59(s,1H),3.48(d,J=5.5Hz,4H),3.40(s,3H),3. 12(s,2H),2.94(d,J=10.1Hz,5H),2.66(s,1H),2.61(s,1H),2.52(d,J=14 .6Hz,3H),2.39(s,1H),2.24(d,J=0.9Hz,2H),1.89(s,1H),1.75–1.65(m, 2H),1.56(s,2H),1.33(d,J=4.8Hz,4H),1.29(s,6H).MS(ESI,m / z):994(M + +1).
[0308] Example 32: Synthesis of Compound S4
[0309]
[0310] The raw material 21 (638 mg, 1 mmol) was dissolved in DMF (5 mL), and 57b (518 mg, 1.5 mmol), DIPEA (0.53 mL, 3 mmol) and NaI (15 mg, 0.1 mmol) were added to the solution. The mixture was reacted at 60 °C for 5 hours. After the reaction was completed, it was concentrated under reduced pressure and purified by column chromatography to obtain compound S4 (193 mg, 20%). 1H NMR (500MHz, DMSO-d6) δ11.02(s,1H),8.57(s,1H),8.11(d,J=4.9Hz,1H),7.90(dd,J=7.2,2.3Hz,1H),7.53–7.41(m ,3H),7.33(s,1H),7.13(s,1H),7.02(t,J=3.7Hz,1H),6.62(d,J=4.9Hz,1H),5.12(s,1H),4.92(s,1H),4.11(d,J=14 .5Hz,2H),3.96(s,1H),3.73(s,4H),3.69–3.61(m,6H),3.59(s,1H),3.47(s,2H),3.44–3.36(m,9H),2.93(s,3H),2 .66(s,1H),2.61(s,1H),2.56–2.47(m,4H),2.39(s,1H),1.99(s,1H),1.89(s,1H),1.29(s,6H).MS(ESI,m / z):966(M + +1).
[0311] Example 33: Synthesis of Compound S5
[0312]
[0313] According to the synthesis of compound S1, the corresponding intermediate was replaced to obtain compound S5. 1 H NMR(500MHz,DMSO-d6)δ9.96(s,1H),8.57(s,1H),8.11(d,J=4.9Hz,1H),7.98(dd,J=7.5,2.0Hz,1H),7.44(t,J=7.5Hz,1 H),7.33(s,1H),7.10–7.02(m,3H),6.62(d,J=4.9Hz,1H),5.12(s,1H),4.92(s,1H),4.17–4.08(m,4H),3.96(s,1H),3.69 (d,J=10.2Hz,6H),3.63(d,J=4.7Hz,4H),3.59(s,1H),3.47(s,2H),3.40(s,3H),2.99(s,4H),2.91(d,J=20.0Hz,5H),2.6 6(s,1H),2.61(s,1H),2.54(s,1H),2.49(s,1H),2.39(s,1H),1.99(s,1H),1.89(s,1H),1.29(s,6H).MS(ESI,m / z):939(M + +1).
[0314] Example 34: Synthesis of Compound S6
[0315]
[0316] According to the synthesis of compound S1, the corresponding intermediate was replaced to obtain compound S6. 1 H NMR (500MHz, DMSO-d6) δ11.02(s,1H),8.57(s,1H),8.11(d,J=4.9Hz,1H),7.96(dd,J=7.5,2.0Hz,1H),7.51(t,J=7.5Hz,1H),7.3 3(s,1H),7.10–7.04(m,3H),6.62(d,J=4.9Hz,1H),5.12(s,1H),4.92(s,1H),4.11(d,J=14.5Hz,2H),4.04–3.93(m,3H),3.69(d, J=8.2Hz,6H),3.63(d,J=4.7Hz,4H),3.59(s,1H),3.47(s,2H),3.40(s,3H),2.94(d,J=10.1Hz,7H),2.66(s,1H),2.61(s,1H),2. 54(s,1H),2.48(d,J=8.1Hz,3H),2.39(s,1H),1.99(s,1H),1.90(d,J=14.5Hz,3H),1.58(s,2H),1.29(s,6H).MS(ESI,m / z):967(M + +1).
[0317] Example 35: Synthesis of Compound S7
[0318]
[0319] According to the synthesis of compound S1, the corresponding intermediate was replaced to obtain compound S7. 1H NMR (500MHz, DMSO-d6) δ11.02(s,1H),8.57(s,1H),8.11(d,J=4.9Hz,1H),7.81(dd,J=7.2,2.3Hz,1H),7.53–7.43(m,2H),7.33(s ,1H),7.04(s,1H),7.02(t,J=3.7Hz,1H),6.62(d,J=4.9Hz,1H),4.92(s,1H),4.39(s,1H),4.26(s,1H),4.15(s,1H),4.10(s,1H) ,4.06(s,1H),4.01(s,1H),3.96(s,1H),3.85(s,1H),3.70–3.61(m,8H),3.61–3.44(m,4H),3.40(s,3H),2.93(s,3H),2.75(s,4H ),2.62–2.53(m,3H),2.39(s,1H),2.19(s,1H),2.12(s,1H),1.89(s,1H),1.32(d,J=3.1Hz,6H),1.26(s,3H).MS(ESI,m / z):933(M + +1).
[0320] Example 36: Synthesis of Compound S8
[0321]
[0322] According to the synthesis of compound S1, the corresponding intermediate was replaced to obtain compound S8. 1H NMR (500MHz, DMSO-d6) δ11.02(s,1H),8.57(s,1H),8.11(d,J=4.9Hz,1H),7.81(dd,J=7.4,2.1Hz,1H),7.56(dd,J=7.4,2.1Hz,1H),7.47(t,J=7.5Hz,1H ),7.33(s,1H),7.08(s,1H),7.02(t,J=3.7Hz,1H),6.62(d,J=4.9Hz,1H),4 .92(s,1H),4.47(s,1H),4.32(s,1H),4.11(d,J=14.5Hz,2H),4.06(s,1H),4 .01(s,1H),3.96(s,1H),3.85(s,1H),3.68(s,4H),3.63(d,J=6.6Hz,2H),3 .59(s,1H),3.53(d,J=17.2Hz,1H),3.51–3.44(m,2H),3.40(s,3H),2.97–2. 91(m,7H),2.75(s,2H),2.63–2.50(m,5H),2.39(s,1H),2.19(s,1H),2.12( s,1H),1.89(s,1H),1.32(d,J=3.1Hz,6H),1.26(s,3H).MS(ESI,m / z):947(M + +1).
[0323] Example 37: Synthesis of Compound S9
[0324]
[0325] According to the synthesis of compound S1, the corresponding intermediate was replaced to obtain compound S9. 1H NMR (500MHz, DMSO-d6) δ11.02(s,1H),8.57(s,1H),8.11(d,J=4.9Hz,1H),7.81(dd,J=7.2,2.3Hz,1H),7.53–7.43(m,2 H),7.33(s,1H),7.04(s,1H),7.02(t,J=3.7Hz,1H),6.62(d,J=4.9Hz,1H),4.92(s,1H),4.39(s,1H),4.26(s,1H),4.15 (s,1H),4.10(s,1H),4.01(s,1H),3.96(s,1H),3.72–3.61(m,12H),3.59(s,1H),3.47(s,2H),3.40(s,3H),2.93(s,3H) ,2.75(s,4H),2.63–2.56(m,3H),2.39(s,1H),2.19(s,1H),2.12(s,1H),1.89(s,1H),1.29(s,6H).MS(ESI,m / z):919(M + +1).
[0326] Example 38: Synthesis of Compound S10
[0327]
[0328] According to the synthesis of compound S1, the corresponding intermediate was replaced to obtain compound S10. 1H NMR (500MHz, DMSO-d6) δ11.02(s,1H),8.57(s,1H),8.11(d,J=4.9Hz,1H),7.81(dd,J=7.4,2.1Hz,1H),7.56(dd,J=7.4,2.1Hz,1H),7.47(t, J=7.5Hz,1H),7.33(s,1H),7.08(s,1H),7.02(t,J=3.7Hz,1H),6.62(d,J=4.9Hz,1H),4.92(s,1H),4.47(s,1H),4.32(s,1H),4.11(d,J=14.5 Hz,2H),4.01(s,1H),3.96(s,1H),3.69(d,J=10.2Hz,6H),3.63(d,J=4.7Hz,4H),3.59(s,1H),3.47(s,2H),3.40(s,3H),2.97–2.91(m,7H),2 .75(s,2H),2.63–2.56(m,4H),2.54(d,J=12.3Hz,1H),2.39(s,1H),2.19(s,1H),2.12(s,1H),1.89(s,1H),1.29(s,6H).MS(ESI,m / z):933(M + +1).
[0329] Example 39: Synthesis of Compound S11
[0330]
[0331] According to the synthesis of compound S1, the corresponding intermediate was replaced to obtain compound S11. 1H NMR(500MHz,DMSO-d6)δ11.02(s,1H),8.57(s,1H),8.11(d,J=4.9Hz,1H),7.81(dd,J=7.0,2.5Hz,1H),7.53–7.43(m,2H),7.33(s,1H) ,7.08(s,1H),7.02(t,J=3.7Hz,1H),6.62(d,J=4.9Hz,1H),4.92(s,1H),4.45(s,1H),4.32(s,1H),4.15(s,1H),4.10(s,1H),4.01(s,1 H),3.96(s,1H),3.69(d,J=8.2Hz,6H),3.63(d,J=4.7Hz,4H),3.59(s,1H),3.47(s,2H),3.40(s,3H),3.02(s,2H),2.94(d,J=10.1Hz,5 H),2.65–2.52(m,7H),2.39(s,1H),2.19(s,1H),2.12(s,1H),1.89(s,1H),1.54(s,2H),1.48(s,2H),1.29(s,6H).MS(ESI,m / z):961(M + +1).
[0332] Example 40: Synthesis of Compound S12
[0333]
[0334] According to the synthesis of compound S1, the corresponding intermediate was replaced to obtain compound S12. 1H NMR(500MHz,DMSO-d6)δ11.02(s,1H),8.57(s,1H),8.11(d,J=4.9Hz,1H),7.81(dd,J=7.0,2.5Hz,1H),7.53–7.43(m,2H),7.33(s,1H),7.0 8(s,1H),7.02(t,J=3.7Hz,1H),6.62(d,J=4.9Hz,1H),4.92(s,1H),4.47(s,1H),4.32(s,1H),4.11(d,J=14.5Hz,2H),4.01(s,1H),3.96(s, 1H),3.69(d,J=8.2Hz,6H),3.63(d,J=4.7Hz,4H),3.59(s,1H),3.47(s,2H),3.40(s,3H),3.12(s,2H),2.94(d,J=10.1Hz,5H),2.64–2.56( m,5H),2.52(s,2H),2.39(s,1H),2.19(s,1H),2.12(s,1H),1.89(s,1H),1.56(s,2H),1.48(s,2H),1.32–1.27(m,10H).MS(ESI,m / z):989(M + +1).
[0335] Example 41: Synthesis of Compound S13
[0336]
[0337] According to the synthesis of compound S1, the corresponding intermediate was replaced to obtain compound S13. 1H NMR (500MHz, DMSO-d6) δ11.02(s,1H),8.57(s,1H),8.11(d,J=4.9Hz,1H),7.89(d,J=7.5Hz,1H),7.69–7.61(m,2H),7.33(s,1H) ,7.04(s,1H),7.02(t,J=3.7Hz,1H),6.62(d,J=4.9Hz,1H),4.92(s,1H),4.58(d,J=1.1Hz,1H),4.48(d,J=0.9Hz,1H),4.15(s,1H ),4.10(s,1H),4.01(s,1H),3.96(s,1H),3.73–3.66(m,8H),3.63(d,J=4.7Hz,4H),3.59(s,1H),3.47(s,2H),3.40(s,3H),2.93( s,3H),2.75(s,4H),2.60(d,J=5.2Hz,3H),2.39(s,1H),2.19(s,1H),2.12(s,1H),1.89(s,1H),1.29(s,6H).MS(ESI,m / z):919(M + +1).
[0338] Example 42: Synthesis of Compound S14
[0339]
[0340] According to the synthesis of compound S1, the corresponding intermediate was replaced to obtain compound S14. 1H NMR (500MHz, DMSO-d6) δ11.02(s,1H),8.57(s,1H),8.11(d,J=4.9Hz,1H),7.90(d,J=7.5Hz,1H),7.74(dd,J=7.4,1.9Hz,1H),7.63(dt, J=1.9,0.9Hz,1H),7.33(s,1H),7.08(s,1H),7.02(t,J=3.7Hz,1H),6.62(d,J=4.9Hz,1H),4.92(s,1H),4.57(dd,J=5.0,1.0Hz,2H),4. 11(d,J=14.5Hz,2H),4.01(s,1H),3.96(s,1H),3.69(d,J=10.2Hz,6H),3.63(d,J=4.7Hz,4H),3.59(s,1H),3.47(s,2H),3.40(s,3H),3 .04–2.91(m,7H),2.75(s,2H),2.63–2.58(m,5H),2.39(s,1H),2.19(s,1H),2.12(s,1H),1.89(s,1H),1.29(s,6H).MS(ESI,m / z):933(M + +1).
[0341] Example 43: Synthesis of Compound S15
[0342]
[0343] According to the synthesis of compound S1, the corresponding intermediate was replaced to obtain compound S15. 1H NMR(500MHz,DMSO-d6)δ11.02(s,1H),8.57(s,1H),8.14–8.06(m,2H),7.50(dd,J=7.5,2.0Hz,1H),7.33(s,1H),7.17(dt ,J=7.6,1.0Hz,1H),7.04(s,1H),7.02(t,J=3.7Hz,1H),6.62(d,J=4.9Hz,1H),4.92(s,1H),4.57(dd,J=5.0,1.0Hz,2H),4 .11(d,J=14.5Hz,2H),4.01(s,1H),3.96(s,1H),3.72–3.61(m,12H),3.59(s,1H),3.47(s,2H),3.40(s,3H),2.93(s,3H), 2.75(s,4H),2.60(d,J=5.2Hz,3H),2.39(s,1H),2.19(s,1H),2.12(s,1H),1.89(s,1H),1.29(s,6H).MS(ESI,m / z):919(M + +1).
[0344] Example 44: Synthesis of Compound S16
[0345]
[0346] According to the synthesis of compound S1, the corresponding intermediate was replaced to obtain compound S16. 1H NMR(500MHz,DMSO-d6)δ11.02(s,1H),8.57(s,1H),8.11(d,J=4.9Hz,1H),7 .92(d,J=2.0Hz,1H),7.47(dd,J=7.5,2.0Hz,1H),7.33(s,1H),7.18(dt,J= 7.5,1.0Hz,1H),7.08(s,1H),7.02(t,J=3.7Hz,1H),6.62(d,J=4.9Hz,1H), 4.92(s,1H),4.57(dd,J=8.3,1.0Hz,2H),4.11(d,J=14.5Hz,2H),4.01(s,1H ),3.96(s,1H),3.69(d,J=10.2Hz,6H),3.63(d,J=4.7Hz,4H),3.59(s,1H), 3.47(s,2H),3.40(s,3H),3.12(s,2H),2.94(d,J=10.1Hz,5H),2.81(s,2H), 2.60(d,J=5.1Hz,3H),2.55(s,2H),2.39(s,1H),2.19(s,1H),2.12(s,1H), 1.92–1.86(m,2H),1.80(d,J=12.5Hz,1H),1.29(s,6H).MS(ESI,m / z):947(M + +1).
[0347] Example 45: Synthesis of Compound S17
[0348]
[0349] According to the synthesis of compound S1, the corresponding intermediate was replaced to obtain compound S17. 1H NMR (500MHz, DMSO-d6) δ11.02(s,1H),8.57(s,1H),8.11(d,J=4.9Hz,1H),7.66(dd,J=7.5,2.0Hz,1H),7.41(t,J=7.5Hz,1H),7.33(s ,1H),7.24(ddt,J=7.5,2.0,0.9Hz,1H),7.04(s,1H),7.02(t,J=3.7Hz,1H),6.62(d,J=4.9Hz,1H),4.92(s,1H),4.58(d,J=1.1Hz,1H ),4.48(d,J=0.9Hz,1H),4.11(d,J=14.5Hz,2H),4.01(s,1H),3.96(s,1H),3.72–3.61(m,12H),3.59(s,1H),3.47(s,2H),3.40(s,3H ),2.93(s,3H),2.75(s,4H),2.63–2.56(m,3H),2.39(s,1H),2.19(s,1H),2.12(s,1H),1.89(s,1H),1.29(s,6H).MS(ESI,m / z):919(M + +1).
[0350] Example 46: Synthesis of Compound S18
[0351]
[0352] According to the synthesis of compound S1, the corresponding intermediate was replaced to obtain compound S18. 1H NMR (500MHz, DMSO-d6) δ11.02(s,1H),8.57(s,1H),8.11(d,J=4.9Hz,1H),7.70(dd,J=7.4,2.1Hz,1H),7.36–7.29(m,2H),7.24(ddt,J=7.5,2.0, 1.0Hz,1H),7.08(s,1H),7.02(t,J=3.7Hz,1H),6.62(d,J=4.9Hz,1H),4 .92(s,1H),4.58(d,J=1.1Hz,1H),4.48(d,J=0.9Hz,1H),4.11(d,J=14.5 Hz, 2H), 4.01 (s, 1H), 3.96 (s, 1H), 3.69 (d, J = 10.2Hz, 6H), 3.63 (d, J = 4. 7Hz,4H),3.59(s,1H),3.47(s,2H),3.40(s,3H),3.12(s,2H),2.94(d,J= 10.1Hz,5H),2.75(s,2H),2.63–2.53(m,5H),2.39(s,1H),2.19(s,1H), 2.12(s,1H),1.95(s,2H),1.89(s,1H),1.29(s,6H).MS(ESI,m / z):947(M + +1).
[0353] Example 47: Synthesis of Compound S19
[0354]
[0355] According to the synthesis of compound S1, the corresponding intermediate was replaced to obtain compound S19. 1H NMR (500MHz, DMSO-d6) δ11.02(s,1H),8.57(s,1H),8.11(d,J=4.9Hz,1H),7.86(d,J=7.5Hz,1H),7.59(d,J=2.0Hz,1H),7.42(dd,J=7.5,2. 0Hz,1H),7.33(s,1H),7.08(s,1H),7.02(t,J=3.7Hz,1H),6.62(d,J=4.9Hz,1H),5.01(s,1H),4.92(s,1H),4.11(d,J=14.5Hz,2H),3.96(s ,1H),3.69(d,J=8.2Hz,6H),3.63(d,J=4.7Hz,4H),3.59(s,1H),3.47(s,2H),3.40(d,J=5.3Hz,5H),3.24(s,2H),3.11(s,1H),2.93(s,3H) ,2.74(s,4H),2.65–2.59(m,3H),2.39(s,1H),2.23(d,J=3.8Hz,2H),1.88(d,J=4.6Hz,3H),1.80(s,2H),1.29(s,6H).MS(ESI,m / z):978(M + +1).
[0356] Example 48: Synthesis of Compound S20
[0357]
[0358] According to the synthesis of compound S1, the corresponding intermediate was replaced to obtain compound S20. 1H NMR (500MHz, DMSO-d6) δ11.02(s,1H),8.57(s,1H),8.11(d,J=4.9Hz,1H),7.83(d,J=7.5Hz,1H),7.49(d,J=2.0Hz ,1H),7.41–7.31(m,2H),7.04(s,1H),7.02(t,J=3.7Hz,1H),6.62(d,J=4.9Hz,1H),5.01(s,1H),4.92(s,1H),4.1 1(d,J=14.5Hz,2H),3.96(s,1H),3.72–3.61(m,12H),3.59(s,1H),3.47(s,2H),3.42–3.36(m,6H),2.93(s,3H),2 .74(s,4H),2.65–2.59(m,3H),2.39(s,1H),2.24(d,J=0.9Hz,2H),1.89(s,1H),1.29(s,6H).MS(ESI,m / z):950(M + +1).
[0359] Example 49: Synthesis of Compound S21
[0360]
[0361] According to the synthesis of compound S1, the corresponding intermediate was replaced to obtain compound S21. 1H NMR (500MHz, DMSO-d6) δ11.02(s,1H),8.57(s,1H),8.11(d,J=4.9Hz,1H),7.86(d,J=7.5Hz,1H),7.59(d,J=2.0Hz,1H),7.42(dd,J=7.5,2.0Hz,1H),7. 33(s,1H),7.08(s,1H),7.02(t,J=3.7Hz,1H),6.62(d,J=4.9Hz,1H),5.01( s,1H),4.92(s,1H),4.11(d,J=14.5Hz,2H),4.06(s,1H),3.96(s,1H),3.85( s,1H),3.69(s,4H),3.63(d,J=6.6Hz,2H),3.61–3.44(m,4H),3.40(d,J=5. 3Hz,5H),3.24(s,2H),3.11(s,1H),2.93(s,3H),2.74(s,4H),2.62(d,J=11 .5Hz,2H),2.55(s,1H),2.39(s,1H),2.23(d,J=3.8Hz,2H),1.88(d,J=4.6H z,3H),1.80(s,2H),1.32(d,J=3.1Hz,6H),1.26(s,3H).MS(ESI,m / z):992(M + +1).
[0362] Example 50: Synthesis of Compound S22
[0363]
[0364] According to the synthesis of compound S1, the corresponding intermediate was replaced to obtain compound S22. 1HNMR(500MHz,DMSO-d6)δ11.02(s,1H),8.57(s,1H),8.11(d,J=4.9Hz,1H),7.83(d,J=7.5Hz,1H),7.49(d,J=2.0Hz,1H),7.41–7.31(m,2H ),7.04(s,1H),7.02(t,J=3.7Hz,1H),6.62(d,J=4.9Hz,1H),5.01(s,1H),4.92(s,1H),4.11(d,J=14.5Hz,2H),4.06(s,1H),3.96(s,1H), 3.85(s,1H),3.70–3.61(m,8H),3.59(s,1H),3.53(d,J=17.2Hz,1H),3.51–3.44(m,2H),3.42–3.36(m,6H),2.93(s,3H),2.74(s,4H),2.6 2(d,J=11.5Hz,2H),2.55(s,1H),2.39(s,1H),2.24(d,J=0.9Hz,2H),1.89(s,1H),1.32(d,J=3.1Hz,6H),1.26(s,3H).MS(ESI,m / z):964(M + +1).
[0365] Example 51: Synthesis of Compound S23
[0366]
[0367] According to the synthesis of compound S1, the corresponding intermediate was replaced to obtain compound S23. 1H NMR (500MHz, DMSO-d6) δ11.02(s,1H),8.57(s,1H),8.11(d,J=4.9Hz,1H),7.77(d,J=7.5Hz,1H),7.59(d,J=2.0Hz,1H),7.41(dd,J=7.5,1 .8Hz,1H),7.33(s,1H),7.08(s,1H),7.02(t,J=3.7Hz,1H),6.62(d,J=4.9Hz,1H),5.01(s,1H),4.92(s,1H),4.11(d,J=14.5Hz,2H),3.96( s,1H),3.69(d,J=10.2Hz,6H),3.63(d,J=4.7Hz,4H),3.59(s,1H),3.47(s,2H),3.40(s,3H),3.32(d,J=10.1Hz,4H),2.93(s,3H),2.75(s, 4H),2.65–2.59(m,3H),2.48(s,2H),2.39(s,1H),2.23(d,J=3.8Hz,2H),2.03(s,1H),1.91–1.84(m,5H),1.29(s,6H).MS(ESI,m / z):992(M + +1).
[0368] Example 52: Synthesis of Compound S24
[0369]
[0370] According to the synthesis of compound S1, the corresponding intermediate was replaced to obtain compound S24. 1H NMR (500MHz, DMSO-d6) δ11.02(s,1H),8.57(s,1H),8.11(d,J=4.9Hz,1H),7.86(d,J=7.5Hz,1H),7.49(d,J=2.0Hz,1H),7.42(dd, J=7.5,2.0Hz,1H),7.33(s,1H),7.08(s,1H),7.02(t,J=3.7Hz,1H),6.62(d,J=4.9Hz,1H),5.01(s,1H),4.92(s,1H),4.11(d,J=14 .5Hz,2H),3.96(s,1H),3.75–3.66(m,10H),3.63(d,J=4.7Hz,4H),3.59(s,1H),3.47(s,2H),3.40(s,3H),2.93(s,3H),2.74(s,4 H),2.65–2.59(m,3H),2.53–2.44(m,2H),2.44–2.37(m,2H),2.23(d,J=3.8Hz,2H),1.89(s,1H),1.29(s,6H).MS(ESI,m / z):964(M + +1).
[0371] Example 53: Synthesis of Compound S25
[0372]
[0373] According to the synthesis of compound S1, the corresponding intermediate was replaced to obtain compound S25. 1H NMR (500MHz, DMSO-d6) δ11.02(s,1H),8.57(s,1H),8.11(d,J=4.9Hz,1H),7.83(d,J=7.5Hz,1H),7.60(d,J=2.0Hz,1H),7.41(dd,J=7.4,1.9Hz,1 H),7.33(s,1H),7.22(s,1H),7.02(t,J=3.7Hz,1H),6.62(d,J=4.9Hz,1H ),5.01(s,1H),4.92(s,1H),4.11(d,J=14.5Hz,2H),3.96(s,1H),3.89(s ,2H),3.72–3.67(m,8H),3.63(d,J=4.7Hz,4H),3.59(s,1H),3.47(s,2H ),3.40(s,3H),3.15(s,1H),2.93(s,3H),2.67(s,4H),2.65–2.59(m,3H) ,2.39(s,1H),2.23(d,J=3.8Hz,2H),1.89(s,1H),1.72(d,J=13.0Hz,2H) ,1.45(s,4H),1.29(s,6H),1.22(d,J=13.0Hz,2H).MS(ESI,m / z):1018(M + +1).
[0374] Example 54: Synthesis of Compound S26
[0375]
[0376] According to the synthesis of compound S1, the corresponding intermediate was replaced to obtain compound S26. 1H NMR (500MHz, DMSO-d6) δ11.02(s,1H),8.57(s,1H),8.11(d,J=4.9Hz,1H),7.83(d,J=7.5Hz,1H),7.60(d,J=2.0Hz,1H),7.41(dd,J= 7.4,1.9Hz,1H),7.33(s,1H),7.22(s,1H),7.02(t,J=3.7Hz,1H),6.62(d,J=4.9Hz,1H),5.01(s,1H),4.92(s,1H),4.11(d,J=14.5H z,2H),3.96(s,1H),3.69(d,J=8.2Hz,6H),3.66–3.57(m,7H),3.55(s,2H),3.47(s,2H),3.40(s,3H),3.02(s,1H),2.93(s,3H),2.7 4(s,2H),2.67(s,2H),2.65–2.59(m,3H),2.39(s,1H),2.23(d,J=3.8Hz,2H),1.97–1.81(m,9H),1.29(s,6H).MS(ESI,m / z):1018(M + +1).
[0377] Example 55: Synthesis of Compound S27
[0378]
[0379] According to the synthesis of compound S1, the corresponding intermediate was replaced to obtain compound S27. 1H NMR (500MHz, DMSO-d6) δ11.02(s,1H),8.57(s,1H),8.11(d,J=4.9Hz,1H),7.77(d,J=7.5Hz,1H),7.55(d,J=2.0Hz,1H),7.41(dd,J=7 .4,1.9Hz,1H),7.33(s,1H),7.17(s,1H),7.02(t,J=3.7Hz,1H),6.62(d,J=4.9Hz,1H),5.01(s,1H),4.92(s,1H),4.11(d,J=14.5Hz, 2H),3.96(s,1H),3.85(s,2H),3.69(d,J=8.2Hz,6H),3.66–3.57(m,7H),3.47(s,2H),3.40(s,3H),2.92(d,J=9.9Hz,4H),2.74(s,4H ),2.65–2.59(m,3H),2.39(s,1H),2.23(d,J=3.8Hz,2H),1.96(d,J=13.0Hz,2H),1.91–1.82(m,3H),1.29(s,6H).MS(ESI,m / z):990(M + +1).
[0380] Example 56: Synthesis of Compound S28
[0381]
[0382] According to the synthesis of compound S1, the corresponding intermediate was replaced to obtain compound S28. 1HNMR(500MHz,DMSO-d6)δ11.02(s,1H),8.57(s,1H),8.11(d,J=4.9Hz,1H),7.77(d,J=7.5Hz,1H),7.55(d,J=2.0Hz,1H),7.41(dd,J=7.4, 1.9Hz,1H),7.33(s,1H),7.22(s,1H),7.02(t,J=3.7Hz,1H),6.62(d,J=4.9Hz,1H),5.01(s,1H),4.92(s,1H),4.11(d,J=14.5Hz,2H),3.9 6(s,1H),3.69(d,J=8.2Hz,6H),3.63(d,J=4.7Hz,4H),3.59(s,1H),3.56–3.44(m,6H),3.40(s,3H),3.10(s,1H),2.93(s,3H),2.67(s,4H ),2.65–2.59(m,3H),2.39(s,1H),2.23(d,J=3.8Hz,2H),2.02(s,2H),1.89(s,1H),1.83–1.73(m,4H),1.29(s,6H).MS(ESI,m / z):1004(M + +1).
[0383] Example 57: Synthesis of Compound S29
[0384]
[0385] According to the synthesis of compound S1, the corresponding intermediate was replaced to obtain compound S29. 1H NMR (500MHz, DMSO-d6) δ11.02(s,1H),8.57(s,1H),8.11(d,J=4.9Hz,1H),7.83(d,J=7.5Hz,1H),7.60(d,J=2.0Hz,1H),7.41–7.31(m ,2H),7.04(s,1H),7.02(t,J=3.7Hz,1H),6.62(d,J=4.9Hz,1H),5.01(s,1H),4.92(s,1H),4.11(d,J=14.5Hz,2H),3.96(s,1H),3.77( s,2H),3.72–3.66(m,8H),3.63(d,J=4.7Hz,4H),3.59(s,1H),3.47(s,2H),3.41(d,J=11.3Hz,4H),3.31(s,1H),3.01(s,2H),2.93(s, 3H),2.84(s,2H),2.73(s,4H),2.65–2.59(m,3H),2.39(s,1H),2.24(d,J=0.9Hz,2H),1.89(s,1H),1.29(s,6H).MS(ESI,m / z):1005(M + +1).
[0386] Example 58: Synthesis of Compound S30
[0387]
[0388] According to the synthesis of compound S1, the corresponding intermediate was replaced to obtain compound S30. 1H NMR (500MHz, DMSO-d6) δ11.02(s,1H),8.57(s,1H),8.11(d,J=4.9Hz,1H),7.83(d,J=7.4Hz,1H),7.51–7.41(m,2H),7.33(s,1H),7.17(s ,1H),7.02(t,J=3.7Hz,1H),6.62(d,J=4.9Hz,1H),5.01(s,1H),4.92(s,1H),4.11(d,J=14.5Hz,2H),3.96(s,1H),3.72–3.66(m,8H),3.6 3(d,J=4.7Hz,4H),3.59(s,1H),3.47(s,2H),3.40(d,J=0.7Hz,5H),3.09(s,1H),3.03(s,1H),2.93(s,3H),2.75(s,4H),2.68(s,2H),2. 65–2.59(m,3H),2.55(s,2H),2.39(s,1H),2.24(d,J=0.9Hz,2H),1.89(s,1H),1.63(d,J=10.1Hz,4H),1.29(s,6H).MS(ESI,m / z):1033(M + +1).
[0389] Example 59: Synthesis of Compound S31
[0390]
[0391] According to the synthesis of compound S1, the corresponding intermediate was replaced to obtain compound S31. 1H NMR (500MHz, DMSO-d6) δ11.02(s,1H),8.57(s,1H),8.11(d,J=4.9Hz,1H),7.86(d,J=7.5Hz,1H),7.59(d,J=2.0Hz,1H),7.42(dd,J=7.5,2. 0Hz,1H),7.33(s,1H),7.04(s,1H),7.02(t,J=3.7Hz,1H),6.62(d,J=4.9Hz,1H),5.01(s,1H),4.92(s,1H),4.11(d,J=14.5Hz,2H),3.96(s, 1H),3.69(d,J=10.2Hz,6H),3.63(d,J=4.7Hz,4H),3.59(s,1H),3.53–3.45(m,6H),3.40(s,3H),3.14(s,1H),2.93(s,3H),2.81(d,J=9.3H z,3H),2.72(d,J=14.1Hz,6H),2.65–2.59(m,3H),2.39(s,1H),2.23(d,J=3.8Hz,2H),1.91–1.81(m,5H),1.29(s,6H).MS(ESI,m / z):1033(M + +1).
[0392] Example 60: Synthesis of Compound S32
[0393]
[0394] According to the synthesis of compound S1, the corresponding intermediate was replaced to obtain compound S32. 1H NMR (500MHz, DMSO-d6) δ11.02(s,1H),8.57(s,1H),8.11(d,J=4.9Hz,1H),7.83(d,J=7.5Hz,1H),7.49(d,J=2.0Hz,1H),7.41–7.31(m,2H ),7.04(s,1H),7.02(t,J=3.7Hz,1H),6.62(d,J=4.9Hz,1H),5.01(s,1H),4.92(s,1H),4.11(d,J=14.5Hz,2H),3.96(s,1H),3.77(d,J=9 .5Hz,1H),3.69(d,J=10.2Hz,6H),3.63(d,J=4.7Hz,4H),3.59(s,1H),3.47(q,J=4.5Hz,4H),3.40(s,3H),3.34(d,J=9.5Hz,1H),2.94(d ,J=10.1Hz,4H),2.72(s,4H),2.65–2.59(m,3H),2.39(s,1H),2.23(d,J=3.8Hz,2H),1.95–1.87(m,3H),1.29(s,6H).MS(ESI,m / z):964(M + +1).
[0395] Example 61: Synthesis of Compound S33
[0396]
[0397] According to the synthesis of compound S1, the corresponding intermediate was replaced to obtain compound S33. 1H NMR (500MHz, DMSO-d6) δ11.02(s,1H),8.57(s,1H),8.11(d,J=4.9Hz,1H),7.83(d,J=7.5Hz,1H),7.49(d,J=2.0Hz,1H),7.41(dd,J=7.4,1.9Hz,1H ),7.33(s,1H),7.22(s,1H),7.02(t,J=3.7Hz,1H),6.62(d,J=4.9Hz,1H) ,5.01(s,1H),4.92(s,1H),4.11(d,J=14.5Hz,2H),3.96(s,1H),3.77(s,2 H),3.69(d,J=8.2Hz,6H),3.63(d,J=4.7Hz,4H),3.59(s,1H),3.49(d,J= 18.1Hz,4H),3.40(s,3H),3.16(d,J=9.4Hz,3H),3.11(s,1H),2.93(s,3H) ,2.69–2.59(m,9H),2.39(s,1H),2.24(d,J=0.9Hz,2H),2.00(s,2H),1.9 5–1.87(m,3H),1.76(d,J=13.0Hz,2H),1.29(s,6H).MS(ESI,m / z):1059(M + +1).
[0398] Example 62: Synthesis of Compound S34
[0399]
[0400] According to the synthesis of compound S1, compound S34 was obtained by replacing the corresponding intermediate. 1H NMR (500MHz, DMSO-d6) δ11.02(s,1H),8.57(s,1H),8.11(d,J=4.9Hz,1H),7.86(d,J=7.5Hz,1H),7.59(d,J=2.0Hz,1H),7.42(dd,J=7.5,2.0Hz,1H), 7.33(s,1H),7.17(s,1H),7.02(t,J=3.7Hz,1H),6.62(d,J=4.9Hz,1H),5. 01(s,1H),4.92(s,1H),4.11(d,J=14.5Hz,2H),3.96(s,1H),3.69(d,J=8.2 Hz,6H),3.63(d,J=4.7Hz,4H),3.59(s,1H),3.49–3.44(m,6H),3.40(s,3H) ),3.11(s,1H),3.00(s,1H),2.93(s,3H),2.74(s,4H),2.68(s,4H),2.65– 2.59(m,3H),2.39(s,1H),2.23(d,J=3.8Hz,2H),2.07(d,J=13.0Hz,2H),1 .88(d,J=4.6Hz,3H),1.86–1.78(m,4H),1.29(s,6H).MS(ESI,m / z):1073(M + +1).
[0401] Example 63: Synthesis of Compound S35
[0402]
[0403] According to the synthesis of compound S1, compound S35 was obtained by replacing the corresponding intermediate. 1H NMR (500MHz, DMSO-d6) δ11.02(s,1H),8.34(s,1H),8.11(d,J=4.9Hz,1H),7.83(d,J=7.5Hz,1H),7.49(d,J=2.0Hz,1H),7.39(dd ,J=7.5,1.8Hz,1H),7.33(s,1H),7.13(s,1H),7.02(t,J=3.7Hz,1H),6.62(d,J=4.9Hz,1H),5.01(s,1H),4.92(s,1H),4.28(s,4H ),4.21(s,2H),4.13(s,1H),4.10(s,1H),4.04(s,2H),3.96(s,1H),3.67(s,2H),3.66–3.60(m,5H),3.59(s,1H),3.47(s,2H),3. 40(s,3H),2.93(s,3H),2.62(d,J=9.2Hz,2H),2.39(s,1H),2.23(d,J=3.8Hz,2H),1.89(s,1H),1.29(s,6H).MS(ESI,m / z):895(M + +1).
[0404] Example 64: Synthesis of Compound S36
[0405]
[0406] According to the synthesis of compound S1, the corresponding intermediate was replaced to obtain compound S36. 1H NMR (500MHz, DMSO-d6) δ11.02(s,1H),8.57(s,1H),8.11(d,J=4.9Hz,1H),7.83(d,J=7.5Hz,1H),7.60(d,J=2.0Hz,1H),7.41–7. 31(m,2H),7.08(s,1H),7.02(t,J=3.7Hz,1H),6.62(d,J=4.9Hz,1H),5.01(s,1H),4.92(s,1H),4.11(d,J=14.5Hz,2H),3.96(s,1 H),3.72–3.61(m,12H),3.59(s,1H),3.55–3.45(m,4H),3.40(s,3H),2.93(s,3H),2.75(s,4H),2.65–2.59(m,3H),2.56(s,2H), 2.39(s,1H),2.23(d,J=3.8Hz,2H),1.94(s,2H),1.89(s,1H),1.66(s,1H),1.61–1.50(m,4H),1.29(s,6H).MS(ESI,m / z):1018(M + +1).
[0407] Example 65: Synthesis of Compound S37
[0408]
[0409] According to the synthesis of compound S1, compound S37 was obtained by replacing the corresponding intermediate. 1H NMR (500MHz, DMSO-d6) δ11.02(s,1H),8.57(s,1H),8.11(d,J=4.9Hz,1H),7.77(d,J=7.5Hz,1H),7.55(d,J=2.0Hz,1H),7.41(dd,J=7.4,1.9Hz,1H ),7.33(s,1H),7.04(s,1H),7.02(t,J=3.7Hz,1H),6.62(d,J=4.9Hz,1H) ,5.01(s,1H),4.92(s,1H),4.11(d,J=14.5Hz,2H),3.96(s,1H),3.69(d,J =10.2Hz,6H),3.63(d,J=4.7Hz,4H),3.59(s,1H),3.56–3.44(m,6H),3.4 0(s,3H),3.14(s,1H),2.98(s,1H),2.93(d,J=2.4Hz,5H),2.84(s,2H),2 .72(s,4H),2.65–2.59(m,3H),2.39(s,1H),2.23(d,J=3.8Hz,2H),2.15( s,2H),1.89(s,1H),1.81–1.71(m,4H),1.29(s,6H).MS(ESI,m / z):1059(M + +1).
[0410] Example 66: Synthesis of Compound S38
[0411]
[0412] According to the synthesis of compound S1, compound S38 was obtained by replacing the corresponding intermediate. 1H NMR(500MHz,DMSO-d6)δ11.02(s,1H),8.57(s,1H),8.11(d,J=4.9Hz,1H),7.83(d ,J=7.5Hz,1H),7.59(d,J=2.0Hz,1H),7.42(dd,J=7.5,2.0Hz,1H),7.33(s,1H),7. 04(s,1H),7.02(t,J=3.7Hz,1H),6.62(d,J=4.9Hz,1H),5.01(s,1H),4.92(s,1H) ,4.15(s,1H),4.10(s,1H),3.96(s,1H),3.69(d,J=8.2Hz,6H),3.63(d,J=4.7Hz,4 H),3.57(d,J=13.9Hz,3H),3.47(d,J=4.6Hz,4H),3.40(s,3H),2.99(d,J=10.8Hz ,2H),2.93(s,3H),2.75(d,J=9.5Hz,1H),2.69(d,J=16.5Hz,5H),2.65–2.59(m,3H ),2.58–2.47(m,2H),2.39(s,1H),2.23(d,J=3.8Hz,2H),2.05(s,4H),1.89(s,1H ),1.70(s,1H),1.67–1.54(m,5H),1.49(s,4H),1.29(s,6H).MS(ESI,m / z):1115(M + +1).
[0413] Example 67: Synthesis of Compound S39
[0414]
[0415] According to the synthesis of compound S1, compound S39 was obtained by replacing the corresponding intermediate. 1H NMR (500MHz, DMSO-d6) δ11.02(s,1H),8.57(s,1H),8.11(d,J=4.9Hz,1H),7.83(d,J=7.5Hz,1H),7.60(d,J=2.0Hz,1H),7.41–7.31(m,2H),7.22(s, 1H),7.02(t,J=3.7Hz,1H),6.62(d,J=4.9Hz,1H),5.01(s,1H),4.92(s,1 H),4.11(d,J=14.5Hz,2H),3.96(s,1H),3.72–3.66(m,8H),3.63(d,J=4.7 Hz,4H),3.59(s,1H),3.47(s,2H),3.40(t,J=11.5Hz,6H),3.17(s,1H),3 .01(d,J=5.3Hz,3H),2.93(s,3H),2.87(s,2H),2.80(d,J=9.5Hz,2H),2.7 4–2.65(m,6H),2.65–2.59(m,3H),2.39(s,1H),2.24(d,J=0.9Hz,2H),1.9 5–1.87(m,5H),1.76(d,J=13.0Hz,2H),1.29(s,6H).MS(ESI,m / z):1114(M + +1).
[0416] Example 68: Synthesis of Compound S40
[0417]
[0418] According to the synthesis of compound S1, the corresponding intermediate was replaced to obtain compound S40. 1H NMR (500MHz, DMSO-d6) δ11.02(s,1H),8.57(s,1H),8.11(d,J=4.9Hz,1H),7.83(d,J=7.4Hz,1H),7.49(d,J=2.0Hz,1H),7.44(dd,J=7.5,2.0Hz,1H),7 .33(s,1H),7.17(s,1H),7.02(t,J=3.7Hz,1H),6.62(d,J=4.9Hz,1H),5.0 1(s,1H),4.92(s,1H),4.11(d,J=14.5Hz,2H),3.96(s,1H),3.73–3.66(m,8 H),3.63(d,J=4.7Hz,4H),3.59(s,1H),3.47(s,2H),3.40(d,J=0.7Hz,5H) ,3.11(s,1H),3.03(s,1H),2.93(s,3H),2.86(s,1H),2.74(s,4H),2.68(s, 4H),2.65–2.59(m,7H),2.39(s,1H),2.24(d,J=0.9Hz,2H),2.14(d,J=13.0 Hz,2H),1.94–1.81(m,5H),1.42(s,2H),1.29(s,6H).MS(ESI,m / z):1128(M + +1).
[0419] Example 69: Synthesis of Compound S41
[0420]
[0421] According to the synthesis of compound S1, the corresponding intermediate was replaced to obtain compound S41. 1H NMR (500MHz, DMSO-d6) δ11.02(s,1H),8.57(s,1H),8.11(d,J=4.9Hz,1H),7.86(d,J=7.5Hz,1H),7.49(d,J=2.0Hz,1H),7.42(dd,J=7.5,2.0Hz ,1H),7.33(s,1H),7.04(s,1H),7.02(t,J=3.7Hz,1H),6.62(d,J=4.9H z,1H),5.01(s,1H),4.92(s,1H),4.11(d,J=14.5Hz,2H),3.96(s,1H),3 .73–3.61(m,14H),3.59(s,1H),3.47(s,2H),3.40(s,3H),3.13(d,J=1 7.4Hz,2H),3.00(d,J=17.5Hz,5H),2.93(s,3H),2.84(d,J=1.8Hz,4H), 2.74(s,4H),2.65–2.59(m,3H),2.39(s,1H),2.23(d,J=3.8Hz,2H),2. 06(s,2H),1.89(s,1H),1.81(s,4H),1.29(s,6H).MS(ESI,m / z):1126(M + +1).
[0422] Example 70: Synthesis of Compound S42
[0423]
[0424] According to the synthesis of compound S1, the corresponding intermediate was replaced to obtain compound S42. 1H NMR (500MHz, DMSO-d6) δ11.02(s,1H),8.57(s,1H),8.11(d,J=4.9Hz,1H),7.86(d,J=7.5Hz,1H),7.49(d,J=2.0Hz,1H),7.42(dd,J=7.5,2. 0Hz,1H),7.33(s,1H),7.22(s,1H),7.02(t,J=3.7Hz,1H),6.62(d,J=4.9Hz,1H),5.01(s,1H),4.92(s,1H),4.11(d,J=14.5Hz,2H),3.96(s, 1H),3.73–3.61(m,14H),3.59(s,1H),3.47(s,2H),3.40(s,3H),3.10(s,1H),3.07–2.99(m,5H),2.95(d,J=17.6Hz,4H),2.73(d,J=8.4Hz, 6H),2.67(s,2H),2.65–2.59(m,3H),2.39(s,1H),2.23(d,J=3.8Hz,2H),2.06(s,2H),1.94–1.81(m,9H),1.29(s,6H).MS(ESI,m / z):1154(M + +1).
[0425] Example 71: Synthesis of Compound S43
[0426]
[0427] According to the synthesis of compound S1, the corresponding intermediate was replaced to obtain compound S43. 1H NMR (500MHz, DMSO-d6) δ11.02(s,1H),8.57(s,1H),8.11(d,J=4.9Hz,1H),7.86(d,J=7.5Hz,1H),7.59(d,J=2.0Hz,1H),7.42(dd,J=7. 5,2.0Hz,1H),7.33(s,1H),7.08(s,1H),7.02(t,J=3.7Hz,1H),6.62(d,J=4.9Hz,1H),5.01(s,1H),4.92(s,1H),4.11(d,J=14.5Hz,2H) ,3.96(s,1H),3.76(s,2H),3.69(d,J=14.1Hz,4H),3.63(s,3H),3.57(d,J=17.2Hz,2H),3.49–3.44(m,6H),3.40(s,3H),3.00(s,1H), 2.93(s,3H),2.65–2.59(m,7H),2.39(s,1H),2.23(d,J=3.8Hz,2H),1.94–1.86(m,7H),1.80(s,2H),1.29(s,6H).MS(ESI,m / z):1006(M + +1).
[0428] Example 72: Synthesis of Compound S44
[0429]
[0430] According to the synthesis of compound S1, the corresponding intermediate was replaced to obtain compound S44. 1H NMR (500MHz, DMSO-d6) δ11.02(s,1H),8.57(s,1H),8.11(d,J=4.9Hz,1H),7.83(d,J=7.4Hz,1H),7.51–7.41(m,2H),7.33(s,1H ),7.08(s,1H),7.02(t,J=3.7Hz,1H),6.62(d,J=4.9Hz,1H),5.01(s,1H),4.92(s,1H),4.11(d,J=14.5Hz,2H),3.96(s,1H),3. 76(s,2H),3.72–3.65(m,6H),3.63(s,3H),3.57(d,J=17.2Hz,2H),3.49(d,J=18.1Hz,4H),3.40(s,3H),3.03(s,1H),2.93(s,3 H),2.87(s,2H),2.68–2.59(m,5H),2.39(s,1H),2.24(d,J=0.9Hz,2H),1.89(d,J=4.4Hz,5H),1.29(s,6H).MS(ESI,m / z):978(M + +1).
[0431] Example 73: Synthesis of Compound S45
[0432]
[0433] According to the synthesis of compound S1, compound S45 was obtained by replacing the corresponding intermediate. 1H NMR (500MHz, DMSO-d6) δ11.02(s,1H),8.57(s,1H),8.11(d,J=4.9Hz,1H),7.78(d,J=7.5Hz,1H),7.59(d,J=2.0Hz,1H),7.41(dd,J =7.5,1.8Hz,1H),7.33(s,1H),7.08(s,1H),7.02(t,J=3.7Hz,1H),6.62(d,J=4.9Hz,1H),5.01(s,1H),4.92(s,1H),4.11(d,J=14.5 Hz,2H),3.96(s,1H),3.78(s,2H),3.70(s,4H),3.63(s,3H),3.57(d,J=17.2Hz,2H),3.52(s,2H),3.47(s,2H),3.42(d,J=13.4Hz,5 H),2.93(s,3H),2.65–2.59(m,3H),2.39(s,1H),2.23(d,J=3.8Hz,2H),1.94(s,4H),1.89(s,1H),1.29(s,6H).MS(ESI,m / z):923(M + +1).
[0434] Example 74: Synthesis of Compound S46
[0435]
[0436] According to the synthesis of compound S1, the corresponding intermediate was replaced to obtain compound S46. 1H NMR (500MHz, DMSO-d6) δ11.02(s,1H),8.57(s,1H),8.11(d,J=4.9Hz,1H),7.83(d,J=7.4Hz,1H),7.51–7.41(m,2H),7.33(s,1H) ,7.08(s,1H),7.02(t,J=3.7Hz,1H),6.62(d,J=4.9Hz,1H),5.01(s,1H),4.92(s,1H),4.11(d,J=14.5Hz,2H),3.96(s,1H),3.77 (d,J=9.7Hz,3H),3.69(d,J=14.1Hz,4H),3.65–3.50(m,7H),3.47(s,2H),3.43–3.37(m,4H),2.93(s,3H),2.86(s,1H),2.66–2. 59(m,7H),2.39(s,1H),2.23(d,J=3.8Hz,2H),2.17(s,1H),1.89(d,J=4.4Hz,5H),1.67(s,1H),1.29(s,6H).MS(ESI,m / z):992(M + +1).
[0437] Example 75: Synthesis of Compound S47
[0438]
[0439] According to the synthesis of compound S1, the corresponding intermediate was replaced to obtain compound S47. 1H NMR (500MHz, DMSO-d6) δ11.02(s,1H),8.57(s,1H),8.11(d,J=4.9Hz,1H),7.78(d,J= 7.5Hz,1H),7.49(d,J=2.0Hz,1H),7.41(dd,J=7.4,1.9Hz,1H),7.33(s,1H),7.08(s, 1H),7.02(t,J=3.7Hz,1H),6.62(d,J=4.9Hz,1H),5.01(s,1H),4.92(s,1H),4.11(d, J=14.5Hz,2H),3.96(s,1H),3.76(s,2H),3.69(d,J=14.1Hz,4H),3.65–3.57(m,5H),3 .57–3.43(m,6H),3.40(s,3H),3.11(s,1H),2.93(s,3H),2.68(s,2H),2.65–2.59(m, 3H),2.56(s,2H),2.39(s,1H),2.23(d,J=3.8Hz,2H),2.12(s,1H),2.00(s,1H),1.91( d,J=16.5Hz,5H),1.85(d,J=13.0Hz,1H),1.79(d,J=13.0Hz,1H),1.69(d,J=13.0Hz, 1H),1.59(d,J=13.0Hz,1H),1.47(d,J=2.0Hz,2H),1.29(s,6H).MS(ESI,m / z):1046(M + +1).
[0440] Example 76: Synthesis of Compound S48
[0441]
[0442] According to the synthesis of compound S1, the corresponding intermediate was replaced to obtain compound S48. 1H NMR (500MHz, DMSO-d6) δ11.02(s,1H),8.57(s,1H),8.11(d,J=4.9Hz,1H),7.77(d,J=7.5Hz,1H),7.55(d,J=2.0Hz,1H),7.41(dd,J=7.4,1.9Hz ,1H),7.33(s,1H),7.08(s,1H),7.02(t,J=3.7Hz,1H),6.62(d,J=4.9H z,1H),5.01(s,1H),4.92(s,1H),4.15(s,1H),4.10(s,1H),3.96(s,1H) ,3.85(s,2H),3.76(s,2H),3.69(d,J=14.1Hz,4H),3.65–3.53(m,7H), 3.47(s,2H),3.40(s,3H),2.97(s,1H),2.93(s,3H),2.65–2.59(m,7H), 2.39(s,1H),2.23(d,J=3.8Hz,2H),1.98(d,J=13.0Hz,2H),1.91(d,J=16.5Hz,5H),1.82(d,J=13.0Hz,2H),1.29(s,6H).MS(ESI,m / z):1018(M + +1).
[0443] Example 77: Synthesis of Compound S49
[0444]
[0445] According to the synthesis of compound S1, the corresponding intermediate was replaced to obtain compound S49. 1H NMR (500MHz, DMSO-d6) δ11.02(s,1H),8.57(s,1H),8.11(d,J=4.9Hz,1H),7.77(d,J=7.5Hz,1H),7.55(d,J=2.0Hz,1H),7.41(dd,J=7.4,1.9Hz, 1H),7.33(s,1H),7.08(s,1H),7.02(t,J=3.7Hz,1H),6.62(d,J=4.9Hz, 1H),5.01(s,1H),4.92(s,1H),4.11(d,J=14.5Hz,2H),3.96(s,1H),3.7 6(s,2H),3.69(d,J=14.1Hz,4H),3.63(s,3H),3.61–3.50(m,4H),3.47( t,J=4.8Hz,4H),3.40(s,3H),2.93(s,3H),2.81(s,1H),2.65–2.59(m,7 H),2.39(s,1H),2.23(d,J=3.8Hz,2H),2.02(t,J=6.5Hz,4H),1.91(d,J=16.5Hz,5H),1.52(d,J=12.8Hz,2H),1.29(s,6H).MS(ESI,m / z):1032(M + +1).
[0446] Example 78: Synthesis of Compound S50
[0447]
[0448] According to the synthesis of compound S1, the corresponding intermediate was replaced to obtain compound S50. 1H NMR (500MHz, DMSO-d6) δ11.02(s,1H),9.96(s,1H),8.57(s,1H),8.11(d,J=4.9Hz,1H),7.86(d,J=7.5Hz,1H),7.59(d,J=2.0Hz,1H),7. 42(dd,J=7.5,2.0Hz,1H),7.33(s,1H),7.08(s,1H),7.02(t,J=3.7Hz,1H),6.62(d,J=4.9Hz,1H),5.01(s,1H),4.92(s,1H),4.11(d,J=1 4.5Hz,2H),3.96(s,1H),3.76(s,2H),3.69(d,J=14.1Hz,4H),3.63(s,3H),3.57(d,J=17.2Hz,2H),3.53–3.45(m,6H),3.40(s,3H),3.09 (s,2H),2.99–2.85(m,7H),2.68–2.57(m,7H),2.39(s,1H),2.23(d,J=3.8Hz,2H),1.94–1.81(m,9H),1.29(s,6H).MS(ESI,m / z):1061(M + +1).
[0449] Example 79: Synthesis of Compound S51
[0450]
[0451] According to the synthesis of compound S1, the corresponding intermediate was replaced to obtain compound S51. 1H NMR (500MHz, DMSO-d6) δ11.02(s,1H),8.57(s,1H),8.11(d,J=4.9Hz,1H),7.83(d,J=7.5Hz,1H),7.60(d,J=2.0Hz,1H),7.41–7.31(m,2H),7 .08(s,1H),7.02(t,J=3.7Hz,1H),6.62(d,J=4.9Hz,1H),5.01(s,1H),4.92(s,1H),4.11(d,J=14.5Hz,2H),3.96(s,1H),3.77(d,J=4.8Hz,4H ),3.69(d,J=14.1Hz,4H),3.63(s,3H),3.57(d,J=17.2Hz,2H),3.49(d,J=18.1Hz,4H),3.40(d,J=1.1Hz,4H),2.93(s,3H),2.71(s,4H),2.67 (s,1H),2.65–2.59(m,7H),2.39(s,1H),2.24(d,J=0.9Hz,2H),2.03(d,J=13.0Hz,2H),1.94–1.87(m,7H),1.29(s,6H).MS(ESI,m / z):1073(M + +1).
[0452] Example 80: Synthesis of Compound S52
[0453]
[0454] According to the synthesis of compound S1, compound S52 was obtained by replacing the corresponding intermediate. 1H NMR(500MHz,DMSO-d6)δ11.02(s,1H),8.57(s,1H),8.11(d,J=4.9Hz,1H),7.83 (d,J=7.5Hz,1H),7.49(d,J=2.0Hz,1H),7.41(dd,J=7.4,1.9Hz,1H),7.33(s,1 H),7.08(s,1H),7.02(t,J=3.7Hz,1H),6.62(d,J=4.9Hz,1H),5.01(s,1H),4.9 2(s,1H),4.11(d,J=14.5Hz,2H),3.96(s,1H),3.77(d,J=4.8Hz,4H),3.69(d,J =14.1Hz,4H),3.63(s,3H),3.57(d,J=17.2Hz,2H),3.49(d,J=18.1Hz,4H),3.4 0(s,3H),3.22(d,J=9.5Hz,2H),3.11(s,1H),3.06(d,J=9.5Hz,2H),2.93(s,3H ),2.65–2.59(m,8H),2.39(s,1H),2.24(d,J=0.9Hz,2H),1.94–1.87(m,7H),1. 84(d,J=13.0Hz,2H),1.76(d,J=13.0Hz,2H),1.29(s,6H).MS(ESI,m / z):1087(M + +1).
[0455] Example 81: Synthesis of Compound S53
[0456]
[0457] According to the synthesis of compound S1, compound S53 was obtained by replacing the corresponding intermediate. 1H NMR (500MHz, DMSO-d) δ11.02(s,1H),8.37(s,1H),8.12(d,J=5.1Hz,1H),7.86(d,J=7.5Hz,1H),7.60(d,J=2.0Hz,1H),7.41–7.34(m, 2H),7.27(s,1H),7.02(t,J=3.7Hz,1H),6.62(d,J=4.9Hz,1H),5.14(s,1H),5.01(s,1H),4.14–4.04(m,3H),3.96(s,1H),3.85(s,1H) ,3.79–3.59(m,12H),3.55(s,1H),3.48(s,1H),3.40(s,3H),3.26(d,J=12.5Hz,1H),2.93(s,3H),2.66–2.56(m,5H),2.46(d,J=9.1H z,3H),2.39(d,J=2.2Hz,2H),2.23(d,J=3.8Hz,2H),1.91(d,J=16.5Hz,4H),1.37(s,3H),1.31(d,J=1.6Hz,7H).MS(ESI,m / z):1006(M + +1).
[0458] Example 82: Synthesis of Compound S54
[0459]
[0460] According to the synthesis of compound S1, the corresponding intermediate was replaced to obtain compound S54. 1H NMR (500MHz, DMSO-d6) δ11.03 (s, 1H), 8.37 (s, 1H), 8.12 (d, J = 5.1Hz, 1H), 7. 81(d,J=7.5Hz,1H),7.64(d,J=2.0Hz,1H),7.38–7.31(m,2H),7.27(s,1H),7. 02(t,J=3.7Hz,1H),6.62(d,J=4.9Hz,1H),5.14(s,1H),5.01(s,1H),4.11(d ,J=9.9Hz,2H),3.96(s,1H),3.76(s,2H),3.69(d,J=10.4Hz,4H),3.62(d,J=9 .7Hz,3H),3.55(s,1H),3.49(d,J=12.1Hz,3H),3.40(s,3H),3.28(d,J=17.0 Hz,4H),2.93(s,3H),2.66–2.59(m,6H),2.56(s,1H),2.51(d,J=12.4Hz,1H), 2.45(d,J=12.5Hz,1H),2.39(s,1H),2.23(d,J=3.8Hz,2H),2.03(s,1H),1.9 1(d,J=16.5Hz,5H),1.84(d,J=2.0Hz,4H),1.34(s,6H).MS(ESI,m / z):1020(M + +1).
[0461] Example 83: Synthesis of Compound S55
[0462]
[0463] According to the synthesis of compound S1, compound S55 was obtained by replacing the corresponding intermediate. 1HNMR (500MHz, DMSO-d6) δ11.03(s,1H),8.37(s,1H),8.12(d,J=5.1Hz,1H),7.86(d,J=7.5Hz,1H),7.60(d,J=2.0Hz,1H),7.38( dd,J=7.5,2.0Hz,1H),7.26(d,J=12.3Hz,2H),7.02(t,J=3.7Hz,1H),6.62(d,J=4.9Hz,1H),5.14(s,1H),5.01(s,1H),4.11(d, J=9.9Hz,2H),3.96(s,1H),3.74–3.59(m,14H),3.49(d,J=12.1Hz,3H),3.40(s,3H),3.10(s,1H),2.92(d,J=13.9Hz,7H),2.63 (d,J=11.5Hz,2H),2.56(s,1H),2.39(s,1H),2.23(d,J=3.8Hz,2H),2.08(s,2H),1.89(s,1H),1.34(s,6H).MS(ESI,m / z):976(M + +1).
[0464] Example 84: Synthesis of Compound S56
[0465]
[0466] According to the synthesis of compound S1, the corresponding intermediate was replaced to obtain compound S56. 1H NMR (500MHz, DMSO-d6) δ11.02(s,1H),8.37(s,1H),8.12(d,J=5.1Hz,1H),7.86(d,J=7.5Hz,1H),7.60(d,J=2.0Hz,1H),7.38(dd,J=7 .5,2.0Hz,1H),7.26(d,J=12.3Hz,2H),7.02(t,J=3.7Hz,1H),6.62(d,J=4.9Hz,1H),5.14(s,1H),5.01(s,1H),4.11(d,J=14.5Hz,2H ),3.96(s,1H),3.76(s,2H),3.73–3.59(m,11H),3.55(s,1H),3.49(d,J=12.1Hz,3H),3.40(s,3H),3.17(s,1H),2.93(s,3H),2.67–2 .60(m,6H),2.56(s,1H),2.39(s,1H),2.23(d,J=3.8Hz,2H),2.06(s,2H),1.91(d,J=16.5Hz,5H),1.34(s,6H).MS(ESI,m / z):1004(M + +1).
[0467] Example 85: Synthesis of Compound S57
[0468]
[0469] According to the synthesis of compound S1, compound S57 was obtained by replacing the corresponding intermediate. 1H NMR (500MHz, DMSO-d6) δ11.04(s,1H),8.37(s,1H),8.12(d,J=5.1Hz,1H),7.83(d,J=7.5Hz,1H),7.66(d,J=1.9Hz,1H),7.34(dd, J=7.5,2.0Hz,1H),7.26(d,J=12.3Hz,2H),7.02(t,J=3.7Hz,1H),6.62(d,J=4.9Hz,1H),5.14(s,1H),5.01(s,1H),4.11(d,J=9.9 Hz,2H),3.96(s,1H),3.76(s,2H),3.69(d,J=10.4Hz,4H),3.65–3.53(m,6H),3.52–3.45(m,5H),3.40(s,3H),2.93(s,3H),2.71– 2.60(m,7H),2.56(s,1H),2.39(s,1H),2.23(d,J=3.8Hz,2H),1.96–1.87(m,9H),1.84(s,4H),1.34(s,6H).MS(ESI,m / z):1046(M + +1).
[0470] Example 86: Synthesis of Compound S58
[0471]
[0472] According to the synthesis of compound S1, the corresponding intermediate was replaced to obtain compound S58. 1H NMR (500MHz, DMSO-d6) δ11.02(s,1H),8.37(s,1H),8.12(d,J=5.1Hz,1H),7.81(d,J=7.5Hz,1H),7.60(d,J=2.0Hz,1H),7.34(dd,J=7.5 ,2.0Hz,1H),7.26(d,J=12.3Hz,2H),7.02(t,J=3.7Hz,1H),6.62(d,J=4.9Hz,1H),5.14(s,1H),5.01(s,1H),4.11(d,J=9.9Hz,2H),3.9 6(s,1H),3.78–3.59(m,12H),3.55(s,1H),3.53–3.46(m,6H),3.40(s,3H),2.93(s,3H),2.75(s,1H),2.70–2.60(m,5H),2.56(s,1H),2 .39(s,1H),2.23(d,J=3.8Hz,2H),1.93(d,J=11.4Hz,5H),1.91–1.83(m,3H),1.77(d,J=13.0Hz,2H),1.34(s,6H).MS(ESI,m / z):1032(M + +1).
[0473] Example 87: Synthesis of Compound S59
[0474]
[0475] According to the synthesis of compound S1, the corresponding intermediate was replaced to obtain compound S59. 1H NMR (500MHz, DMSO-d6) δ11.02(s,1H),8.37(s,1H),8.12(d,J=5.1Hz,1H),7.88(d,J=7.4Hz,1H),7.60(dt,J=2.1,0.9Hz,1H),7.45(dd,J=7.5,2. 0Hz,1H),7.26(d,J=12.3Hz,2H),7.02(t,J=3.7Hz,1H),6.62(d,J=4.9Hz,1H),5.14(s,1H),4.47(dd,J=9.4,1.0Hz,1H),4.32(dd,J=9.4,1.0Hz, 1H),4.11(d,J=9.9Hz,2H),4.01(s,1H),3.96(s,1H),3.76(s,2H),3.73 –3.66(m,7H),3.62(d,J=9.7Hz,3H),3.55(s,1H),3.49(d,J=12.1Hz,3H) ,3.40(s,3H),2.93(s,3H),2.63–2.53(m,6H),2.39(s,1H),2.17(s,1H), 2.12(s,1H),1.93(s,4H),1.89(s,1H),1.34(s,6H).MS(ESI,m / z):947(M + +1).
[0476] Example 88: Synthesis of Compound S60
[0477]
[0478] According to the synthesis of compound S1, the corresponding intermediate was replaced to obtain compound S60. 1H NMR (500MHz, DMSO-d6) δ11.03(s,1H),8.37(s,1H),8.12(d,J=5.1Hz,1H),7.81(dd,J=5.4,4.1Hz,1H),7.51–7.44(m,2H),7.36(s,1H),7.27 (s,1H),7.02(t,J=3.7Hz,1H),6.62(d,J=4.9Hz,1H),5.14(s,1H),4.38(s,1H),4.32(s,1H),4.11(d,J=9.9Hz,2H),4.01(s,1H),3.96(s,1H ),3.76(s,2H),3.69(d,J=10.4Hz,4H),3.62(d,J=9.7Hz,3H),3.55(s,1H),3.49(d,J=12.1Hz,3H),3.40(s,3H),2.93(s,3H),2.78(s,2H),2 .63–2.54(m,7H),2.46(s,2H),2.39(s,1H),2.17(s,1H),2.07(s,1H),1.91(d,J=16.5Hz,5H),1.80(s,2H),1.34(s,6H).MS(ESI,m / z):975(M + +1).
[0479] Example 89: Synthesis of Compound S61
[0480]
[0481] According to the synthesis of compound S1, the corresponding intermediate was replaced to obtain compound S61. 1H NMR(500MHz,DMSO-d6)δ11.03(s,1H),8.37(s,1H),8.12(d,J=5.1Hz,1H),7.81(dd,J=6.8,2.7Hz,1H),7.50–7.41(m,2H),7.36(s,1H),7.2 7(s,1H),7.02(t,J=3.7Hz,1H),6.62(d,J=4.9Hz,1H),5.14(s,1H),4.38(s,1H),4.28(s,1H),4.11(d,J=9.9Hz,2H),4.01(s,1H),3.96(s, 1H),3.76(s,2H),3.69(d,J=10.4Hz,4H),3.62(d,J=9.7Hz,3H),3.55(s,1H),3.49(d,J=12.1Hz,3H),3.40(s,3H),2.93(s,3H),2.66–2.54 (m,9H),2.46(s,2H),2.39(s,1H),2.17(s,1H),2.07(s,1H),1.91(d,J=16.5Hz,5H),1.52–1.46(m,6H),1.34(s,6H).MS(ESI,m / z):1003(M + +1).
[0482] Example 90: Synthesis of Compound S62
[0483]
[0484] According to the synthesis of compound S1, the corresponding intermediate was replaced to obtain compound S62. 1H NMR (500MHz, DMSO-d6) δ11.03(s,1H),8.57(s,1H),8.11(d,J=4.9Hz,1H),7.81(dd,J=7.0,2.5Hz,1H),7.53–7.43(m,2H),7.33(s,1H),7. 17(s,1H),7.02(t,J=3.7Hz,1H),6.62(d,J=4.9Hz,1H),4.92(s,1H),4.47(s,1H),4.32(s,1H),4.11(d,J=14.5Hz,2H),4.01(s,1H),3.96( s,1H),3.76(s,2H),3.69(d,J=14.1Hz,4H),3.63(s,3H),3.57(d,J=17.2Hz,2H),3.47(s,2H),3.40(s,3H),2.93(s,3H),2.64–2.56(m,9H) ,2.46(s,2H),2.39(s,1H),2.19(s,1H),2.12(s,1H),1.91(d,J=16.5Hz,5H),1.54–1.47(m,4H),1.34–1.25(m,12H).MS(ESI,m / z):1031(M + +1).
[0485] Example 91: Synthesis of Compound S63
[0486]
[0487] According to the synthesis of compound S1, compound S63 was obtained by replacing the corresponding intermediate. 1H NMR (500MHz, DMSO-d6) δ11.03(s,1H),8.57(s,1H),8.11(d,J=4.9Hz,1H),7.89(d,J=7.5Hz,1H),7.71(dd,J=7.5,2.0Hz,1H),7.63(dt,J=2.0 ,0.9Hz,1H),7.33(s,1H),7.08(s,1H),7.02(t,J=3.7Hz,1H),6.62(d,J=4.9Hz,1H),4.92(s,1H),4.58(d,J=1.1Hz,1H),4.48(d,J=0.9Hz,1H) ,4.11(d,J=14.5Hz,2H),4.01(s,1H),3.96(s,1H),3.76(s,2H),3.72– 3.61(m,9H),3.57(d,J=17.2Hz,2H),3.47(s,2H),3.40(s,3H),2.93(s ,3H),2.60(d,J=5.2Hz,3H),2.56(s,4H),2.39(s,1H),2.19(s,1H),2. 12(s,1H),1.93(s,4H),1.89(s,1H),1.29(s,6H).MS(ESI,m / z):1031(M + +1).
[0488] Example 92: Synthesis of Compound S64
[0489]
[0490] According to the synthesis of compound S1, compound S64 was obtained by replacing the corresponding intermediate. 1H NMR (500MHz, DMSO-d6) δ11.02(s,1H),8.57(s,1H),8.11(d,J=4.9Hz,1H),7.88(d,J=7.5Hz,1H),7.70(dd,J=7.4,1.9Hz,1H),7.64(dt,J=2.0,1.0 Hz,1H),7.33(s,1H),7.17(s,1H),7.02(t,J=3.7Hz,1H),6.62(d,J=4.9H z,1H),4.92(s,1H),4.58(d,J=1.1Hz,1H),4.48(d,J=0.9Hz,1H),4.11(d, J=14.5Hz,2H),4.01(s,1H),3.96(s,1H),3.76(s,2H),3.69(d,J=14.1Hz ,4H),3.63(s,3H),3.57(d,J=17.2Hz,2H),3.47(s,2H),3.40(s,3H),2.9 3(s,3H),2.74(s,2H),2.63–2.57(m,7H),2.46(s,2H),2.39(s,1H),2.19 (s,1H),2.12(s,1H),1.94–1.87(m,7H),1.29(s,6H).MS(ESI,m / z):975(M + +1).
[0491] Example 93: Synthesis of Compound S65
[0492]
[0493] According to the synthesis of compound S1, compound S65 was obtained by replacing the corresponding intermediate. 1HNMR(500MHz,DMSO-d6)δ11.04(s,1H),8.57(s,1H),8.11(d,J=4.9Hz,1H),7.71(dd,J=7.5,2.0Hz,1H),7.41(t,J=7.5Hz,1H),7.33(s,1H),7 .24(ddt,J=7.5,2.0,0.9Hz,1H),7.08(s,1H),7.02(t,J=3.7Hz,1H),6.62(d,J=4.9Hz,1H),4.92(s,1H),4.58(d,J=1.1Hz,1H),4.48(d,J=0. 9Hz,1H),4.11(d,J=14.5Hz,2H),4.01(s,1H),3.96(s,1H),3.76(s,2H ),3.72–3.65(m,5H),3.65–3.57(m,5H),3.55(s,1H),3.47(s,2H),3.4 0(s,3H),2.93(s,3H),2.63–2.56(m,7H),2.39(s,1H),2.19(s,1H),2. 12(s,1H),1.93(s,4H),1.89(s,1H),1.29(s,6H).MS(ESI,m / z):947(M + +1).
[0494] Example 94: Synthesis of Compound S66
[0495]
[0496] According to the synthesis of compound S1, the corresponding intermediate was replaced to obtain compound S66. 1H NMR (500MHz, DMSO-d6) δ11.04(s,1H),8.57(s,1H),8.11(d,J=4.9Hz,1H),7.70(dd,J=7.4,2.1Hz,1H),7.36–7.29(m,2H),7.24(ddt,J=7.5,2.0,1.0 Hz,1H),7.17(s,1H),7.02(t,J=3.7Hz,1H),6.62(d,J=4.9Hz,1H),4.92(s ,1H),4.58(d,J=1.1Hz,1H),4.48(d,J=0.9Hz,1H),4.11(d,J=14.5Hz,2H) ,4.01(s,1H),3.96(s,1H),3.76(s,2H),3.69(d,J=14.1Hz,4H),3.63(s,3 H),3.57(d,J=17.2Hz,2H),3.47(s,2H),3.40(s,3H),2.93(s,3H),2.75(s ,2H),2.63–2.56(m,7H),2.45(s,2H),2.39(s,1H),2.19(s,1H),2.12(s,1 H),1.99(s,2H),1.91(d,J=16.5Hz,5H),1.29(s,6H).MS(ESI,m / z):975(M + +1).
[0497] Example 95: Synthesis of Compound S67
[0498]
[0499] According to the synthesis of compound S1, the corresponding intermediate was replaced to obtain compound S67. 1H NMR (500MHz, DMSO-d6) δ11.04(s,1H),8.57(s,1H),8.11(d,J=4.9Hz,1H),7.83(d,J=7.5Hz,1H),7.49(d,J=2.0Hz,1H),7.41(dd,J=7.4,1.9Hz ,1H),7.33(s,1H),7.04(s,1H),7.02(t,J=3.7Hz,1H),6.62(d,J=4.9H z,1H),5.01(s,1H),4.92(s,1H),4.11(d,J=14.5Hz,2H),3.96(s,1H),3 .67(d,J=8.4Hz,4H),3.65–3.57(m,5H),3.46(d,J=10.1Hz,6H),3.39(d,J=11.7Hz,5H),3.27(s,1H),2.93(s,3H),2.78(d,J=9.5Hz,2H),2.69 (d,J=9.3Hz,2H),2.65–2.59(m,3H),2.38(d,J=6.0Hz,3H),2.24(d,J=0.9Hz,2H),1.89(s,1H),1.31(s,3H),1.26(s,3H).MS(ESI,m / z):964(M + +1).
[0500] Example 96: Synthesis of Compound S68
[0501]
[0502] According to the synthesis of compound S1, compound S68 was obtained by replacing the corresponding intermediate. 1H NMR (500MHz, DMSO-d6) δ11.04(s,1H),8.57(s,1H),8.11(d,J=4.9Hz,1H),7. 81(dd,J=7.4,2.1Hz,1H),7.56(dd,J=7.4,2.1Hz,1H),7.47(t,J=7.5Hz,1H) ,7.33(s,1H),7.08(s,1H),7.02(t,J=3.7Hz,1H),6.62(d,J=4.9Hz,1H),4.9 2(s,1H),4.47(s,1H),4.33(d,J=7.5Hz,4H),4.11(d,J=14.5Hz,2H),4.01(s ,1H),3.96(s,1H),3.72–3.57(m,9H),3.47(s,2H),3.40(s,3H),3.19(d,J=9 .5Hz,2H),2.99–2.90(m,5H),2.78(d,J=9.5Hz,2H),2.71(d,J=9.5Hz,2H),2 .63–2.56(m,4H),2.52(d,J=12.4Hz,1H),2.47(s,2H),2.39(s,1H),2.19(s, 1H),2.12(s,1H),1.89(s,1H),1.31(s,3H),1.26(s,3H).MS(ESI,m / z):962(M + +1).
[0503] Example 97: Synthesis of Compound S69
[0504]
[0505] According to the synthesis of compound S1, compound S69 was obtained by replacing the corresponding intermediate. 1H NMR (500MHz, DMSO-d6) δ11.04(s,1H),8.57(s,1H),8.11(d,J=4.9Hz,1H),7.86(d,J=7.5Hz,1H),7.59(d,J=2.0Hz,1H),7.42(dd,J=7.5, 2.0Hz,1H),7.33(s,1H),7.08(s,1H),7.02(t,J=3.7Hz,1H),6.62(d,J=4.9Hz,1H),5.01(s,1H),4.92(s,1H),4.11(d,J=14.5Hz,2H),3. 96(s,1H),3.69–3.57(m,7H),3.46(d,J=10.1Hz,6H),3.40(d,J=5.3Hz,5H),3.24(s,2H),3.02(s,1H),2.93(s,3H),2.74(d,J=9.3Hz,2H ),2.70–2.59(m,5H),2.39(s,1H),2.25–2.19(m,4H),1.88(d,J=4.6Hz,3H),1.80(s,2H),1.31(s,3H),1.26(s,3H).MS(ESI,m / z):992(M + +1).
[0506] Example 98: Synthesis of Compound S70
[0507]
[0508] According to the synthesis of compound S1, the corresponding intermediate was replaced to obtain compound S70. 1H NMR (500MHz, DMSO-d6) δ11.03(s,1H),8.57(s,1H),8.11(d,J=4.9Hz,1H),7.77(d,J=7.5Hz,1H),7.59(d,J=2.0Hz,1H),7.41(dd,J=7.5,1. 8Hz,1H),7.33(s,1H),7.08(s,1H),7.02(t,J=3.7Hz,1H),6.62(d,J=4.9Hz,1H),5.01(s,1H),4.92(s,1H),4.11(d,J=14.5Hz,2H),3.96(s ,1H),3.72–3.60(m,9H),3.59(s,1H),3.47(s,2H),3.40(s,3H),3.32(d,J=10.1Hz,5H),3.19(d,J=9.5Hz,2H),2.95–2.84(m,7H),2.65–2. 58(m,3H),2.43(s,2H),2.39(s,1H),2.23(d,J=3.8Hz,2H),2.03(s,1H),1.91–1.84(m,5H),1.31(s,3H),1.26(s,3H).MS(ESI,m / z):1006(M + +1).
[0509] Example 99: Synthesis of Compound S71
[0510]
[0511] Intermediate 50 (612 mg, 1 mmol) and intermediate 135 (736 mg, 2 mmol) were dissolved in dichloromethane (8 mL) and ethanol (4 mL) solution, reacted at room temperature for 3 h, and NaBH(OAc)3 (424 mg, 2 mmol) was added, and reacted at room temperature for 16 hours. After the reaction was complete, water was added to quench, and dichloromethane was extracted (10 mL×3). The organic phases were combined, washed with saturated NaCl solution, dried over anhydrous Na2SO4, filtered to remove salt, concentrated under reduced pressure, and purified by column chromatography to obtain the intermediate (402 mg, 40%). 1H NMR (500MHz, DMSO-d6) δ11.02(s,1H),8.57(s,1H),8.11(d,J=4.9Hz,1H),7.69(q,J=1.0Hz,1H),7.45(s,1H),7.33(s,1H),7.12( s,1H),7.02(t,J=3.7Hz,1H),6.62(d,J=4.9Hz,1H),5.01(s,1H),4.92(s,1H),4.11(d,J=14.5Hz,2H),3.96(s,1H),3.80(s,4H), 3.70(d,J=1.6Hz,4H),3.63(s,3H),3.61–3.51(m,4H),3.47(s,2H),3.40(s,3H),3.29(s,1H),2.93(s,3H),2.72(s,2H),2.64–2. 59(m,3H),2.55(s,2H),2.39(s,1H),2.24(d,J=0.9Hz,2H),2.18(d,J=0.9Hz,3H),1.89(s,1H),1.24(s,6H).MS(ESI,m / z):964(M + +1).
[0512] Example 100: Synthesis of Compound S72
[0513]
[0514] According to the synthesis of compound S71, compound S72 was obtained by replacing the corresponding intermediate. 1 H NMR(500MHz,DMSO-d6)δ11.02(s,1H),8.57(s,1H),8.11(d,J=4.9Hz,1H),7.69(s,1H),7.49(s,1H),7.33(s,1H), 7.12(s,1H),7.02(t,J=3.7Hz,1H),6.62(d,J=4.9Hz,1H),5.01(s,1H),4.92(s,1H),4.11(d,J=14.5Hz,2H),3.96 (s,1H),3.70(d,J=1.8Hz,8H),3.63(s,3H),3.61–3.51(m,4H),3.47(s,2H),3.40(s,3H),3.29(s,1H),2.93(s,3H ),2.64–2.59(m,5H),2.41(d,J=17.9Hz,3H),2.23(d,J=3.8Hz,2H),1.89(s,1H),1.24(s,6H).MS(ESI,m / z):968(M + +1).
[0515] Example 101: Synthesis of Compound S73
[0516]
[0517] According to the synthesis of compound S71, compound S73 was obtained by replacing the corresponding intermediate. 1 H NMR (500MHz, DMSO-d6) δ11.03(s,1H),8.57(s,1H),8.11(d,J=4.9Hz,1H),7.78(d,J=7.5Hz,1H),7.49(d,J=2.0Hz,1H),7.41(dd,J=7.4, 1.9Hz,1H),7.33(s,1H),7.12(s,1H),7.02(t,J=3.7Hz,1H),6.62(d,J=4.9Hz,1H),5.01(s,1H),4.92(s,1H),4.11(d,J=14.5Hz,2H),3.9 6(s,1H),3.88(s,2H),3.80(s,2H),3.70(s,2H),3.63(s,3H),3.61–3.53(m,4H),3.47(s,2H),3.40(s,3H),3.33(s,2H),3.26(s,1H),2.9 3(s,3H),2.87(s,2H),2.68–2.59(m,5H),2.39(s,1H),2.23(d,J=3.8Hz,2H),1.89(s,1H),1.78(s,4H),1.24(s,6H).MS(ESI,m / z):978(M + +1).
[0518] Example 102: Synthesis of Compound S74
[0519]
[0520] According to the synthesis of compound S71, compound S74 was obtained by replacing the corresponding intermediate. 1H NMR (500MHz, DMSO-d6) δ11.03(s,1H),8.57(s,1H),8.11(d,J=4.9Hz,1H),7.83(d,J=7.5Hz,1H),7.60(d,J=2.0Hz,1H),7.41(dd ,J=7.4,1.9Hz,1H),7.33(s,1H),7.28(s,1H),7.02(t,J=3.7Hz,1H),6.62(d,J=4.9Hz,1H),5.01(s,1H),4.92(s,1H),4.11(d,J= 14.5Hz,2H),3.96(s,1H),3.70(s,2H),3.63(s,3H),3.61–3.53(m,4H),3.49–3.38(m,7H),3.28(s,3H),3.22(s,2H),2.93(s,3H) ,2.84(s,2H),2.74(s,2H),2.65–2.59(m,3H),2.39(s,1H),2.23(d,J=3.8Hz,2H),1.89(s,1H),1.24(s,6H).MS(ESI,m / z):938(M + +1).
[0521] Example 103: Synthesis of Compound S75
[0522]
[0523] According to the synthesis of compound S71, compound S75 was obtained by replacing the corresponding intermediate. 1H NMR (500MHz, DMSO-d6) δ11.03(s,1H),8.57(s,1H),8.11(d,J=4.9Hz,1H),7.78(d,J=7.5Hz,1H),7.59(d,J=2.0Hz,1H),7.41(dd,J=7.5 ,1.8Hz,1H),7.33(s,1H),7.28(s,1H),7.02(t,J=3.7Hz,1H),6.62(d,J=4.9Hz,1H),5.01(s,1H),4.92(s,1H),4.13(s,1H),4.10(s,1H) ,3.96(s,1H),3.70(s,2H),3.62(d,J=5.4Hz,6H),3.59(s,1H),3.55(s,1H),3.52(s,2H),3.47(s,2H),3.46–3.38(m,7H),3.29(s,1H),2 .93(d,J=1.6Hz,8H),2.62(d,J=9.2Hz,2H),2.39(s,1H),2.23(d,J=3.8Hz,2H),1.90(d,J=8.4Hz,5H),1.24(s,5H).MS(ESI,m / z):978(M + +1).
[0524] Example 104: Synthesis of Compound S76
[0525]
[0526] According to the synthesis of compound S71, compound S76 was obtained by replacing the corresponding intermediate. 1H NMR (500MHz, DMSO-d6) δ11.03(s,1H),8.57(s,1H),8.11(d,J=4.9Hz,1H),7.83(d,J=7.5Hz,1H),7.49(d,J=2.0Hz,1H),7.4 2(dd,J=7.5,2.0Hz,1H),7.33(s,1H),7.12(s,1H),7.02(t,J=3.7Hz,1H),6.62(d,J=4.9Hz,1H),5.01(s,1H),4.92(s,1H), 4.11(d,J=14.5Hz,2H),3.96(s,1H),3.73–3.61(m,11H),3.61–3.51(m,4H),3.49–3.38(m,6H),2.93(s,3H),2.65–2.59(m, 5H),2.50(d,J=9.5Hz,2H),2.39(s,1H),2.23(d,J=3.8Hz,2H),2.08(s,2H),1.89(s,1H),1.24(s,6H).MS(ESI,m / z):964(M + +1).
[0527] Example 105: Synthesis of Compound S77
[0528]
[0529] According to the synthesis of compound S1, compound S77 was obtained by replacing the corresponding intermediate. 1H NMR (500MHz, DMSO-d6) δ11.04(s,1H),8.57(s,1H),8.11(d,J=4.9Hz,1H),7.86( d,J=7.5Hz,1H),7.49(d,J=2.0Hz,1H),7.42(dd,J=7.5,2.0Hz,1H),7.33(s,1H) ,7.28(s,1H),7.02(t,J=3.7Hz,1H),6.62(d,J=4.9Hz,1H),5.01(s,1H),4.92(s ,1H),4.11(d,J=14.5Hz,2H),4.06(s,1H),3.96(s,1H),3.85(s,1H),3.74–3.67( m,6H),3.63(d,J=6.6Hz,2H),3.57(d,J=17.2Hz,2H),3.54–3.48(m,2H),3.42(d ,J=15.6Hz,5H),3.26(s,1H),2.93(s,3H),2.81(s,1H),2.65–2.56(m,4H),2.46( d,J=7.5Hz,7H),2.40(d,J=12.3Hz,2H),2.28(d,J=12.3Hz,1H),2.23(d,J=3.8H z,2H),1.89(s,1H),1.32(s,3H),1.27(s,3H),1.22(s,3H).MS(ESI,m / z):1021(M + +1).
[0530] Example 106: Synthesis of Compound S78
[0531]
[0532] According to the synthesis of compound S1, compound S78 was obtained by replacing the corresponding intermediate. 1H NMR (500MHz, DMSO-d6) δ11.04(s,1H),8.57(s,1H),8.11(d,J=4.9Hz,1H),7.83(d,J=7.5Hz,1H),7.60(d,J=2.0Hz,1H),7.41–7.31(m,2H),7.28( s,1H),7.02(t,J=3.7Hz,1H),6.62(d,J=4.9Hz,1H),5.01(s,1H),4.92(s ,1H),4.11(d,J=14.5Hz,2H),4.06(s,1H),3.96(s,1H),3.85(s,1H),3.6 9(d,J=10.1Hz,4H),3.63(d,J=6.6Hz,2H),3.57(d,J=17.2Hz,2H),3.54– 3.36(m,9H),3.26(s,1H),3.05(s,1H),2.93(s,3H),2.81(s,1H),2.65–2 .56(m,4H),2.47(d,J=11.5Hz,6H),2.39(s,1H),2.24(d,J=0.9Hz,2H),1 .89(s,1H),1.32(s,3H),1.27(s,3H),1.22(s,3H).MS(ESI,m / z):1007(M + +1).
[0533] Example 107: Synthesis of Compound S79
[0534]
[0535] According to the synthesis of compound S1, compound S79 was obtained by replacing the corresponding intermediate. 1H NMR (500MHz, DMSO-d6) δ11.04(s,1H),8.57(s,1H),8.11(d,J=4.9Hz,1H),7.83(d,J=7.5Hz,1H),7.60(d,J=2.0Hz,1H),7.41–7.31(m,2H),7.28( s,1H),7.02(t,J=3.7Hz,1H),6.62(d,J=4.9Hz,1H),5.01(s,1H),4.92(s ,1H),4.11(d,J=14.5Hz,2H),4.06(s,1H),3.96(s,1H),3.85(s,1H),3.6 9(d,J=10.1Hz,4H),3.63(d,J=6.6Hz,2H),3.57(d,J=17.2Hz,2H),3.54– 3.36(m,9H),3.26(s,1H),3.05(s,1H),2.93(s,3H),2.81(s,1H),2.65–2 .56(m,4H),2.47(d,J=11.5Hz,6H),2.39(s,1H),2.24(d,J=0.9Hz,2H),1 .89(s,1H),1.32(s,3H),1.27(s,3H),1.22(s,3H).MS(ESI,m / z):1007(M + +1).
[0536] Example 108: Synthesis of Compound S80
[0537]
[0538] According to the synthesis of compound S1, the corresponding intermediate was replaced to obtain compound S80. 1H NMR (500MHz, DMSO-d6) δ11.04(s,1H),8.57(s,1H),8.11(d,J=4.9Hz,1H),7.83(d,J=7.5Hz,1H),7.60(d,J=2.0Hz,1H),7.41–7.3 1(m,2H),7.28(s,1H),7.02(t,J=3.7Hz,1H),6.62(d,J=4.9Hz,1H),5.01(s,1H),4.92(s,1H),4.11(d,J=14.5Hz,2H),3.96(s,1H ),3.69(d,J=9.9Hz,6H),3.63(s,3H),3.57(d,J=17.2Hz,2H),3.47(s,2H),3.45–3.36(m,7H),3.26(s,1H),3.05(s,1H),2.93(s, 3H),2.65–2.56(m,5H),2.47(d,J=11.5Hz,6H),2.39(s,1H),2.24(d,J=0.9Hz,2H),1.89(s,1H),1.24(s,6H).MS(ESI,m / z):993(M + +1).
[0539] Example 109: Synthesis of Compound S81
[0540]
[0541] According to the synthesis of compound S1, the corresponding intermediate was replaced to obtain compound S81. 1H NMR (500MHz, DMSO-d6) δ11.04(s,1H),8.57(s,1H),8.11(d,J=4.9Hz,1H),7.64(d,J=7.5Hz,1H),7.41–7.31(m,2H),7.28(s,1H ),7.02(t,J=3.7Hz,1H),6.89(dt,J=2.0,1.0Hz,1H),6.62(d,J=4.9Hz,1H),4.92(s,1H),4.57(dd,J=5.0,1.0Hz,2H),4.11(d,J =14.5Hz,2H),4.01(s,1H),3.96(s,1H),3.70(s,4H),3.65–3.53(m,9H),3.49–3.38(m,7H),3.26(s,1H),2.93(s,3H),2.63–2.5 6(m,5H),2.54(s,1H),2.49–2.43(m,8H),2.39(s,1H),2.19(s,1H),2.12(s,1H),1.89(s,1H),1.24(s,6H).MS(ESI,m / z):993(M + +1).
[0542] Example 110: Synthesis of Compound S82
[0543]
[0544] According to the synthesis of compound S1, compound S82 was obtained by replacing the corresponding intermediate. 1H NMR (500MHz, DMSO-d6) δ11.04(s,1H),8.57(s,1H),8.11(d,J=4.9Hz,1H),7.60(d,J=7.5Hz,1H),7.36–7.31(m,2H),7.28(s,1H),7.02(t,J= 3.7Hz,1H),6.89(dt,J=2.0,1.0Hz,1H),6.62(d,J=4.9Hz,1H),4.92(s,1H),4.47(d,J=0.9Hz,1H),4.34(d,J=1.1Hz,1H),4.11(d,J=14.5Hz ,2H),4.01(s,1H),3.96(s,1H),3.70(s,4H),3.63(s,3H),3.57(d,J=17.2Hz,2H),3.49–3.38(m,9H),3.26(d,J=2.9Hz,3H),3.11(s,1H),2. 93(s,3H),2.63–2.56(m,5H),2.47(d,J=11.5Hz,6H),2.39(s,1H),2.13(s,1H),2.06(s,1H),1.89(s,1H),1.24(s,6H).MS(ESI,m / z):979(M + +1).
[0545] Example 111: Synthesis of Compound S83
[0546]
[0547] According to the synthesis of compound S1, compound S83 was obtained by replacing the corresponding intermediate. 1H NMR (500MHz, DMSO-d6) δ11.04(s,1H),8.57(s,1H),8.11(d,J=4.9Hz,1H),7.69(s,1H),7.53(s,1H),7.33(s,1H),7.28 (s,1H),7.02(t,J=3.7Hz,1H),6.62(d,J=4.9Hz,1H),5.01(s,1H),4.92(s,1H),4.11(d,J=14.5Hz,2H),3.96(s,1H),3. 89(s,2H),3.71(d,J=5.9Hz,6H),3.63(s,3H),3.57(d,J=17.2Hz,2H),3.49–3.38(m,7H),3.26(s,1H),2.93(s,3H),2.6 4–2.53(m,4H),2.51–2.42(m,10H),2.39(s,1H),2.23(d,J=3.8Hz,2H),1.89(s,1H),1.24(s,6H).MS(ESI,m / z):1025(M + +1).
[0548] Example 112: Synthesis of Compound S84
[0549]
[0550] According to the synthesis of compound S1, compound S84 was obtained by replacing the corresponding intermediate. 1 H NMR (500MHz, DMSO-d6) δ11.04(s,1H),8.57(s,1H),8.11(d,J=4.9Hz,1H),7.69(s,1H),7.59(s,1H),7.33(s,1H),7.28(s, 1H),7.02(t,J=3.7Hz,1H),6.62(d,J=4.9Hz,1H),5.01(s,1H),4.92(s,1H),4.11(d,J=14.5Hz,2H),3.96(s,1H),3.80(s,2 H),3.71(d,J=11.4Hz,5H),3.63(d,J=1.9Hz,5H),3.57(d,J=17.2Hz,2H),3.49–3.38(m,7H),3.26(s,1H),2.93(s,3H),2.6 4–2.59(m,3H),2.47(d,J=11.5Hz,8H),2.39(s,1H),2.24(d,J=0.9Hz,2H),1.89(s,1H),1.24(s,6H).MS(ESI,m / z):1011(M + +1).
[0551] Example 113: Synthesis of Compound S85
[0552]
[0553] According to the synthesis of compound S1, compound S85 was obtained by replacing the corresponding intermediate. 1 H NMR (500MHz, DMSO-d6) δ11.03(s,1H),8.57(s,1H),8.11(d,J=4.9Hz,1H),7.81(dd,J=7.4,2.1Hz,1H),7.56(dd,J=7.4,2.1Hz,1H),7.47(t,J=7 .5Hz,1H),7.33(s,1H),7.28(s,1H),7.02(t,J=3.7Hz,1H),6.62(d,J=4 .9Hz,1H),4.92(s,1H),4.47(s,1H),4.32(s,1H),4.11(d,J=14.5Hz,2H) ,4.01(s,1H),3.96(s,1H),3.70(s,4H),3.63(s,3H),3.57(d,J=17.2Hz ,2H),3.49–3.38(m,7H),3.26(s,1H),3.03(d,J=12.4Hz,1H),2.98(d,J= 12.3Hz,1H),2.93(s,3H),2.64–2.56(m,7H),2.47(s,6H),2.39(s,1H), 2.19(s,1H),2.12(s,1H),1.89(s,1H),1.24(s,6H).MS(ESI,m / z):976(M + +1).
[0554] Example 114: Synthesis of Compound S86
[0555]
[0556] According to the synthesis of compound S1, compound S86 was obtained by replacing the corresponding intermediate. 1H NMR (500MHz, DMSO-d6) δ11.03(s,1H),8.57(s,1H),8.11(d,J=4.9Hz,1H),7.81(dd,J=7.2,2.3Hz,1H),7.53–7.43(m,2H),7.33(s ,1H),7.28(s,1H),7.02(t,J=3.7Hz,1H),6.62(d,J=4.9Hz,1H),4.92(s,1H),4.39(s,1H),4.26(s,1H),4.11(d,J=14.5Hz,2H),4 .01(s,1H),3.96(s,1H),3.70(s,4H),3.64(d,J=11.1Hz,5H),3.57(d,J=17.2Hz,2H),3.49–3.38(m,7H),3.26(s,1H),2.93(s,3H ),2.63–2.56(m,7H),2.46(d,J=5.3Hz,4H),2.39(s,1H),2.19(s,1H),2.12(s,1H),1.89(s,1H),1.24(s,6H).MS(ESI,m / z):962(M + +1).
[0557] Example 115: Synthesis of Compound S87
[0558]
[0559] According to the synthesis of compound S1, compound S87 was obtained by replacing the corresponding intermediate. 1H NMR (500MHz, DMSO-d6) δ11.03(s,1H),8.57(s,1H),8.17(d,J=4.9Hz,1H),7.81(dd,J=7.0,2.5Hz,1H),7.53–7.43(m,2H),7.33(s,1H),7.28(s ,1H),7.02(t,J=3.7Hz,1H),6.62(d,J=4.9Hz,1H),5.29(d,J=5.1Hz,1H ),4.79(s,1H),4.47(s,1H),4.32(s,1H),4.14–4.04(m,3H),4.01(s,1H ),3.70(s,4H),3.62(d,J=9.7Hz,3H),3.55(s,1H),3.49–3.39(m,5H),3 .26(s,1H),2.93(s,3H),2.64(s,2H),2.62–2.51(m,7H),2.48(d,J=14. 8Hz,5H),2.19(s,1H),2.10(d,J=19.1Hz,2H),2.03(s,1H),1.56(s,2H),1.48(s,2H),1.30(d,J=1.4Hz,4H),1.24(s,6H).MS(ESI,m / z):1017(M + +1).
[0560] Example 116: Synthesis of Compound S88
[0561]
[0562] According to the synthesis of compound S1, compound S88 was obtained by replacing the corresponding intermediate. 1H NMR (500MHz, DMSO-d6) δ11.03(s,1H),8.57(s,1H),8.11(d,J=4.9Hz,1H),7.90(d,J=7.5Hz,1H),7.74(dd,J=7.4,1.9Hz,1H),7.63(dt,J=1. 9,0.9Hz,1H),7.33(s,1H),7.28(s,1H),7.02(t,J=3.7Hz,1H),6.62(d,J=4.9Hz,1H),4.92(s,1H),4.57(dd,J=5.0,1.0Hz,2H),4.11(d,J=14 .5Hz,2H),4.01(s,1H),3.96(s,1H),3.70(s,4H),3.63(s,3H),3.57(d,J=17.2Hz,2H),3.49–3.38(m,7H),3.26(s,1H),2.98–2.92(m,4H),2 .88(d,J=12.5Hz,1H),2.63–2.55(m,7H),2.47(s,6H),2.39(s,1H),2.19(s,1H),2.12(s,1H),1.89(s,1H),1.24(s,6H).MS(ESI,m / z):976(M + +1).
[0563] Example 117: Synthesis of Compound S89
[0564]
[0565] According to the synthesis of compound S1, compound S89 was obtained by replacing the corresponding intermediate. 1H NMR (500MHz, DMSO-d6) δ11.03(s,1H),8.57(s,1H),8.11(d,J=4.9Hz,1H),7.98(d,J=7.5Hz,1H),7.84(d,J=2.0Hz,1H),7.71(dd ,J=7.5,2.0Hz,1H),7.33(s,1H),7.28(s,1H),7.02(t,J=3.7Hz,1H),6.62(d,J=4.9Hz,1H),5.01(s,1H),4.92(s,1H),4.11(d,J =14.5Hz,2H),3.96(s,1H),3.70(s,4H),3.64(d,J=8.7Hz,5H),3.57(d,J=17.2Hz,2H),3.49–3.38(m,7H),3.26(s,1H),2.93(s, 3H),2.65–2.56(m,7H),2.46(d,J=5.3Hz,4H),2.39(s,1H),2.23(d,J=3.8Hz,2H),1.89(s,1H),1.24(s,6H).MS(ESI,m / z):976(M + +1).
[0566] Example 118: Synthesis of Compound S90
[0567]
[0568] According to the synthesis of compound S1, the corresponding intermediate was replaced to obtain compound S90. 1H NMR (500MHz, DMSO-d6) δ11.03(s,1H),8.57(s,1H),8.11(d,J=4.9Hz,1H),7.89(d,J=7.5Hz,1H),7.70(dd,J=7.5,1.8Hz,1H),7.63(dt,J=2.0,1.0 Hz,1H),7.33(s,1H),7.28(s,1H),7.02(t,J=3.7Hz,1H),6.62(d,J=4.9H z,1H),4.92(s,1H),4.58(d,J=1.1Hz,1H),4.48(d,J=0.9Hz,1H),4.11(d, J=14.5Hz,2H),4.01(s,1H),3.96(s,1H),3.70(s,4H),3.63(s,3H),3.57 (d,J=17.2Hz,2H),3.49–3.38(m,7H),3.26(s,1H),2.93(s,3H),2.66–2.4 5(m,15H),2.39(s,1H),2.19(s,1H),2.12(s,1H),1.89(s,1H),1.56(s,2 H),1.48(s,2H),1.30(d,J=1.4Hz,4H),1.24(s,6H).MS(ESI,m / z):1032(M + +1).
[0569] Example 119: Synthesis of Compound S91
[0570]
[0571] According to the synthesis of compound S1, compound S91 was obtained by replacing the corresponding intermediate. 1H NMR (500MHz, DMSO-d6) δ11.03(s,1H),8.57(s,1H),8.11(d,J=4.9Hz,1H),7.83(d,J=7.5Hz,1H),7.60(d,J=2.0Hz,1H),7.41–7.31(m,2H) ,7.28(s,1H),7.02(t,J=3.7Hz,1H),6.62(d,J=4.9Hz,1H),5.01(s,1H),4.92(s,1H),4.11(d,J=14.5Hz,2H),3.96(s,1H),3.77(d,J=9.5H z,1H),3.70(s,4H),3.63(s,3H),3.59(s,1H),3.57–3.45(m,5H),3.44–3.38(m,6H),3.26(s,1H),2.93(s,3H),2.87(s,1H),2.65–2.56(m ,7H),2.47(d,J=2.6Hz,4H),2.39(s,1H),2.23(d,J=3.8Hz,2H),2.14(s,1H),1.89(s,1H),1.64(s,1H),1.24(s,6H).MS(ESI,m / z):1007(M + +1).
[0572] Example 120: Synthesis of Compound S92
[0573]
[0574] According to the synthesis of compound S1, compound S92 was obtained by replacing the corresponding intermediate. 1HNMR(500MHz,DMSO-d6)δ11.03(s,1H),8.57(s,1H),8.11(d,J=4.9Hz,1H),7.77(d,J=7.5Hz,1H),7.55(d,J=2.0Hz,1H),7.41(dd,J=7.4,1 .9Hz,1H),7.33(s,1H),7.28(s,1H),7.02(t,J=3.7Hz,1H),6.62(d,J=4.9Hz,1H),5.01(s,1H),4.92(s,1H),4.11(d,J=14.5Hz,2H),3.96(s ,1H),3.85(s,2H),3.70(s,2H),3.62(d,J=3.9Hz,5H),3.61–3.53(m,4H),3.49–3.38(m,7H),3.29(s,1H),2.93(s,3H),2.67(s,1H),2.65– 2.59(m,3H),2.49(s,8H),2.39(s,1H),2.23(d,J=3.8Hz,2H),1.92–1.86(m,3H),1.81(d,J=13.0Hz,2H),1.24(s,6H).MS(ESI,m / z):1033(M + +1).
[0575] Example 121: Synthesis of Compound S93
[0576]
[0577] According to the synthesis of compound S1, compound S93 was obtained by replacing the corresponding intermediate. 1H NMR (500MHz, DMSO-d6) δ11.03(s,1H),8.57(s,1H),8.11(d,J=4.9Hz,1H),7.83(d,J=7.5Hz,1H),7.60(d,J=2.0Hz,1H),7.41(dd,J= 7.4,1.9Hz,1H),7.33(s,1H),7.28(s,1H),7.02(t,J=3.7Hz,1H),6.62(d,J=4.9Hz,1H),5.01(s,1H),4.92(s,1H),4.11(d,J=14.5H z,2H),3.96(s,1H),3.89(s,2H),3.70(s,2H),3.65–3.53(m,9H),3.49–3.38(m,7H),3.26(s,1H),2.93(s,3H),2.75(s,1H),2.65–2 .56(m,9H),2.53(s,2H),2.39(s,1H),2.23(d,J=3.8Hz,2H),1.89(s,1H),1.47(d,J=4.4Hz,8H),1.24(s,6H).MS(ESI,m / z):1061(M + +1).
[0578] Example 122: Synthesis of Compound S94
[0579]
[0580] According to the synthesis of compound S1, compound S94 was obtained by replacing the corresponding intermediate. 1H NMR (500MHz, DMSO-d6) δ11.03(s,1H),8.57(s,1H),8.11(d,J=4.9Hz,1H),7.83(d,J=7.5Hz,1H),7.60(d,J=2.0Hz,1H),7.41–7.31(m ,2H),7.28(s,1H),7.02(t,J=3.7Hz,1H),6.62(d,J=4.9Hz,1H),5.01(s,1H),4.92(s,1H),4.11(d,J=14.5Hz,2H),3.96(s,1H),3.77 (s,2H),3.69(d,J=9.9Hz,6H),3.63(s,3H),3.57(d,J=17.2Hz,2H),3.49–3.38(m,8H),3.26(s,1H),3.03(s,1H),2.91(d,J=18.7Hz, 5H),2.81(s,2H),2.65–2.59(m,3H),2.49(s,8H),2.39(s,1H),2.24(d,J=0.9Hz,2H),1.89(s,1H),1.24(s,6H).MS(ESI,m / z):1048(M + +1).
[0581] Example 123: Synthesis of Compound S95
[0582]
[0583] According to the synthesis of compound S1, compound S95 was obtained by replacing the corresponding intermediate. 1H NMR (500MHz, DMSO-d6) δ11.03(s,1H),8.57(s,1H),8.11(d,J=4.9Hz,1H),7.83(d,J=7.5Hz,1H),7.60(d,J=2.0Hz,1H),7.41(dd,J=7 .4,1.9Hz,1H),7.33(s,1H),7.28(s,1H),7.02(t,J=3.7Hz,1H),6.62(d,J=4.9Hz,1H),5.01(s,1H),4.92(s,1H),4.11(d,J=14.5Hz, 2H),3.96(s,1H),3.70(s,2H),3.65–3.53(m,9H),3.51(s,2H),3.49–3.38(m,7H),3.26(s,1H),2.93(s,3H),2.67(s,1H),2.65–2.56 (m,5H),2.48(d,J=7.5Hz,6H),2.39(s,1H),2.23(d,J=3.8Hz,2H),1.94(s,4H),1.92–1.79(m,5H),1.24(s,6H).MS(ESI,m / z):1061(M + +1).
[0584] Example 124: Synthesis of Compound S96
[0585]
[0586] According to the synthesis of compound S1, compound S96 was obtained by replacing the corresponding intermediate. 1H NMR (500MHz, DMSO-d6) δ11.03(s,1H),8.57(s,1H),8.11(d,J=4.9Hz,1H),7.83(d,J=7.5Hz,1H),7.60(d,J=2.0Hz,1H),7.41–7.31(m,2H),7.0 8(s,1H),7.02(t,J=3.7Hz,1H),6.62(d,J=4.9Hz,1H),5.01(s,1H),4.9 2(s,1H),4.11(d,J=14.5Hz,2H),3.96(s,1H),3.77(s,2H),3.70(s,2H) ,3.63(d,J=4.7Hz,4H),3.59(s,3H),3.49(d,J=18.0Hz,6H),3.41(d,J=11.4Hz,4H),3.29(s,1H),3.01(s,2H),2.93(s,3H),2.86(d,J=2.0Hz, 4H),2.75(s,2H),2.65–2.59(m,3H),2.54(s,1H),2.39(d,J=4.0Hz,2H) ,2.24(d,J=0.9Hz,2H),1.89(s,1H),1.29(s,6H).MS(ESI,m / z):1019(M + +1).
[0587] Example 125: Synthesis of Compound S97
[0588]
[0589] According to the synthesis of compound S1, compound S97 was obtained by replacing the corresponding intermediate. 1H NMR (500MHz, DMSO-d6) δ11.03(s,1H),8.57(s,1H),8.11(d,J=4.9Hz,1H),7.83(d,J=7.4Hz,1H),7.52–7.43(m,2H),7.3 3(s,1H),7.28(s,1H),7.02(t,J=3.7Hz,1H),6.65–6.60(m,2H),5.01(s,1H),4.92(s,1H),4.11(d,J=14.5Hz,2H),3.96 (s,1H),3.70(s,4H),3.63(s,3H),3.57(d,J=17.2Hz,2H),3.51–3.38(m,9H),3.29(s,1H),2.93(s,3H),2.65–2.56(m,5 H),2.49(d,J=15.0Hz,8H),2.39(s,1H),2.24(d,J=0.9Hz,2H),1.88(d,J=4.6Hz,3H),1.24(s,6H).MS(ESI,m / z):995(M + +1).
[0590] Example 126: Synthesis of Compound S98
[0591]
[0592] According to the synthesis of compound S1, compound S98 was obtained by replacing the corresponding intermediate. 1H NMR (500MHz, DMSO-d6) δ11.03(s,1H),8.57(s,1H),8.11(d,J=4.9Hz,1H),7.91(d,J=7.5Hz,1H),7.53(dd,J=7.5,2.0Hz,1H),7.38(d,J=2 .0Hz,1H),7.33(s,1H),7.28(s,1H),7.02(t,J=3.7Hz,1H),6.62(d,J=4.9Hz,1H),6.55(s,1H),5.01(s,1H),4.92(s,1H),4.11(d,J=14.5H z,2H),3.96(s,1H),3.70(s,2H),3.63(s,3H),3.61–3.53(m,4H),3.49–3.43(m,8H),3.40(s,3H),3.35(d,J=3.0Hz,2H),3.03(s,1H),2.9 3(s,3H),2.79(s,2H),2.65–2.59(m,3H),2.52(s,4H),2.39(s,1H),2.24(d,J=0.9Hz,2H),1.89(s,1H),1.24(s,6H).MS(ESI,m / z):1009(M + +1).
[0593] Example 127: Synthesis of Compound S99
[0594]
[0595] According to the synthesis of compound S1, compound S99 was obtained by replacing the corresponding intermediate. 1H NMR (500MHz, DMSO-d6) δ11.03(s,1H),8.57(s,1H),8.11(d,J=4.9Hz,1H),7.81(d,J=7.5Hz,1H),7.33(s,1H),7.28(s,1H),7.22(d,J=2.0Hz,1H ),7.06(dd,J=7.5,2.0Hz,1H),7.02(t,J=3.7Hz,1H),6.62(d,J=4.9Hz,1H),5.01(s,1H),4.92(s,1H),4.20(s,2H),4.11(d,J=14.5Hz,2H),3.96 (s,1H),3.70(s,4H),3.63(s,3H),3.57(d,J=17.2Hz,2H),3.49–3.38(m ,7H),3.35(s,1H),2.93(s,3H),2.64–2.59(m,3H),2.55(s,2H),2.46(d, J=4.9Hz,8H),2.39(s,1H),2.24(d,J=0.9Hz,2H),2.18(d,J=12.3Hz,1H),2.00(d,J=12.5Hz,1H),1.89(s,1H),1.24(s,6H).MS(ESI,m / z):996(M + +1).
[0596] Example 128: Synthesis of Compound S100
[0597]
[0598] Compound 24 (682 mg, 1.0 mmol) and compound 11 (331 mg, 1.0 mmol) were dissolved in DMF (5 mL), HATU (470 mg, 1.5 mmol) and DIPEA (287 μL, 3.0 mmol) were added, and the mixture was heated to 100°C for 4 hours until the reaction was complete. After cooling to room temperature, the mixture was extracted with EA three times. The organic phases were combined, dried over anhydrous sodium sulfate, filtered, concentrated, and separated by column chromatography to obtain compound S100 (348 mg, 35%). 1H NMR (500MHz, DMSO-d6) δ11.03(s,1H),8.57(s,1H),8.11(d,J=4.9Hz,1H),7.96(dd,J=7.5,2.0Hz,1H),7.48(dd,J=7.5,2.0Hz,1H),7.3 5–7.25(m,3H),7.02(t,J=3.7Hz,1H),6.62(d,J=4.9Hz,1H),6.12(s,1H),5.12(s,1H),4.92(s,1H),4.65(d,J=12.4Hz,1H),4.51(d,J=1 2.4Hz,1H),4.11(d,J=14.5Hz,2H),3.96(s,1H),3.70(s,2H),3.63(s,3H),3.61–3.50(m,8H),3.47(d,J=5.9Hz,4H),3.40(s,3H),3.03( s,1H),2.93(s,3H),2.66(s,1H),2.63–2.52(m,6H),2.39(s,1H),2.25(d,J=11.2Hz,2H),1.89(s,1H),1.24(s,6H).MS(ESI,m / z):995(M + +1).
[0599] Example 129: Synthesis of Compound S101
[0600]
[0601] According to the synthesis of compound S71, the corresponding intermediate was replaced to obtain compound S101. 1H NMR(500MHz,DMSO-d6)δ11.02(s,1H),8.34(s,1H),8.11(d,J=4.9Hz,1H),7 .78(d,J=7.5Hz,1H),7.59(d,J=2.0Hz,1H),7.41(dd,J=7.5,1.8Hz,1H),7.3 3(s,1H),7.08(s,1H),7.02(t,J=3.7Hz,1H),6.62(d,J=4.9Hz,1H),5.01(s, 1H),4.92(s,1H),4.11(d,J=14.5Hz,2H),3.96(s,1H),3.78(s,1H),3.70(s, 2H),3.63(d,J=4.7Hz,4H),3.57(d,J=16.3Hz,2H),3.52(s,2H),3.46(d,J=8 .6Hz,6H),3.40(s,3H),2.93(s,3H),2.65–2.55(m,7H),2.47(d,J=13.9Hz,3 H),2.39(s,1H),2.23(d,J=3.8Hz,2H),1.89(s,1H),1.82(s,2H),1.77(s,2H ),1.72(s,2H),1.60(s,1H),1.52(s,1H),1.29(s,6H).MS(ESI,m / z):1020(M + +1).
[0602] Example 130: Synthesis of Compound S102
[0603]
[0604] According to the synthesis of compound S71, the corresponding intermediate was replaced to obtain compound S102. 1H NMR (500 MHz, DMSO-d6) δ11.02 (s, 1H), 8.57 (s, 1H), 8.11 (d, J = 4.9 Hz, 1H), 7.78 (d, J = 7.5 Hz, 1H), 7.59 (d, J = 2.0 Hz, 1H), 7.41 (dd, J = 7.5, 1.8 Hz, 1H), 7.33 (s, 1H), 7.12 (s, 1H), 7.02 (t, J = 3.7 Hz, 1H), 6.62 (d, J = 4.9 Hz, 1H), 5.01 (s, 1H), 4.92 (s, 1H), 4.11 (d, J = 14.5 Hz, 2H), 3.96 (s, 1H), 3.78 (s, 1H), 3 .70(s,2H),3.63(s,3H),3.61–3.53(m,5H),3.46(d,J=8.8Hz,4H),3.40(s ,3H),3.33(s,2H),3.26(s,1H),2.93(s,3H),2.86(s,4H),2.65–2.59(m,3 H),2.39(s,1H),2.23(d,J=3.8Hz,2H),1.89(s,1H),1.74(s,2H),1.67(d, J=3.8Hz,4H),1.54(s,1H),1.48(s,1H),1.24(s,6H).MS(ESI,m / z):1006(M + +1).
[0605] Example 131: Synthesis of Compound S103
[0606]
[0607] According to the synthesis of compound S71, compound S103 was obtained by replacing the corresponding intermediate. 1H NMR (500MHz, DMSO-d6) δ11.02(s,1H),8.34(s,1H),8.11(d,J=4.9Hz,1H),7.78(d,J=7.5Hz,1H),7.55(d,J=2.0Hz,1H),7.41(dd,J=7.5,1.8Hz,1H ),7.33(s,1H),7.08(s,1H),7.02(t,J=3.7Hz,1H),6.62(d,J=4.9Hz,1H) ,5.01(s,1H),4.92(s,1H),4.15(s,1H),4.10(s,1H),3.96(s,1H),3.70( s,2H),3.63(d,J=4.7Hz,4H),3.59(s,3H),3.52(s,2H),3.47(d,J=2.9Hz ,6H),3.40(s,3H),2.93(s,3H),2.67(s,2H),2.65–2.59(m,5H),2.50(s, 2H),2.39(s,1H),2.25–2.17(m,4H),2.03(s,1H),1.89(s,1H),1.68(d,J =5.7Hz,4H),1.53(s,1H),1.46(s,1H),1.29(s,6H).MS(ESI,m / z):1020(M + +1).
[0608] Example 132: Synthesis of Compound S104
[0609]
[0610] According to the synthesis of compound S71, compound S104 was obtained by replacing the corresponding intermediate. 1HNMR (500MHz, DMSO-d6) δ11.02(s,1H),8.57(s,1H),8.11(d,J=4.9Hz,1H),7.78(d,J=7.5Hz,1H),7.55(d,J=2.0Hz,1H),7.44(dd,J=7. 5,2.0Hz,1H),7.33(s,1H),7.28(s,1H),7.02(t,J=3.7Hz,1H),6.62(d,J=4.9Hz,1H),5.01(s,1H),4.92(s,1H),4.11(d,J=14.5Hz,2H) ,3.96(s,1H),3.70(d,J=1.6Hz,4H),3.63(s,3H),3.57(d,J=17.2Hz,2H),3.52(s,2H),3.49–3.38(m,9H),3.02(s,1H),2.93(s,3H),2. 67–2.56(m,7H),2.39(s,1H),2.25–2.17(m,4H),1.89(s,1H),1.69(s,4H),1.53(s,1H),1.44(s,1H),1.24(s,6H).MS(ESI,m / z):1006(M + +1).
[0611] Example 133: Synthesis of Compound S105
[0612]
[0613] According to the synthesis of compound S71, compound S105 was obtained by replacing the corresponding intermediate. 1H NMR (500MHz, DMSO-d6) δ11.02(s,1H),8.57(s,1H),8.11(d,J=4.9Hz,1H),7.83(d,J=7.5Hz,1H),7.60(d,J=2.0Hz,1H),7.41(dd,J=7.4,1.9H z,1H),7.33(s,1H),7.12(s,1H),7.02(t,J=3.7Hz,1H),6.62(d,J=4.9Hz,1H),5.01(s,1H),4.92(s,1H),4.11(d,J=14.5Hz,2H),3.96(s,1H) ,3.70(s,2H),3.63(s,3H),3.61–3.53(m,4H),3.47(s,2H),3.40(s,3H ),3.33(s,2H),3.20(s,4H),3.02(s,1H),2.93(s,3H),2.65–2.57(m,1 1H),2.45(s,2H),2.39(s,1H),2.23(d,J=3.8Hz,2H),1.89(s,1H),1.74(s,1H),1.67(s,2H),1.60(s,2H),1.24(s,6H).MS(ESI,m / z):1035(M + +1).
[0614] Example 134: Synthesis of Compound S106
[0615]
[0616] According to the synthesis of compound S71, compound S106 was obtained by replacing the corresponding intermediate. 1H NMR(500MHz,DMSO-d6)δ11.02(s,1H),9.51(s,1H),8.34(s,1H),7.90(s,1H),7.83(d,J=7.4Hz,1H),7.51–7.41(m,2H) ,7.12(s,1H),7.02(t,J=3.7Hz,1H),5.29(d,J=5.1Hz,1H),5.20(s,1H),5.01(s,1H),4.12(d,J=4.9Hz,1H),3.72–3.6 1(m,10H),3.55(s,1H),3.45(d,J=18.3Hz,4H),3.33(s,1H),3.22(s,4H),2.93(s,3H),2.75(s,1H),2.65–2.58(m,11H ),2.23(d,J=3.8Hz,2H),2.12(s,3H),2.02(d,J=15.2Hz,2H),1.63(d,J=17.6Hz,4H),1.24(s,6H).MS(ESI,m / z):994(M + +1).
[0617] Example 135: Synthesis of Compound S107
[0618]
[0619] According to the synthesis of compound S71, the corresponding intermediate was replaced to obtain compound S107. 1H NMR (500MHz, DMSO-d6) δ11.02(s,1H),8.57(s,1H),8.11(d,J=4.9Hz,1H),7.83(d,J=7.5Hz,1H),7.49(d,J=2.0Hz,1H),7.39(dd,J=7.5,1 .8Hz,1H),7.33(s,1H),7.12(s,1H),7.02(t,J=3.7Hz,1H),6.62(d,J=4.9Hz,1H),5.01(s,1H),4.92(s,1H),4.11(d,J=14.5Hz,2H),3.96( s,1H),3.73–3.61(m,11H),3.57(d,J=17.2Hz,2H),3.49–3.38(m,7H),3.33(s,1H),2.93(s,3H),2.74–2.69(m,3H),2.69–2.63(m,3H),2.6 1(d,J=3.8Hz,6H),2.39(s,1H),2.23(d,J=3.8Hz,2H),2.16(s,2H),1.88(d,J=9.5Hz,3H),1.37(s,2H),1.24(s,6H).MS(ESI,m / z):1047(M + +1).
[0620] Example 136: Synthesis of Compound S108
[0621]
[0622] According to the synthesis of compound S71, compound S108 was obtained by replacing the corresponding intermediate. 1HNMR (500MHz, DMSO-d6) δ11.02(s,1H),8.57(s,1H),8.11(d,J=4.9Hz,1H),7.80(d,J=7.4Hz,1H),7.48(dd,J=7.4,1.9Hz,1H),7. 38(d,J=2.0Hz,1H),7.33(s,1H),7.28(s,1H),7.02(t,J=3.7Hz,1H),6.62(d,J=4.9Hz,1H),6.34(s,1H),5.01(s,1H),4.92(s,1H ),4.11(d,J=14.5Hz,2H),3.96(s,1H),3.70(s,4H),3.63(s,3H),3.57(d,J=17.2Hz,2H),3.52–3.38(m,9H),3.26(s,1H),2.93(s ,3H),2.68–2.56(m,7H),2.47(d,J=2.6Hz,6H),2.39(s,1H),2.24(d,J=0.9Hz,2H),1.89(s,1H),1.24(s,6H).MS(ESI,m / z):981(M + +1).
[0623] Example 137: Synthesis of Compound S109
[0624]
[0625] According to the synthesis of compound S71, compound S109 was obtained by replacing the corresponding intermediate. 1H NMR (500MHz, DMSO-d6) δ11.02(s,1H),8.57(s,1H),8.11(d,J=4.9Hz,1H),7.83(d,J=7.5Hz,1H),7.49(d,J=2.0Hz,1H),7.39(dd,J=7.5,1 .8Hz,1H),7.33(s,1H),7.12(s,1H),7.02(t,J=3.7Hz,1H),6.62(d,J=4.9Hz,1H),5.01(s,1H),4.92(s,1H),4.11(d,J=14.5Hz,2H),3.96 (s,1H),3.73–3.68(m,8H),3.63(s,3H),3.57(d,J=17.2Hz,2H),3.49–3.38(m,7H),3.33(s,1H),2.93(s,3H),2.86(s,1H),2.67(s,2H),2 .65–2.58(m,7H),2.49(s,2H),2.39(s,1H),2.23(d,J=3.8Hz,2H),1.89(s,1H),1.63(d,J=10.1Hz,4H),1.24(s,6H).MS(ESI,m / z):1033(M + +1).
[0626] Example 138: Synthesis of Compound S110
[0627]
[0628] According to the synthesis of compound S71, the corresponding intermediate was replaced to obtain compound S110. 1H NMR(500MHz,DMSO-d6)δ11.02(s,1H),8.57(s,1H),8.11(d,J=4.9Hz,1H),7.96(dd,J=5.7,3.8Hz,1H),7.51(s,1H),7.49–7.41(m,2H),7.3 3(s,1H),7.12(s,1H),7.02(t,J=3.7Hz,1H),6.62(d,J=4.9Hz,1H),5.12(s,1H),4.92(s,1H),4.11(d,J=14.5Hz,2H),3.96(s,1H),3.70(d, J=1.6Hz,4H),3.63(s,3H),3.57(d,J=17.2Hz,2H),3.49–3.38(m,9H),3.02(s,1H),2.93(s,3H),2.66(s,1H),2.60(d,J=5.5Hz,5H),2.54( s,1H),2.39(s,1H),2.24(d,J=0.9Hz,2H),1.95(s,2H),1.89(s,1H),1.79(d,J=20.0Hz,3H),1.70(s,2H),1.24(s,6H).MS(ESI,m / z):980(M + +1).
[0629] Example 139: Synthesis of Compound S111
[0630]
[0631] According to the synthesis of compound S71, the corresponding intermediate was replaced to obtain compound S111. 1HNMR(500MHz,DMSO-d6)δ11.02(s,1H),8.57(s,1H),8.11(d,J=4.9Hz,1H),7.83(d,J=7.5Hz,1H),7.49(d,J=2.0Hz,1H),7.41– 7.31(m,2H),7.12(s,1H),7.02(t,J=3.7Hz,1H),6.62(d,J=4.9Hz,1H),5.01(s,1H),4.92(s,1H),4.11(d,J=14.5Hz,2H),3.96( s,1H),3.72–3.66(m,6H),3.63(s,3H),3.61–3.51(m,4H),3.47(s,2H),3.40(d,J=0.7Hz,5H),3.33(s,1H),3.11(s,1H),2.95–2 .81(m,9H),2.65–2.58(m,5H),2.39(s,1H),2.30(s,2H),2.24(d,J=0.9Hz,2H),1.89(s,1H),1.24(s,6H).MS(ESI,m / z):1019(M + +1).
[0632] Example 140: Synthesis of Compound S112
[0633]
[0634] According to the synthesis of compound S71, the corresponding intermediate was replaced to obtain compound S112. 1H NMR (500MHz, DMSO-d6) δ11.02 (s, 1H), 8.57 (s, 1H), 8.11 (d, J = 4.9 Hz, 1H), 7.83 (d, J = 7.5 Hz, 1H), 7.49 (d, J = 2.0 Hz, 1H), 7.41–7.31 (m, 2H), 7.12 (s, 1H), 7.02 (t, J = 3.7 Hz, 1H), 6.62 (d, J = 4.9 Hz, 1H), 5.01 (s, 1H), 4.92 (s, 1H), 4.11 (d, J = 14.5 Hz, 2H), 3. 96(s,1H),3.72–3.66(m,6H),3.63(s,3H),3.61–3.51(m,4H),3.47(s,2H),3.42–3.38(m,6H),3.29(s,1H),2.93(s,3H),2.7 4(s,4H),2.67(s,2H),2.65–2.59(m,5H),2.39(s,1H),2.24(d,J=0.9Hz,2H),1.89(s,1H),1.24(s,6H).MS(ESI,m / z):1005(M + +1).
[0635] Example 141: Synthesis of Compound S113
[0636]
[0637] According to the synthesis of compound S1, the corresponding intermediate was replaced to obtain compound S113. 1H NMR (500MHz, DMSO-d6) δ11.02(s,1H),8.60(s,1H),8.11(d,J=4.9Hz,1H),7.83(d,J=7.5Hz,1H),7.60(d,J=2.0Hz,1H),7.45(s,1H),7.38 (dd,J=7.5,2.0Hz,1H),7.26(s,1H),7.02(t,J=3.7Hz,1H),6.62(d,J=4.9Hz,1H),5.01(s,1H),4.92(s,1H),4.11(d,J=14.5Hz,2H),3.96( s,1H),3.70(s,2H),3.63(s,3H),3.57(d,J=17.2Hz,2H),3.50–3.38(m,5H),3.28(d,J=17.0Hz,4H),2.93(d,J=3.7Hz,4H),2.65–2.54(m,7 H),2.50(s,2H),2.39(s,1H),2.23(d,J=3.8Hz,2H),1.89(s,1H),1.76–1.70(m,5H),1.68–1.58(m,6H),1.29(s,6H).MS(ESI,m / z):1017(M + +1).
[0638] Example 142: Synthesis of Compound S114
[0639]
[0640] According to the synthesis of compound S1, the corresponding intermediate was replaced to obtain compound S114. 1H NMR (500MHz, DMSO-d6) δ11.02(s,1H),8.60(s,1H),8.11(d,J=4.9Hz,1H),7.83(d,J=7.5Hz,1H),7.60(d,J=2.0Hz,1H),7.45(s,1H),7. 38(dd,J=7.5,2.0Hz,1H),7.26(s,1H),7.02(t,J=3.7Hz,1H),6.62(d,J=4.9Hz,1H),5.01(s,1H),4.92(s,1H),4.11(d,J=14.5Hz,2H), 3.96(s,1H),3.70(s,2H),3.63(s,3H),3.57(d,J=17.2Hz,2H),3.50–3.38(m,5H),3.21(d,J=7.3Hz,4H),2.93(d,J=3.7Hz,4H),2.65–2 .54(m,11H),2.50(s,4H),2.39(s,1H),2.23(d,J=3.8Hz,2H),1.89(s,1H),1.74(s,2H),1.66(s,2H),1.29(s,6H).MS(ESI,m / z):1018(M + +1).
[0641] Example 143: Synthesis of Compound S115
[0642]
[0643] According to the synthesis of compound S1, the corresponding intermediate was replaced to obtain compound S115. 1H NMR (500MHz, DMSO-d6) δ11.02(s,1H),8.60(s,1H),8.11(d,J=4.9Hz,1H),7.83(d,J=7.5Hz,1H),7.60(d,J=2.0Hz,1H),7.48(s, 1H),7.38(dd,J=7.5,2.0Hz,1H),7.26(s,1H),7.02(t,J=3.7Hz,1H),6.62(d,J=4.9Hz,1H),5.01(s,1H),4.92(s,1H),4.11(d,J =14.5Hz,2H),3.96(s,1H),3.67(d,J=8.4Hz,4H),3.65–3.57(m,5H),3.50–3.36(m,8H),2.93(d,J=1.1Hz,4H),2.86(s,2H),2.7 0(s,2H),2.62(d,J=11.5Hz,2H),2.56(s,1H),2.39(s,1H),2.24(d,J=0.9Hz,2H),1.89(s,1H),1.29(s,6H).MS(ESI,m / z):933(M + +1).
[0644] Example 144: Synthesis of Compound S116
[0645]
[0646] According to the synthesis of compound S1, the corresponding intermediate was replaced to obtain compound S116. 1H NMR (500MHz, DMSO-d6) δ11.02(s,1H),8.60(s,1H),8.11(d,J=4.9Hz,1H),7.86(d,J=7.5Hz,1H),7.59(d,J=2.0Hz,1H),7.48(s,1H),7.42(dd ,J=7.5,2.0Hz,1H),7.26(s,1H),7.02(t,J=3.7Hz,1H),6.62(d,J=4.9Hz,1H),5.01(s,1H),4.92(s,1H),4.11(d,J=14.5Hz,2H),3.96(s,1H) ,3.67(s,2H),3.65–3.57(m,5H),3.47(d,J=12.3Hz,1H),3.45–3.35(m ,8H),3.08(s,1H),2.92(d,J=10.2Hz,4H),2.82(s,2H),2.70(s,2H),2 .62(d,J=11.5Hz,2H),2.56(s,1H),2.39(s,1H),2.23(d,J=3.8Hz,2H),1.88(d,J=4.6Hz,3H),1.80(s,2H),1.29(s,6H).MS(ESI,m / z):961(M + +1).
[0647] Example 145: Synthesis of Compound S117
[0648]
[0649] According to the synthesis of compound S1, the corresponding intermediate was replaced to obtain compound S117. 1H NMR (500MHz, DMSO-d6) δ11.02(s,1H),8.60(s,1H),8.11(d,J=4.9Hz,1H),7.86(d,J=7.5Hz,1H),7.51–7.46(m,2H),7. 42(dd,J=7.5,2.0Hz,1H),7.26(s,1H),7.02(t,J=3.7Hz,1H),6.62(d,J=4.9Hz,1H),5.01(s,1H),4.92(s,1H),4.11(d ,J=14.5Hz,2H),3.96(s,1H),3.74–3.57(m,11H),3.50–3.38(m,5H),3.09(d,J=2.9Hz,3H),2.93(s,3H),2.65–2.54(m ,5H),2.47–2.37(m,3H),2.31(d,J=12.3Hz,1H),2.23(d,J=3.8Hz,2H),1.89(s,1H),1.29(s,6H).MS(ESI,m / z):947(M + +1).
[0650] Example 146: Synthesis of Compound S118
[0651]
[0652] According to the synthesis of compound S1, the corresponding intermediate was replaced to obtain compound S118. 1HNMR(500MHz,DMSO-d6)δ11.02(s,1H),8.60(s,1H),8.11(d,J=4.9Hz,1H),7.77(d,J=7.5Hz,1H),7.59(d,J=2.0Hz,1H),7.48(s,1H),7 .41(dd,J=7.5,1.8Hz,1H),7.26(s,1H),7.02(t,J=3.7Hz,1H),6.62(d,J=4.9Hz,1H),5.01(s,1H),4.92(s,1H),4.11(d,J=14.5Hz,2H), 3.96(s,1H),3.67(s,2H),3.65–3.57(m,5H),3.50–3.38(m,5H),3.32(d,J=13.0Hz,4H),3.00–2.91(m,6H),2.84(s,2H),2.62(d,J=11.5 Hz,2H),2.56(s,1H),2.47(s,2H),2.39(s,1H),2.23(d,J=3.8Hz,2H),2.03(s,1H),1.91–1.84(m,5H),1.29(s,6H).MS(ESI,m / z):975(M + +1).
[0653] Example 147: Synthesis of Compound S119
[0654]
[0655] According to the synthesis of compound S1, the corresponding intermediate was replaced to obtain compound S119. 1H NMR (500MHz, DMSO-d6) δ11.02(s,1H),8.60(s,1H),8.11(d,J=4.9Hz,1H),7.83(d,J=7.5Hz,1H),7.60(d,J=2.0Hz,1H),7.48(s,1H),7.38(dd,J=7 .5,2.0Hz,1H),7.26(s,1H),7.02(t,J=3.7Hz,1H),6.62(d,J=4.9Hz,1H) ,5.01(s,1H),4.92(s,1H),4.11(d,J=14.5Hz,2H),3.96(s,1H),3.67(s,2 H),3.65–3.57(m,5H),3.50–3.38(m,7H),3.32(s,2H),2.98(s,1H),2.93 (s,3H),2.81(s,2H),2.69(s,2H),2.62(d,J=11.5Hz,2H),2.56(s,1H),2 .47(s,2H),2.39(s,1H),2.23(d,J=3.8Hz,2H),1.89(s,1H),1.81(s,1H) ,1.70(s,2H),1.64(s,2H),1.60(s,2H),1.29(s,6H).MS(ESI,m / z):989(M + +1).
[0656] Example 148: Synthesis of Compound S120
[0657]
[0658] According to the synthesis of compound S1, the corresponding intermediate was replaced to obtain compound S120. 1H NMR (500MHz, DMSO-d6) δ11.02(s,1H),8.60(s,1H),8.11(d,J=4.9Hz,1H),7.77(d,J=7.5Hz,1H),7.59(d,J=2.0Hz,1H),7.48(s,1H),7. 41(dd,J=7.5,1.8Hz,1H),7.26(s,1H),7.02(t,J=3.7Hz,1H),6.62(d,J=4.9Hz,1H),5.01(s,1H),4.92(s,1H),4.11(d,J=14.5Hz,2H),3 .96(s,1H),3.67(s,2H),3.65–3.57(m,5H),3.50–3.38(m,5H),3.32(d,J=13.0Hz,4H),3.00–2.91(m,6H),2.84(s,2H),2.62(d,J=11.5 Hz,2H),2.56(s,1H),2.47(s,2H),2.39(s,1H),2.23(d,J=3.8Hz,2H),2.03(s,1H),1.91–1.84(m,5H),1.29(s,6H).MS(ESI,m / z):975(M + +1).
[0659] Example 149: Synthesis of Compound S121
[0660]
[0661] According to the synthesis of compound S1, the corresponding intermediate was replaced to obtain compound S121. 1H NMR (500MHz, DMSO-d6) δ11.02(s,1H),8.60(s,1H),8.11(d,J=4.9Hz,1H),7.83(d,J=7.5Hz,1H),7.60(d,J=2.0Hz,1H),7.48(s,1H),7.3 8(dd,J=7.5,2.0Hz,1H),7.26(s,1H),7.02(t,J=3.7Hz,1H),6.62(d,J=4.9Hz,1H),5.01(s,1H),4.92(s,1H),4.11(d,J=14.5Hz,2H),3.9 6(s,1H),3.67(s,2H),3.65–3.57(m,5H),3.50–3.38(m,5H),3.21(d,J=7.3Hz,4H),2.98(s,1H),2.93(s,3H),2.81(s,2H),2.69(s,2H),2 .62(d,J=11.5Hz,2H),2.56(s,1H),2.53–2.47(m,8H),2.39(s,1H),2.23(d,J=3.8Hz,2H),1.89(s,1H),1.29(s,6H).MS(ESI,m / z):990(M + +1).
[0662] Example 150: Synthesis of Compound S122
[0663]
[0664] According to the synthesis of compound S1, the corresponding intermediate was replaced to obtain compound S122. 1H NMR (500MHz, DMSO-d6) δ11.02(s,1H),8.60(s,1H),8.11(d,J=4.9Hz,1H),7.83(d,J=7.5Hz,1H),7.59(d,J=2.0Hz,1H),7.48(s,1H),7.41(dd,J=7.4, 1.9Hz,1H),7.26(s,1H),7.02(t,J=3.7Hz,1H),6.62(d,J=4.9Hz,1H),5.0 1(s,1H),4.92(s,1H),4.11(d,J=14.5Hz,2H),3.96(s,1H),3.67(s,2H),3. 65–3.57(m,5H),3.50–3.38(m,5H),3.28(d,J=17.0Hz,4H),3.20(s,1H),2 .91(d,J=18.7Hz,5H),2.74(s,2H),2.62(d,J=11.5Hz,2H),2.58–2.49(m,2 H),2.47–2.37(m,2H),2.23(d,J=3.8Hz,2H),1.89(s,1H),1.72(d,J=12.2 Hz,1H),1.69–1.58(m,6H),1.55(s,2H),1.29(s,6H).MS(ESI,m / z):1003(M + +1).
[0665] Example 151: Synthesis of Compound S123
[0666]
[0667] According to the synthesis of compound S1, the corresponding intermediate was replaced to obtain compound S123. 1H NMR (500MHz, DMSO-d6) δ11.02(s,1H),8.60(s,1H),8.11(d,J=4.9Hz,1H),7.86(d,J=7.5Hz,1H),7.59(d,J=2.0Hz,1H),7.48(s,1H), 7.42(dd,J=7.5,2.0Hz,1H),7.26(s,1H),7.02(t,J=3.7Hz,1H),6.62(d,J=4.9Hz,1H),5.01(s,1H),4.92(s,1H),4.11(d,J=14.5Hz, 2H),3.96(s,1H),3.69–3.57(m,7H),3.51(s,2H),3.50–3.38(m,8H),3.14(s,1H),2.98–2.91(m,9H),2.80(s,1H),2.71(s,2H),2.62 (d,J=11.5Hz,2H),2.56(s,1H),2.41(d,J=19.6Hz,3H),2.23(d,J=3.8Hz,2H),1.91–1.81(m,5H),1.29(s,5H).MS(ESI,m / z):1016(M + +1).
[0668] Example 152: Synthesis of Compound S124
[0669]
[0670] According to the synthesis of compound S1, the corresponding intermediate was replaced to obtain compound S124. 1H NMR (500 MHz, DMSO-d6) δ11.02 (s, 1H), 8.60 (s, 1H), 8.11 (d, J = 4.9 Hz, 1H), 7.83 (d, J = 7.4 Hz, 1H), 7.51–7.41 (m, 3H), 7.26 (s, 1H), 7.02 (t, J = 3.7 Hz, 1H), 6.62 (d, J = 4.9 Hz, 1H), 5.01 (s, 1H), 4.92 (s, 1H), 4.11 (d, J = 14.5 Hz, 2H), 3.96 (s, 1H), 3.67 (d, J = 8.4 Hz, 4H), 3 .65–3.57(m,5H),3.50–3.38(m,7H),3.03(s,1H),3.00–2.91(m,6H),2.86(s,1H),2.72(s,2H),2.68(s,2H),2.62(d,J=11.5Hz,2H) ,2.56(d,J=6.2Hz,3H),2.39(s,1H),2.24(d,J=0.9Hz,2H),1.89(s,1H),1.63(d,J=10.1Hz,4H),1.29(s,6H).MS(ESI,m / z):1016(M + +1).
[0671] Example 153: Synthesis of Compound S125
[0672]
[0673] According to the synthesis of compound S1, the corresponding intermediate was replaced to obtain compound S125. 1H NMR (500MHz, DMSO-d6) δ11.02(s,1H),8.60(s,1H),8.11(d,J=4.9Hz,1H),7.83(d,J=7.5Hz,1H),7.60(d,J=2.0Hz,1H),7.48(s,1H),7 .38(dd,J=7.5,2.0Hz,1H),7.26(s,1H),7.02(t,J=3.7Hz,1H),6.62(d,J=4.9Hz,1H),5.01(s,1H),4.92(s,1H),4.11(d,J=14.5Hz,2H ),3.96(s,1H),3.77(s,2H),3.67(d,J=8.4Hz,4H),3.65–3.57(m,5H),3.50–3.38(m,6H),3.29(s,1H),3.01(s,2H),2.98–2.87(m,8H) ,2.70(s,2H),2.62(d,J=11.5Hz,2H),2.56(s,1H),2.39(s,1H),2.24(d,J=0.9Hz,2H),1.89(s,1H),1.29(s,6H).MS(ESI,m / z):988(M + +1).
[0674] Example 154: Synthesis of Compound S126
[0675]
[0676] According to the synthesis of compound S1, the corresponding intermediate was replaced to obtain compound S126. 1HNMR(500MHz,DMSO-d6)δ11.02(s,1H),8.60(s,1H),8.11(d,J=4.9Hz,1H),7.77(d,J=7.5Hz,1H),7.55(d,J=2.0Hz,1H),7.48(s,1H) ,7.41(dd,J=7.4,1.9Hz,1H),7.26(s,1H),7.02(t,J=3.7Hz,1H),6.62(d,J=4.9Hz,1H),5.01(s,1H),4.92(s,1H),4.11(d,J=14.5Hz ,2H),3.96(s,1H),3.85(s,2H),3.69–3.57(m,9H),3.50–3.38(m,5H),3.21(s,1H),3.00–2.91(m,6H),2.72(s,2H),2.62(d,J=11.5H z,2H),2.56(s,1H),2.39(s,1H),2.23(d,J=3.8Hz,2H),1.92–1.86(m,3H),1.78(d,J=13.0Hz,2H),1.29(s,6H).MS(ESI,m / z):973(M + +1).
[0677] Example 155: Synthesis of Compound S127
[0678]
[0679] According to the synthesis of compound S1, the corresponding intermediate was replaced to obtain compound S128. 1HNMR(500MHz,DMSO-d6)δ11.02(s,1H),8.60(s,1H),8.11(d,J=4.9Hz,1H), 7.83(d,J=7.5Hz,1H),7.60(d,J=2.0Hz,1H),7.48(s,1H),7.41(dd,J=7.4, 1.9Hz,1H),7.26(s,1H),7.02(t,J=3.7Hz,1H),6.62(d,J=4.9Hz,1H),5.01 (s,1H),4.92(s,1H),4.11(d,J=14.5Hz,2H),3.96(s,1H),3.78(s,2H),3.6 8(d,J=12.4Hz,4H),3.65–3.57(m,5H),3.50–3.38(m,5H),3.20(s,1H),2.9 8(s,1H),2.92(d,J=9.3Hz,5H),2.71(s,2H),2.62(d,J=11.5Hz,2H),2.56( s,1H),2.39(s,1H),2.23(d,J=3.8Hz,2H),1.89(s,1H),1.72(d,J=13.0Hz, 2H),1.45(s,4H),1.29(s,6H),1.22(d,J=13.0Hz,2H).MS(ESI,m / z):1001(M + +1).
[0680] Example 156: Synthesis of Compound S128
[0681]
[0682] According to the synthesis of compound S1, the corresponding intermediate was replaced to obtain compound S128. 1H NMR(500MHz,DMSO-d6)δ11.02(s,1H),8.60(s,1H),8.11(d,J=4.9Hz,1H),7.81(dd,J=7.4,2.1Hz,1H),7.55–7.43(m,2H),7.33(s,1H),7.1 7(s,1H),7.02(t,J=3.7Hz,1H),6.62(d,J=4.9Hz,1H),4.92(s,1H),4.46(d,J=11.5Hz,2H),4.11(d,J=14.5Hz,2H),4.01(s,1H),3.98–3.8 9(m,2H),3.80(d,J=12.3Hz,1H),3.70(s,2H),3.65–3.57(m,4H),3.50–3.39(m,5H),3.37(s,1H),2.93(s,3H),2.81(s,2H),2.62–2.55(m, 3H),2.53(d,J=8.4Hz,2H),2.47(s,8H),2.39(s,1H),2.19(s,1H),2.12(s,1H),1.89(s,1H),1.80(s,2H),1.26(s,6H).MS(ESI,m / z):949(M + +1).
[0683] Example 157: Synthesis of Compound S129
[0684]
[0685] According to the synthesis of compound S1, the corresponding intermediate was replaced to obtain compound S129. 1H NMR (500MHz, DMSO-d6) δ11.02(s,1H),8.60(s,1H),8.11(d,J=4.9Hz,1H),7.81(dd,J=7.4,2.1Hz,1H),7.56(dd,J=7.4,2.1Hz,1H),7.47(t,J=7 .5Hz,1H),7.33(s,1H),7.17(s,1H),7.02(t,J=3.7Hz,1H),6.62(d,J=4 .9Hz,1H),4.92(s,1H),4.47(s,1H),4.32(s,1H),4.11(d,J=14.5Hz,2H) ,4.01(s,1H),3.98–3.89(m,2H),3.80(d,J=12.3Hz,1H),3.70(s,2H),3 .65–3.57(m,4H),3.50–3.39(m,5H),3.37(s,1H),3.01(d,J=12.4Hz,1H ),2.94(d,J=15.0Hz,4H),2.62–2.53(m,5H),2.47(s,8H),2.39(s,1H), 2.19(s,1H),2.12(s,1H),1.89(s,1H),1.26(s,6H).MS(ESI,m / z):935(M + +1).
[0686] Example 158: Synthesis of Compound S130
[0687]
[0688] According to the synthesis of compound S71, compound S130 was obtained by replacing the corresponding intermediate. 1H NMR (500MHz, DMSO-d6) δ11.02(s,1H),8.60(s,1H),8.11(d,J=4.9Hz,1H),7.81(dd,J=7.0,2.5Hz,1H),7.53–7.43(m,2H),7.21( s,1H),7.17(s,1H),7.02(t,J=3.7Hz,1H),6.62(d,J=4.9Hz,1H),4.92(s,1H),4.47(s,1H),4.32(s,1H),4.15–4.05(m,3H),4.0 1(s,1H),3.98–3.89(m,2H),3.70(s,2H),3.65–3.57(m,4H),3.50–3.35(m,6H),2.93(s,3H),2.72(s,2H),2.62–2.54(m,7H),2. 39(s,1H),2.19(s,1H),2.12(s,1H),1.89(d,J=5.7Hz,2H),1.61(d,J=5.1Hz,4H),1.54(s,2H),1.26(s,6H).MS(ESI,m / z):934(M + +1).
[0689] Example 159: Synthesis of Compound S131
[0690]
[0691] According to the synthesis of compound S71, the corresponding intermediate was replaced to obtain compound S131. 1H NMR (500MHz, DMSO-d6) δ11.02(s,1H),8.60(s,1H),8.11(d,J=4.9Hz,1H),7.87(dd,J=7.5,2.0Hz,1H),7.54(td,J=7.5,2.1Hz,1H),7.43(td,J= 7.5,2.0Hz,1H),7.33(s,1H),7.19–7.10(m,2H),7.02(t,J=3.7Hz,1H), 6.62(d,J=4.9Hz,1H),5.51(td,J=2.0,1.0Hz,1H),4.92(s,1H),4.15–4. 05(m,3H),3.98–3.90(m,2H),3.76(d,J=12.4Hz,1H),3.70(s,2H),3.65 –3.57(m,4H),3.50–3.39(m,5H),3.37(s,1H),2.91(d,J=18.9Hz,5H),2. 62–2.55(m,3H),2.51(dd,J=12.5,2.0Hz,1H),2.44–2.37(m,4H),2.25– 2.17(m,3H),1.89(s,1H),1.58(s,2H),1.26(s,6H).MS(ESI,m / z):906(M + +1).
[0692] Example 160: Synthesis of Compound S132
[0693]
[0694] According to the synthesis of compound S1, the corresponding intermediate was replaced to obtain compound S132. 1H NMR(500MHz,DMSO-d6)δ11.02(s,1H),8.60(s,1H),8.11(d,J=4.9Hz,1H),7.90(dd,J=6.7,2.8Hz,1H),7.50–7.41(m,3H) ,7.26(s,1H),7.02(t,J=3.7Hz,1H),6.88(s,1H),6.62(d,J=4.9Hz,1H),5.12(s,1H),4.92(s,1H),4.11(d,J=14.5Hz,2H ),3.96(s,1H),3.67(s,2H),3.65–3.57(m,5H),3.50–3.38(m,7H),3.08(s,1H),2.93(d,J=4.6Hz,5H),2.66(s,1H),2.55 (d,J=13.7Hz,2H),2.51–2.42(m,5H),2.39(s,1H),1.99(s,1H),1.88(d,J=4.6Hz,3H),1.29(s,6H).MS(ESI,m / z):935(M + +1).
[0695] Example 161: Synthesis of Compound S133
[0696]
[0697] According to the synthesis of compound S1, the corresponding intermediate was replaced to obtain compound S133. 1 HNMR(500MHz,DMSO-d6)δ11.02(s,1H),8.60(s,1H),8.11(d,J=4.9Hz,1H),7.96(dd,J=7.1,2.4Hz,1H),7.50–7.39(m,3H),7.26 (s,1H),7.02(t,J=3.7Hz,1H),6.88(s,1H),6.62(d,J=4.9Hz,1H),5.12(s,1H),4.92(s,1H),4.11(d,J=14.5Hz,2H),3.96(s,1H ),3.67(s,2H),3.65–3.57(m,5H),3.51–3.38(m,7H),3.20(s,1H),2.93(s,3H),2.71–2.64(m,5H),2.58–2.50(m,4H),2.39(s,1 H),2.24(d,J=0.9Hz,2H),1.89(s,1H),1.66–1.60(m,3H),1.57(d,J=12.3Hz,1H),1.43(s,2H),1.29(s,6H).MS(ESI,m / z):963(M+ +1).
[0698] Example 162: Synthesis of Compound S134
[0699]
[0700] According to the synthesis of compound S1, compound S134 was obtained by replacing the corresponding intermediate. 1 H NMR (500MHz, DMSO-d6) δ11.02(s,1H),8.39(s,1H),8.15(d,J=4.9Hz,1H),7.83(d,J=7.5Hz,1H),7.62–7.57(m,2H),7.38(dd, J=7.5,2.0Hz,1H),7.26(s,1H),7.02(t,J=3.7Hz,1H),6.62(d,J=4.9Hz,1H),5.17(s,1H),5.01(s,1H),4.28(s,1H),4.01(s, 1H),3.90(s,1H),3.68(s,2H),3.67–3.54(m,6H),3.51(s,1H),3.45(s,1H),3.38(s,3H),2.99(d,J=12.3Hz,1H),2.93(s,3H) ,2.72–2.59(m,5H),2.42(d,J=18.7Hz,4H),2.36(s,1H),2.24(d,J=0.9Hz,2H),1.86(s,1H),1.29(s,6H).MS(ESI,m / z):986(M + +1).
[0701] Example 163: Synthesis of Compound S135
[0702]
[0703] According to the synthesis of compound S1, compound S135 was obtained by replacing the corresponding intermediate. 1H NMR (500MHz, DMSO-d6) δ11.02(s,1H),8.42(s,1H),8.36(s,1H),8.13(d,J=5.1Hz,1H),8.02(d,J=7.4Hz,1H),7.87(d, J=5.1Hz,1H),7.81(d,J=14.8Hz,2H),7.72–7.64(m,2H),6.36(s,1H),4.25(s,1H),3.78(s,1H),3.40(s,1H),3.24(s, 1H),2.94(s,1H),2.87(d,J=8.8Hz,2H),2.81(s,2H),2.65(s,2H),2.60–2.51(m,5H),2.46–2.37(m,5H),2.29–2.20(m ,5H),2.19(s,1H),2.14–2.07(m,5H),1.98–1.89(m,8H),1.80(s,2H),1.43(s,2H),1.32(s,6H).MS(ESI,m / z):1005(M + +1).
[0704] Example 164: Synthesis of Compound S136
[0705]
[0706] According to the synthesis of compound S1, compound S136 was obtained by replacing the corresponding intermediate. 1 H NMR (500MHz, DMSO-d6) δ11.02(s,1H),8.42(s,1H),8.36(s,1H),8.13(d,J=5.1Hz,1H),8.02(d,J=7.4Hz,1H),7.87(d, J=5.1Hz,1H),7.79(d,J=8.0Hz,2H),7.72–7.64(m,2H),4.25(s,1H),3.78(s,1H),3.40(s,1H),3.28(s,1H),3.24(s,1 H),2.94(s,1H),2.90–2.79(m,9H),2.65(s,2H),2.59–2.51(m,5H),2.42(s,2H),2.29–2.20(m,5H),2.19(s,1H),2.10 (d,J=19.4Hz,2H),1.99–1.89(m,9H),1.83–1.77(m,3H),1.43(s,2H),0.97(s,3H),0.79(s,3H).MS(ESI,m / z):1020(M + +1).
[0707] Example 165: Synthesis of Compound S137
[0708]
[0709] According to the synthesis of compound S1, compound S137 was obtained by replacing the corresponding intermediate. 1 H NMR (500MHz, DMSO-d6) δ11.02(s,1H),8.42(s,1H),8.36(s,1H),8.13(d,J=5.1Hz,1H),8.02(d,J=7.4Hz,1H),7.87 (d,J=5.1Hz,1H),7.80(s,1H),7.72–7.64(m,3H),6.36(s,1H),4.25(s,1H),3.78(s,1H),3.40(s,1H),3.24(s,1H) ,2.96–2.77(m,6H),2.71(s,2H),2.65(s,2H),2.57(s,2H),2.52(d,J=12.4Hz,2H),2.30(s,2H),2.28–2.16(m,8H) ,2.09(s,1H),1.95–1.87(m,5H),1.72(d,J=12.3Hz,1H),1.43(s,2H),1.33(d,J=9.0Hz,12H).MS(ESI,m / z):1006(M + +1).
[0710] Example 166: Synthesis of Compound S138
[0711]
[0712] According to the synthesis of compound S1, the corresponding intermediate was replaced to obtain compound S138. 1H NMR (500MHz, DMSO-d6) δ11.02(s,1H),8.42(s,1H),8.36(s,1H),8.13(d,J=5.1Hz,1H),8.02(d,J=7.4Hz,1H),7.87(d,J =5.1Hz,1H),7.81(d,J=13.5Hz,2H),7.72–7.64(m,2H),7.42(s,1H),6.36(s,1H),4.25(s,1H),3.79(d,J=5.8Hz,5H),3 .40(s,1H),3.24(s,1H),2.94(s,1H),2.87(d,J=8.8Hz,2H),2.81(s,2H),2.67–2.60(m,5H),2.57(s,2H),2.53(s,2H), 2.47(d,J=16.7Hz,5H),2.40(s,2H),2.29–2.17(m,4H),1.95–1.89(m,6H),1.31(d,J=11.4Hz,9H).MS(ESI,m / z):994(M + +1).
[0713] Example 167: Synthesis of Compound S139
[0714]
[0715] According to the synthesis of compound S1, the corresponding intermediate was replaced to obtain compound S139. 1H NMR (500 MHz, DMSO-d6) δ 11.02 (s, 1H), 8.45 (s, 1H), 8.34 (s, 1H), 8.11 (d, J = 4.9 Hz, 1H), 7.98 (d, J = 7.5 Hz, 1H), 7.83 (d, J = 2.0 Hz, 1H), 7.71 (dd, J = 7.5, 2.0 Hz, 1H), 7.33 (s, 1H), 7.13 (s, 1H), 7.02 (t, J = 3.7 Hz, 1H), 6.62 (d, J = 4.9 Hz, 1H), 5.01 (s, 1H), 4.92 (s, 1H), 4.11 (d, J = 14.5 Hz, 2H), 3.96 (s, 1H ),3.68(s,4H),3.66–3.61(m,6H),3.57(d,J=12.1Hz,3H),3.40(s,3H),2 .96(dd,J=12.4,3.8Hz,2H),2.81(d,J=12.4Hz,1H),2.74(d,J=9.3Hz,4H) ,2.71(s,1H),2.62(d,J=11.5Hz,2H),2.39(s,1H),2.23(d,J=3.8Hz,2H) ,2.17(s,1H),1.89(s,1H),1.29(s,6H),1.22(s,3H).MS(ESI,m / z):994(M + +1).
[0716] Example 168: Synthesis of Compound S140
[0717]
[0718] According to the synthesis of compound S1, the corresponding intermediate was replaced to obtain compound S140. 1H NMR(500MHzDMSO-d6)δ1102(s,1H),8.34(s,1H),8.16(d,J=5.1Hz,1H),7.86(d,J=7.5Hz,1H),7.59(d,J=2.0Hz,1H),7.42(dd,J=7.5,2.0Hz, 1H),7.33(s,1H),7.06(s,1H),7.02(t,J=3.7Hz,1H),6.73(d,J=4.9Hz ,1H),5.01(s,1H),3.73–3.66(m,9H),3.63(s,2H),3.56(s,2H),3.47( s,2H),3.39(s,2H),3.24(d,J=4.0Hz,5H),3.11(s,1H),2.93(s,3H),2 .81(s,1H),2.74(s,4H),2.65–2.59(m,3H),2.35(s,2H),2.23(d,J=3. 8Hz,2H),1.86(d,J=16.7Hz,4H),1.80(s,2H),1.66(d,J=12.3Hz,1H),1.50(d,J=12.5Hz,1H),1.19(s,3H),0.79(s,3H).MS(ESI,m / z):974(M + +1).
[0719] Example 169: Synthesis of Compound S141
[0720]
[0721] According to the synthesis of compound S1, the corresponding intermediate was replaced to obtain compound S141. 1H NMR (500MHz, DMSO-d6) δ11.02(s,1H),8.42(s,1H),8.36(s,1H),8.13(d,J=5.1Hz,1H),8.00(d,J=7.5Hz,1H),7.87(d,J=5 .1Hz,1H),7.80(s,1H),7.67(dd,J=7.5,2.0Hz,1H),7.44–7.38(m,2H),6.36(s,1H),4.25(s,1H),3.85(s,4H),3.78(s,1H ),3.42–3.37(m,2H),3.24–3.18(m,2H),2.94(s,3H),2.93–2.81(m,6H),2.79(s,1H),2.65(s,2H),2.57(s,2H),2.55–2.4 7(m,6H),2.26(d,J=11.9Hz,2H),2.17(s,1H),2.12(s,1H),1.98–1.89(m,6H),1.33(d,J=9.0Hz,12H).MS(ESI,m / z):995(M + +1).
[0722] Example 170: Synthesis of Compound S142
[0723]
[0724] According to the synthesis of compound S1, the corresponding intermediate was replaced to obtain compound S142. 1HNMR (500MHz, DMSO-d6) δ11.02(s,1H),8.57(s,1H),8.11(d,J=4.9Hz,1H),7.86(d,J=7.5Hz,1H),7.59(d,J=2.0Hz,1H),7.42(dd,J=7.5, 2.0Hz,1H),7.33(s,1H),7.08(s,1H),7.02(t,J=3.7Hz,1H),6.62(d,J=4.9Hz,1H),4.91(d,J=11.2Hz,2H),4.11(d,J=14.5Hz,2H),3.96(s ,1H),3.69(d,J=8.2Hz,6H),3.63(d,J=4.7Hz,4H),3.59(s,1H),3.47(s,2H),3.40(d,J=5.3Hz,5H),3.24(s,2H),3.11(s,1H),2.93(s,3H) ,2.74(s,4H),2.65–2.59(m,3H),2.39(s,1H),2.23(d,J=3.8Hz,2H),1.88(d,J=4.6Hz,3H),1.80(s,2H),1.29(s,6H).MS(ESI,m / z):978(M + +1).
[0725] Example 171: Synthesis of Compound S143
[0726]
[0727] According to the synthesis of compound S1, compound S143 was obtained by replacing the corresponding intermediate. 1H NMR (500MHz, DMSO-d6) δ11.02 (s, 1H), 8.57 (s, 1H), 8.11 (d, J = 4.9Hz, 1H), 7. 86(d,J=7.5Hz,1H),7.59(d,J=2.0Hz,1H),7.42(dd,J=7.5,2.0Hz,1H),7.33( s,1H),7.06(s,1H),7.02(t,J=3.7Hz,1H),6.62(d,J=4.9Hz,1H),4.91(d,J= 11.2Hz,2H),4.11(d,J=14.5Hz,2H),3.96(s,1H),3.69(d,J=8.2Hz,6H),3.63 (s,3H),3.59(s,1H),3.47(s,2H),3.40(d,J=5.3Hz,5H),3.24(s,2H),3.11( s,1H),2.93(s,3H),2.81(s,1H),2.74(s,4H),2.65–2.59(m,3H),2.39(s,1H) ,2.23(d,J=3.8Hz,2H),1.88(d,J=4.6Hz,3H),1.80(s,2H),1.66(d,J=12.3H z,1H),1.50(d,J=12.5Hz,1H),1.19(s,3H),0.79(s,3H).MS(ESI,m / z):992(M + +1).
[0728] Example 172: Synthesis of Compound S144
[0729]
[0730] According to the synthesis of compound S1, the corresponding intermediate was replaced to obtain compound S144. 1H NMR (500MHz, DMSO-d6) δ11.02(s,1H),8.57(s,1H),8.11(d,J=4.9Hz,1H),7.81(dd,J=7.4,2.1Hz,1H),7.56(dd,J=7.4,2.1Hz,1H),7.47(t, J=7.5Hz,1H),7.33(s,1H),7.08(s,1H),7.02(t,J=3.7Hz,1H),6.62(d,J=4.9Hz,1H),4.92(s,1H),4.47(s,1H),4.32(s,1H),4.11(d,J=14.5 Hz,2H),4.01(s,1H),3.96(s,1H),3.69(d,J=10.2Hz,6H),3.63(d,J=4.7Hz,4H),3.59(s,1H),3.47(s,2H),3.40(s,3H),2.97–2.91(m,7H),2 .75(s,2H),2.63–2.57(m,4H),2.54(d,J=12.3Hz,1H),2.39(s,1H),2.19(s,1H),2.12(s,1H),1.89(s,1H),1.29(s,6H).MS(ESI,m / z):933(M + +1).
[0731] Example 173: Synthesis of Compound S145
[0732]
[0733] According to the synthesis of compound S1, the corresponding intermediate was replaced to obtain compound S145. 1H NMR (500MHz, DMSO-d6) δ11.02(s,1H),8.57(s,1H),8.11(d,J=4.9Hz,1H),7.81(dd,J=7.4,2.1Hz,1H),7.56(dd,J=7.4,2.1Hz,1H),7.47(t, J=7.5Hz,1H),7.33(s,1H),7.08(s,1H),7.02(t,J=3.7Hz,1H),6.62(d,J=4.9Hz,1H),4.92(s,1H),4.47(s,1H),4.32(s,1H),4.11(d,J=14.5 Hz,2H),4.01(s,1H),3.96(s,1H),3.69(d,J=10.2Hz,6H),3.63(d,J=4.7Hz,4H),3.59(s,1H),3.47(s,2H),3.40(s,3H),2.97–2.91(m,7H),2 .75(s,2H),2.63–2.57(m,4H),2.54(d,J=12.3Hz,1H),2.39(s,1H),2.19(s,1H),2.12(s,1H),1.89(s,1H),1.29(s,6H).MS(ESI,m / z):933(M + +1).
[0734] Example 174: Synthesis of Compound S146
[0735]
[0736] According to the synthesis of compound S1, the corresponding intermediate was replaced to obtain compound S146. 1H NMR (500MHz, DMSO-d6) δ11.02(s,1H),8.57(s,1H),8.11(d,J=4.9Hz,1H),7.77(d,J=7.5Hz,1H),7.59(d,J=2.0Hz,1H),7.41(dd,J=7.5,1.8Hz,1H) ,7.33(s,1H),7.17(s,1H),7.02(t,J=3.7Hz,1H),6.62(d,J=4.9Hz,1H), 4.91(d,J=11.2Hz,2H),4.11(d,J=14.5Hz,2H),3.96(s,1H),3.76(s,2H), 3.69(d,J=14.1Hz,4H),3.63(s,3H),3.57(d,J=17.2Hz,2H),3.47(s,2H) ,3.40(s,3H),3.28(d,J=17.0Hz,4H),2.93(s,3H),2.65–2.56(m,7H),2.5 1(d,J=12.4Hz,1H),2.45(d,J=12.5Hz,1H),2.39(s,1H),2.23(d,J=3.8H z,2H),2.03(s,1H),1.94–1.84(m,9H),1.29(s,6H).MS(ESI,m / z):1020(M + +1).
[0737] Example 175: Synthesis of Compound S147
[0738]
[0739] According to the synthesis of compound S1, the corresponding intermediate was replaced to obtain compound S147. 1HNMR (500MHz, DMSO-d6) δ11.02(s,1H),8.57(s,1H),8.11(d,J=4.9Hz,1H),7.77(d,J=7.5Hz,1H),7.59(d,J=2.0Hz,1H),7.41(dd,J=7.5,1.8Hz,1H ),7.33(s,1H),7.17(s,1H),7.02(t,J=3.7Hz,1H),6.62(d,J=4.9Hz,1H) ,4.91(d,J=11.2Hz,2H),4.11(d,J=14.5Hz,2H),3.96(s,1H),3.76(s,2H) ,3.69(d,J=14.1Hz,4H),3.63(s,3H),3.57(d,J=17.2Hz,2H),3.47(s,2H ),3.40(s,3H),3.28(d,J=17.0Hz,4H),2.93(s,3H),2.65–2.56(m,7H),2. 51(d,J=12.4Hz,1H),2.45(d,J=12.5Hz,1H),2.39(s,1H),2.23(d,J=3.8H z,2H),2.03(s,1H),1.94–1.84(m,9H),1.29(s,6H).MS(ESI,m / z):1020(M + +1).
[0740] Example 176: Synthesis of Compound S148
[0741]
[0742] According to the synthesis of compound S1, the corresponding intermediate was replaced to obtain compound S148. 1H NMR (500MHz, DMSO-d6) δ11.02(s,1H),8.57(s,1H),8.11(d,J=4.9Hz,1H),7.86(d,J=7.5Hz,1H),7.59(d,J=2.0Hz,1H),7.42(dd,J=7. 5,2.0Hz,1H),7.33(s,1H),7.28(s,1H),7.02(t,J=3.7Hz,1H),6.62(d,J=4.9Hz,1H),4.91(d,J=11.2Hz,2H),4.11(d,J=14.5Hz,2H),3 .96(s,1H),3.70(s,4H),3.63(s,3H),3.57(d,J=17.2Hz,2H),3.49–3.35(m,11H),3.29(s,1H),2.93(s,3H),2.75(s,1H),2.65–2.59(m ,3H),2.49(d,J=1.3Hz,8H),2.39(s,1H),2.23(d,J=3.8Hz,2H),1.88(d,J=4.6Hz,3H),1.80(s,2H),1.24(s,6H).MS(ESI,m / z):1021(M + +1).
[0743] Example 177: Synthesis of Compound S149
[0744]
[0745] According to the synthesis of compound S1, the corresponding intermediate was replaced to obtain compound S149. 1H NMR (500 MHz, DMSO-d6) δ11.02 (s, 1H), 8.57 (s, 1H), 8.11 (d, J = 4.9 Hz, 1H), 7.86 (d, J = 7.5 Hz, 1H), 7.59 (d, J = 2.0 Hz, 1H), 7.42 (dd, J = 7.5, 2.0 Hz, 1H), 7.33 (s, 1H), 7.28 (s, 1H), 7.02 (t, J = 3.7 Hz, 1H), 6.62 (d, J = 4.9 Hz, 1H), 4.91 (d, J = 11.2 Hz, 2H), 4.11 (d ,J=14.5Hz,2H),3.96(s,1H),3.70(s,4H),3.63(s,3H),3.57(d,J=17.2 Hz,2H),3.49–3.35(m,11H),3.29(s,1H),2.93(s,3H),2.75(s,1H),2.6 5–2.59(m,3H),2.49(d,J=1.3Hz,8H),2.39(s,1H),2.23(d,J=3.8Hz,2H ),1.88(d,J=4.6Hz,3H),1.80(s,2H),1.24(s,6H).MS(ESI,m / z):1021(M + +1).
[0746] Example 178: Synthesis of Compound S150
[0747]
[0748] According to the synthesis of compound S1, the corresponding intermediate was replaced to obtain compound S150. 1H NMR (500MHz, DMSO-d6) δ11.02(s,1H),8.34(s,1H),8.15(d,J=4.9Hz,1H),7.81(dd,J=7.4,2.1Hz,1H),7.56(dd,J=7.4,2.1Hz ,1H),7.47(t,J=7.5Hz,1H),7.33(s,1H),7.02(t,J=3.7Hz,1H),6.99(s,1H),6.64(d,J=4.9Hz,1H),4.47(s,1H),4.32(s,1H), 4.01(s,1H),3.69–3.57(m,8H),3.47(s,2H),3.43(s,2H),3.29–3.20(m,7H),3.04–2.91(m,5H),2.68(s,1H),2.63–2.56(m,3 H),2.55–2.44(m,10H),2.19(s,1H),2.14–2.05(m,3H),1.86(s,1H),1.80(d,J=7.9Hz,4H),1.29(s,6H).MS(ESI,m / z):1000(M + +1).
[0749] Example 179: Synthesis of Compound S151
[0750]
[0751] According to the synthesis of compound S1, the corresponding intermediate was replaced to obtain compound S151. 1H NMR (500 MHz, DMSO-d6) δ11.02 (s, 1H), 8.34 (s, 1H), 8.11 (d, J = 4.9 Hz, 1H), 7.81 (dd, J = 7.0, 2.5 Hz, 1H), 7.53–7.43 (m, 2H), 7.33 (s, 1H), 7.02 (t, J = 3.7 Hz, 1H), 6.99 (s, 1H), 6.62 (d, J = 4.9 Hz, 1H), 4.92 (s, 1H), 4.45 (s, 1H), 4.32 (s, 1H), 4.11 (d, J = 14.5 Hz, 2H), 4.01 (s, 1H), 3.96 (s, 1H), 3.69– 3.60(m,6H),3.59(s,1H),3.47(s,2H),3.41(d,J=11.5Hz,5H),3.22(s, 2H),2.93(s,3H),2.68(s,1H),2.63–2.54(m,11H),2.49(s,4H),2.39(s, 1H),2.19(s,1H),2.12(s,1H),1.89(s,1H),1.80(d,J=7.9Hz,4H),1.59 (d,J=12.4Hz,1H),1.56–1.47(m,3H),1.29(s,6H).MS(ESI,m / z):1032(M + +1).
[0752] Example 180: Synthesis of Compound S152
[0753]
[0754] According to the synthesis of compound S1, the corresponding intermediate was replaced to obtain compound S152. 1H NMR(500MHz,DMSO-d6)δ11.02(s,1H),8.34(s,1H),8.11(d,J=4.9Hz,1H),7.90(dd,J=6.7,2.8Hz,1H),7.50–7.41(m,2H),7.33(s,1H), 7.02(t,J=3.7Hz,1H),6.99(s,1H),6.88(s,1H),6.62(d,J=4.9Hz,1H),5.12(s,1H),4.92(s,1H),4.11(d,J=14.5Hz,2H),3.96(s,1H), 3.69–3.60(m,6H),3.59(s,1H),3.47(s,2H),3.44–3.38(m,7H),3.22(s,2H),2.99(s,1H),2.93(s,3H),2.66(s,1H),2.61(s,1H),2.59 –2.47(m,10H),2.47(s,2H),2.39(s,1H),1.99(s,1H),1.88(d,J=4.6Hz,3H),1.80(d,J=7.9Hz,4H),1.29(s,6H).MS(ESI,m / z):1023(M + +1).
[0755] Example 181: Synthesis of Compound S153
[0756]
[0757] According to the synthesis of compound S1, compound S153 was obtained by replacing the corresponding intermediate. 1H NMR (500MHz, DMSO-d6) δ11.02 (s, 1H), 8.34 (s, 1H), 8.11 (d, J = 4.9Hz, 1H), 7. 83(d,J=7.5Hz,1H),7.60(d,J=2.0Hz,1H),7.41–7.31(m,2H),7.02(t,J=3.7 Hz,1H),7.00(s,1H),6.62(d,J=4.9Hz,1H),5.01(s,1H),4.92(s,1H),4.11( d,J=14.5Hz,2H),4.06(s,1H),3.96(s,1H),3.85(s,1H),3.68(s,2H),3.66– 3.61(m,3H),3.59(s,1H),3.54–3.48(m,2H),3.48–3.38(m,7H),3.22(s,2H) ,3.05(s,1H),2.93(s,3H),2.68(s,1H),2.62(d,J=11.5Hz,2H),2.55(s,1H) ,2.47(d,J=11.5Hz,8H),2.39(s,1H),2.24(d,J=0.9Hz,2H),1.89(s,1H),1. 80(d,J=7.9Hz,4H),1.32(d,J=3.1Hz,6H),1.26(s,3H).MS(ESI,m / z):1035(M + +1).
[0758] Example 182: Synthesis of Compound S154
[0759]
[0760] According to the synthesis of compound S1, compound S154 was obtained by replacing the corresponding intermediate. 1H NMR (500MHz, DMSO-d6) δ11.02(s,1H),8.82(s,1H),8.11(d,J=4.9Hz,1H),7.86(d,J=7.5Hz,1H),7.60(d,J=2.0Hz,1H),7.41–7. 31(m,2H),7.21(s,1H),7.02(t,J=3.7Hz,1H),6.62(d,J=4.9Hz,1H),5.01(s,1H),4.92(s,1H),4.11(d,J=14.5Hz,2H),3.96(s, 1H),3.69(d,J=9.5Hz,4H),3.63(s,3H),3.57(d,J=17.2Hz,2H),3.47(s,2H),3.39(d,J=11.7Hz,5H),3.32(s,2H),3.17(s,2H), 3.05(s,1H),2.93(s,3H),2.65–2.59(m,7H),2.39(s,1H),2.24(d,J=0.9Hz,2H),1.89(s,1H),1.29(s,6H).MS(ESI,m / z):938(M + +1).
[0761] Example 183: Synthesis of Compound S155
[0762]
[0763] According to the synthesis of compound S1, the corresponding intermediate was replaced to obtain compound S155. 1H NMR (500 MHz, DMSO-d6) δ11.02 (s, 1H), 8.82 (s, 1H), 8.11 (d, J = 4.9 Hz, 1H), 7.86 (d, J = 7.5 Hz, 1H), 7.49 (d, J = 2.0 Hz, 1H), 7.42 (dd, J = 7.5, 2.0 Hz, 1H), 7.33 (s, 1H), 7.12 (s, 1H), 7.02 (t, J = 3.7 Hz, 1H), 6.62 (d, J = 4.9 Hz, 1H), 5.01 (s, 1H), 4.92 (s, 1H), 4.15 (s, 1H), 4.10 (s, 1H), 3.96 (s, 1H), 3.72 (d, J=15.9Hz,6H),3.63(s,3H),3.57(d,J=17.2Hz,2H),3.47(s,2H),3.40(s ,3H),3.23(s,2H),3.09(s,2H),2.93(s,3H),2.65–2.58(m,9H),2.55(s,2 H),2.50(s,1H),2.48–2.40(m,2H),2.40–2.34(m,2H),2.23(d,J=3.8Hz,2 H),1.89(s,1H),1.70(d,J=1.8Hz,4H),1.29(s,6H).MS(ESI,m / z):1035(M + +1).
[0764] Example 184: Synthesis of Compound S156
[0765]
[0766] According to the synthesis of compound S1, the corresponding intermediate was replaced to obtain compound S156. 1H NMR (500MHz, DMSO-d6) δ11.02(s,1H),8.82(s,1H),8.11(d,J=4.9Hz,1H),7.86(d,J=7.5Hz,1H),7.49(d,J=2.0Hz,1H),7.42(dd,J= 7.5,2.0Hz,1H),7.33(s,1H),7.03(s,1H),7.02(t,J=3.7Hz,1H),6.62(d,J=4.9Hz,1H),5.01(s,1H),4.92(s,1H),4.11(d,J=14.5H z,2H),3.96(s,1H),3.74–3.67(m,6H),3.63(s,3H),3.57(d,J=17.2Hz,2H),3.47(s,2H),3.40(s,3H),3.12(s,2H),2.92(d,J=6.0H z,5H),2.65–2.59(m,7H),2.45(s,1H),2.40(d,J=9.1Hz,3H),2.23(d,J=3.8Hz,2H),1.89(s,1H),1.29(s,6H).MS(ESI,m / z):952(M + +1).
[0767] Example 185: Synthesis of Compound S157
[0768]
[0769] According to the synthesis of compound S1, the corresponding intermediate was replaced to obtain compound S157. 1H NMR (500MHz, DMSO-d6) δ11.02(s,1H),8.82(s,1H),8.11(d,J=4.9Hz,1H),7.77(d,J=7.5Hz,1H),7.59(d,J=2.0Hz,1H),7.41(dd,J=7.5 ,1.8Hz,1H),7.33(s,1H),7.21(s,1H),7.02(t,J=3.7Hz,1H),6.62(d,J=4.9Hz,1H),5.01(s,1H),4.92(s,1H),4.11(d,J=14.5Hz,2H),3 .96(s,1H),3.70(s,2H),3.63(s,3H),3.57(d,J=17.2Hz,2H),3.47(s,2H),3.40(s,3H),3.31(s,2H),3.17(d,J=15.0Hz,6H),2.93(s,3H ),2.65–2.59(m,7H),2.45(s,2H),2.39(s,1H),2.23(d,J=3.8Hz,2H),2.05(s,1H),1.91–1.84(m,5H),1.29(s,6H).MS(ESI,m / z):980(M + +1).
[0770] Example 186: Synthesis of Compound S158
[0771]
[0772] According to the synthesis of compound S1, the corresponding intermediate was replaced to obtain compound S158. 1H NMR (500MHz, DMSO-d6) δ11.02(s,1H),8.82(s,1H),8.11(d,J=4.9Hz,1H),7.81(dd,J=7.4,2.1Hz,1H),7.56(dd,J=7.4,2.1Hz,1H),7.47 (t,J=7.5Hz,1H),7.33(s,1H),7.21(s,1H),7.02(t,J=3.7Hz,1H),6.62(d,J=4.9Hz,1H),4.92(s,1H),4.47(s,1H),4.32(s,1H),4.11(d, J=14.5Hz,2H),4.01(s,1H),3.96(s,1H),3.70(s,2H),3.63(s,3H),3.57(d,J=17.2Hz,2H),3.47(s,2H),3.40(s,3H),3.16(d,J=12.6Hz ,4H),3.07(s,2H),2.93(s,3H),2.63–2.56(m,9H),2.39(s,1H),2.19(s,1H),2.12(s,1H),1.89(s,1H),1.29(s,6H).MS(ESI,m / z):921(M + +1).
[0773] Example 187: Synthesis of Compound S159
[0774]
[0775] According to the synthesis of compound S1, compound S159 was obtained by replacing the corresponding intermediate. 1H NMR (500MHz, DMSO-d6) δ11.02(s,1H),8.82(s,1H),8.11(d,J=4.9Hz,1H),7.81(dd,J=7.0,2.5Hz,1H),7.53–7.43(m,2H),7.33(s,1 H),7.03(s,1H),7.02(t,J=3.7Hz,1H),6.62(d,J=4.9Hz,1H),4.92(s,1H),4.45(s,1H),4.32(s,1H),4.15(s,1H),4.10(s,1H),4.0 1(s,1H),3.96(s,1H),3.70(s,2H),3.63(s,3H),3.57(d,J=17.2Hz,2H),3.47(s,2H),3.40(s,3H),3.16(s,4H),2.93(s,3H),2.63– 2.56(m,9H),2.53(s,2H),2.39(s,1H),2.19(s,1H),2.12(s,1H),1.89(s,1H),1.62–1.47(m,4H),1.29(s,6H).MS(ESI,m / z):949(M + +1).
[0776] Example 188: Synthesis of Compound S160
[0777]
[0778] According to the synthesis of compound S71, compound S160 was obtained by replacing the corresponding intermediate. 1H NMR (500MHz, DMSO-d6) δ11.02(s,1H),8.57(s,1H),8.11(d,J=4.9Hz,1H),7.83(d,J=7.4Hz,1H),7.51–7.41(m,2H),7.33(s,1H), 7.08(s,1H),7.02(t,J=3.7Hz,1H),6.62(d,J=4.9Hz,1H),5.01(s,1H),4.92(s,1H),4.11(d,J=14.5Hz,2H),3.96(s,1H),3.71(d, J=13.2Hz,4H),3.64(d,J=14.8Hz,5H),3.57(d,J=17.2Hz,2H),3.47(s,2H),3.40(s,3H),3.22(s,4H),2.93(s,3H),2.83(s,1H),2 .65–2.56(m,7H),2.39(s,1H),2.23(d,J=3.8Hz,2H),1.91–1.85(m,3H),1.78(d,J=13.0Hz,2H),1.29(s,6H).MS(ESI,m / z):978(M + +1).
[0779] Example 189: Synthesis of Compound S161
[0780]
[0781] According to the synthesis of compound S71, the corresponding intermediate was replaced to obtain compound S161. NMR(500MHz,DMSO-d6)δ11.02(s,1H),8.57(s,1H),8.11(d,J=4.9Hz,1H),7 .83(d,J=7.5Hz,1H),7.60(d,J=2.0Hz,1H),7.41–7.31(m,2H),7.06(s,1H), 7.02(t,J=3.7Hz,1H),6.62(d,J=4.9Hz,1H),5.01(s,1H),4.92(s,1H),4.1 1(d,J=14.5Hz,2H),3.96(s,1H),3.73(s,2H),3.71–3.61(m,9H),3.59(s,1H ),3.47(s,2H),3.40(d,J=0.7Hz,5H),3.05(s,1H),2.94(d,J=9.5Hz,4H),2 .85(s,1H),2.65–2.59(m,3H),2.48(d,J=1.4Hz,8H),2.39(s,1H),2.24(d,J =0.9Hz,2H),1.92–1.85(m,3H),1.80(d,J=13.0Hz,2H),1.67(d,J=12.5Hz, 1H),1.62(d,J=12.3Hz,1H),1.19(s,3H),0.79(s,3H).MS(ESI,m / z):1047(M + +1).
[0782] Example 190: Synthesis of Compound S162
[0783]
[0784] According to the synthesis of compound S71, compound S162 was obtained by replacing the corresponding intermediate. 1H NMR (500MHz, DMSO-d6) δ11.02(s,1H),8.57(s,1H),8.11(d,J=4.9Hz,1H),7.83(d,J=7.4Hz,1H),7.51–7.41(m,2H),7.33(s,1H),7.17(s,1H),7. 02(t,J=3.7Hz,1H),6.62(d,J=4.9Hz,1H),5.01(s,1H),4.92(s,1H),4. 15(s,1H),4.10(s,1H),3.96(s,1H),3.71(d,J=13.2Hz,4H),3.64(d,J=1 4.8Hz,5H),3.57(d,J=17.2Hz,2H),3.47(s,2H),3.40(s,3H),3.22(s,4 H),3.11(s,1H),2.93(s,3H),2.75(s,1H),2.65–2.59(m,11H),2.39(s,1 H),2.23(d,J=3.8Hz,2H),1.98(d,J=13.0Hz,2H),1.89(s,1H),1.80(d,J=13.0Hz,2H),1.63(d,J=17.6Hz,4H),1.29(s,6H).MS(ESI,m / z):1061(M + +1).
[0785] Example 191: Synthesis of Compound S163
[0786]
[0787] According to the synthesis of compound S71, compound S163 was obtained by replacing the corresponding intermediate. 1H NMR (500 MHz, DMSO-d6) δ11.02 (s, 1H), 8.57 (s, 1H), 8.11 (d, J = 4.9 Hz, 1H), 7.83 (d, J = 7.5 Hz, 1H), 7.60 (d, J = 2.0 Hz, 1H), 7.41 (dd, J = 7.4, 1.9 Hz, 1H), 7.33 (s, 1H), 7.13 (s, 1H), 7.02 (t, J = 3.7 Hz, 1H), 6.62 (d, J = 4.9 Hz, 1H), 5.01 (s, 1H), 4.92 (s, 1H), 4.11 (d, J = 14.5 Hz, 2H), 3.96 (s, 1H), 3.71 (d, J = 13.2 Hz, 2H). z,4H),3.64(d,J=14.8Hz,5H),3.57(d,J=17.2Hz,2H),3.47(s,2H),3.40( s,3H),3.28(s,2H),3.22(s,2H),3.13(d,J=14.5Hz,3H),2.93(s,3H),2.73 (s,4H),2.65–2.59(m,5H),2.56(s,2H),2.39(s,1H),2.23(d,J=3.8Hz,2H) ,1.89(s,1H),1.58(s,4H),1.53(s,1H),1.29(s,6H).MS(ESI,m / z):1047(M + +1).
[0788] Example 192: Synthesis of Compound S164
[0789]
[0790] According to the synthesis of compound S71, compound S164 was obtained by replacing the corresponding intermediate. 1H NMR (500MHz, DMSO-d6) δ11.02(s,1H),8.57(s,1H),8.11(d,J=4.9Hz,1H),7.83(d,J=7.5Hz,1H),7.49(d,J=2.0Hz,1H),7.41(dd,J=7.4,1.9H z,1H),7.33(s,1H),7.08(s,1H),7.02(t,J=3.7Hz,1H),6.62(d,J=4.9Hz,1H),5.01(s,1H),4.92(s,1H),4.15(s,1H),4.10(s,1H),3.96(s,1 H),3.71(d,J=9.2Hz,4H),3.63(s,3H),3.61–3.53(m,4H),3.47(s,2H) ,3.40(s,3H),3.19(s,4H),2.93(s,3H),2.65–2.57(m,7H),2.49(s,2H ),2.39(s,1H),2.23(d,J=3.8Hz,2H),1.89(s,1H),1.85–1.75(m,2H),1.62(d,J=12.4Hz,1H),1.57(s,4H),1.29(s,6H).MS(ESI,m / z):1006(M + +1).
[0791] Example 193: Synthesis of Compound S165
[0792]
[0793] According to the synthesis of compound S71, compound S165 was obtained by replacing the corresponding intermediate. 1H NMR (500MHz, DMSO-d6) δ11.02(s,1H),8.57(s,1H),8.11(d,J=4.9Hz,1H),7.83(d,J=7.5Hz,1H),7.60(d,J=2.0Hz,1H),7.41(dd,J=7.4,1 .9Hz,1H),7.33(s,1H),7.13(s,1H),7.02(t,J=3.7Hz,1H),6.62(d,J=4.9Hz,1H),5.01(s,1H),4.92(s,1H),4.15(s,1H),4.10(s,1H),3. 96(s,1H),3.71(d,J=13.2Hz,4H),3.64(d,J=14.8Hz,5H),3.57(d,J=17.2Hz,2H),3.47(s,2H),3.40(s,3H),3.21(s,4H),2.93(s,3H),2. 65–2.59(m,7H),2.48(s,2H),2.39(s,1H),2.23(d,J=3.8Hz,2H),1.89(s,1H),1.70(s,1H),1.58(s,4H),1.29(s,6H).MS(ESI,m / z):992(M + +1).
[0794] Example 194: Synthesis of Compound S166
[0795]
[0796] According to the synthesis of compound S71, compound S166 was obtained by replacing the corresponding intermediate. 1HNMR(500MHz,DMSO-d6)δ11.02(s,1H),8.57(s,1H),8.11(d,J=4.9Hz,1H),7.83(d,J=7.5Hz,1H),7.49(d,J=2.0Hz,1H),7.41(dd,J=7.4,1.9H z,1H),7.33(s,1H),7.13(s,1H),7.02(t,J=3.7Hz,1H),6.62(d,J=4.9H z,1H),5.01(s,1H),4.92(s,1H),4.11(d,J=14.5Hz,2H),4.05(s,2H),3 .97(d,J=6.0Hz,3H),3.70(s,2H),3.63(s,3H),3.57(d,J=17.2Hz,2H) ,3.47(s,2H),3.40(s,3H),3.28(s,2H),3.22(s,2H),2.97(s,1H),2.93 (s,3H),2.65–2.59(m,7H),2.39(s,1H),2.23(d,J=3.8Hz,2H),1.89(s, 1H),1.57(s,4H),1.51–1.39(m,4H),1.29(s,6H).MS(ESI,m / z):1006(M + +1).
[0797] Example 195: Synthesis of Compound S167
[0798]
[0799] According to the synthesis of compound S71, compound S167 was obtained by replacing the corresponding intermediate. 1H NMR(500MHz,DMSO-d6)δ11.02(s,1H),8.57(s,1H),8.11(d,J=4.9Hz,1H),7.83(d, J=7.5Hz,1H),7.60(d,J=2.0Hz,1H),7.41–7.31(m,2H),7.06(s,1H),7.02(t,J=3. 7Hz,1H),6.62(d,J=4.9Hz,1H),5.01(s,1H),4.92(s,1H),4.11(d,J=14.5Hz,2H), 4.05(s,2H),3.97(d,J=6.0Hz,3H),3.69(d,J=9.5Hz,4H),3.63(s,3H),3.59(s,1H ),3.47(s,2H),3.39(d,J=11.7Hz,5H),3.05(s,1H),2.97(s,1H),2.93(s,3H),2.8 5(s,1H),2.65–2.56(m,9H),2.46(s,2H),2.39(s,1H),2.24(d,J=0.9Hz,2H),1.89 (s,1H),1.67(d,J=12.4Hz,1H),1.62(d,J=12.3Hz,1H),1.57(s,4H),1.48(d,J=13 .0Hz,2H),1.42(d,J=13.0Hz,2H),1.19(s,3H),0.79(s,3H).MS(ESI,m / z):1075(M + +1).
[0800] Example 196: Synthesis of Compound S168
[0801]
[0802] According to the synthesis of compound S71, compound S168 was obtained by replacing the corresponding intermediate. 1H NMR (500MHz, DMSO-d6) δ11.02 (s, 1H), 8.57 (s, 1H), 8.11 (d, J = 4.9Hz, 1H), 7. 83(d,J=7.5Hz,1H),7.60(d,J=2.0Hz,1H),7.41(dd,J=7.4,1.9Hz,1H),7.33( s,1H),7.04(s,1H),7.02(t,J=3.7Hz,1H),6.62(d,J=4.9Hz,1H),5.01(s,1H ),4.92(s,1H),4.15(s,1H),4.10(s,1H),4.05(s,2H),3.97(d,J=6.0Hz,3H), 3.70(s,2H),3.63(s,3H),3.57(d,J=17.2Hz,2H),3.47(s,2H),3.40(s,3H), 3.21(s,4H),2.93(s,3H),2.65–2.59(m,7H),2.51(d,J=12.4Hz,1H),2.45(d, J=12.5Hz,1H),2.39(s,1H),2.23(d,J=3.8Hz,2H),1.89(s,1H),1.78(d,J=13 .0Hz,2H),1.63(s,4H),1.39(s,1H),1.32–1.25(m,8H).MS(ESI,m / z):1020(M + +1).
[0803] Example 197: Synthesis of Compound S169
[0804]
[0805] According to the synthesis of compound S1, the corresponding intermediate was replaced to obtain compound S169. 1H NMR (500MHz, DMSO-d6) δ11.02(s,1H),8.57(s,1H),8.11(d,J=4.9Hz,1H),7.86(d,J=7.5Hz,1H),7.49(d,J=2.0Hz,1H),7.4 2(dd,J=7.5,2.0Hz,1H),7.33(s,1H),7.04(s,1H),7.02(t,J=3.7Hz,1H),6.62(d,J=4.9Hz,1H),5.01(s,1H),4.92(s,1H),4 .11(d,J=14.5Hz,2H),3.96(s,1H),3.74–3.61(m,14H),3.59(s,1H),3.47(s,2H),3.40(s,3H),3.10(s,1H),2.92(d,J=13. 9Hz,7H),2.65–2.59(m,3H),2.39(s,1H),2.23(d,J=3.8Hz,2H),2.10(s,2H),1.89(s,1H),1.29(s,6H).MS(ESI,m / z):976(M + +1).
[0806] Example 198: Synthesis of Compound S170
[0807]
[0808] According to the synthesis of compound S1, the corresponding intermediate was replaced to obtain compound S170. 1H NMR (500MHz, DMSO-d6) δ11.02(s,1H),8.57(s,1H),8.11(d,J=4.9Hz,1H),7.86(d,J=7.5Hz,1H),7.49(d,J=2.0Hz,1H),7.42(dd,J=7.5 ,2.0Hz,1H),7.33(s,1H),7.08(s,1H),7.02(t,J=3.7Hz,1H),6.62(d,J=4.9Hz,1H),5.01(s,1H),4.92(s,1H),4.15(s,1H),4.10(s,1H) ,3.96(s,1H),3.76(s,2H),3.70(t,J=4.8Hz,4H),3.68–3.61(m,7H),3.57(d,J=17.2Hz,2H),3.47(s,2H),3.40(s,3H),3.17(s,1H),2.9 3(s,3H),2.67–2.59(m,7H),2.39(s,1H),2.23(d,J=3.8Hz,2H),2.06(s,2H),1.91(d,J=16.5Hz,5H),1.29(s,6H).MS(ESI,m / z):1004(M + +1).
[0809] Example 199: Synthesis of Compound S171
[0810]
[0811] According to the synthesis of compound S1, the corresponding intermediate was replaced to obtain compound S171. 1H NMR (500MHz, DMSO-d6) δ11.02(s,1H),8.57(s,1H),8.11(d,J=4.9Hz,1H),7.86(d,J=7.5Hz,1H),7.49(d,J=2.0Hz,1H),7.42(dd, J=7.5,2.0Hz,1H),7.33(s,1H),7.08(s,1H),7.02(t,J=3.7Hz,1H),6.62(d,J=4.9Hz,1H),5.01(s,1H),4.92(s,1H),4.11(d,J=1 4.5Hz,2H),3.96(s,1H),3.73–3.61(m,10H),3.59(s,3H),3.47(s,4H),3.40(s,3H),3.10(s,1H),3.05(d,J=3.8Hz,4H),2.93(s, 3H),2.65–2.59(m,3H),2.43(s,1H),2.39(s,1H),2.25–2.19(m,3H),2.06(s,2H),1.89(s,1H),1.29(s,6H).MS(ESI,m / z):990(M + +1).
[0812] Example 200: Synthesis of Compound S172
[0813]
[0814] According to the synthesis of compound S1, the corresponding intermediate was replaced to obtain compound S172. 1H NMR (500 MHz, DMSO-d6) δ 11.02 (s, 1H), 8.57 (s, 1H), 8.11 (d, J = 4.9 Hz, 1H), 7.86 (d, J = 7.5 Hz, 1H), 7.49 (d, J = 2.0 Hz, 1H), 7.42 (dd, J = 7.5, 2.0 Hz, 1H), 7.33 (s, 1H), 7.28 (s, 1H), 7.02 (t, J = 3.7 Hz, 1H), 6.62 (d, J = 4.9 Hz, 1H), 5.01 (s, 1H), 4.92 (s, 1H), 4.11 (d, J = 14.5Hz,2H),3.96(s,1H),3.73–3.61(m,11H),3.57(d,J=17.2Hz,2H),3.49–3.38(m,7H),3.29(s,1H),3.01(s,1H),2.93(s,3H), 2.65–2.59(m,7H),2.49(s,4H),2.39(s,1H),2.23(d,J=3.8Hz,2H),2.06(s,2H),1.89(s,1H),1.24(s,6H).MS(ESI,m / z):1019(M + +1).
[0815] Example 201: Synthesis of Compound S173
[0816]
[0817] According to the synthesis of compound S1, compound S173 was obtained by replacing the corresponding intermediate. 1H NMR (500MHz, DMSO-d6) δ11.02(s,1H),8.57(s,1H),8.11(d,J=4.9Hz,1H),7.86(d,J=7.5Hz,1H),7.59(d,J=2.0Hz,1H),7.42(dd,J=7.5,2. 0Hz,1H),7.33(s,1H),7.12(s,1H),7.02(t,J=3.7Hz,1H),6.62(d,J=4.9Hz,1H),5.01(s,1H),4.92(s,1H),4.11(d,J=14.5Hz,2H),3.96(s ,1H),3.70(d,J=1.6Hz,4H),3.63(s,3H),3.59(s,1H),3.57–3.45(m,9H),3.40(s,3H),3.26(s,1H),3.14(s,1H),2.93(s,3H),2.81(d,J=9 .3Hz,3H),2.76–2.65(m,10H),2.65–2.59(m,3H),2.39(s,1H),2.23(d,J=3.8Hz,2H),1.91–1.81(m,5H),1.24(s,6H).MS(ESI,m / z):1088(M + +1).
[0818] Example 202: Synthesis of Compound S174
[0819]
[0820] According to the synthesis of compound S1, the corresponding intermediate was replaced to obtain compound S174. 1H NMR (500MHz, DMSO-d6) δ11.02(s,1H),8.57(s,1H),8.11(d,J=4.9Hz,1H),7.86(d,J=7.5Hz,1H),7.59(d,J=2.0Hz,1H),7.42(dd,J=7.5,2.0Hz,1 H),7.33(s,1H),7.12(s,1H),7.02(t,J=3.7Hz,1H),6.62(d,J=4.9Hz,1H ),5.01(s,1H),4.92(s,1H),4.15(s,1H),4.10(s,1H),3.96(s,1H),3.70 (d,J=1.6Hz,4H),3.63(s,3H),3.61–3.45(m,10H),3.40(s,3H),3.26(s, 1H),3.09(s,2H),3.02(s,1H),2.92(d,J=10.2Hz,4H),2.87–2.75(m,6H) ,2.69(d,J=9.3Hz,2H),2.65–2.57(m,5H),2.39(s,1H),2.30(s,2H),2.2 3(d,J=3.8Hz,2H),1.91–1.81(m,5H),1.24(s,6H).MS(ESI,m / z):1102(M + +1).
[0821] Example 203: Synthesis of Compound S175
[0822]
[0823] According to the synthesis of compound S71, compound S175 was obtained by replacing the corresponding intermediate. 1H NMR (500MHz, DMSO-d6) δ11.02(s,1H),8.57(s,1H),8.11(d,J=4.9Hz,1H),7.83(d,J=7.5Hz,1H),7.60(d,J=2.0Hz,1H),7.41(dd,J=7.4,1.9Hz,1H),7. 33(s,1H),7.28(s,1H),7.02(t,J=3.7Hz,1H),6.62(d,J=4.9Hz,1H),5.01( s,1H),4.92(s,1H),4.15(s,1H),4.10(s,1H),3.96(s,1H),3.70(d,J=1.6H z,4H),3.63(s,3H),3.61–3.51(m,4H),3.47(s,2H),3.40(s,3H),3.30–3.2 0(m,5H),3.12(s,2H),3.00(s,1H),2.93(s,3H),2.90–2.82(m,4H),2.76–2 .67(m,3H),2.65–2.59(m,5H),2.56(s,2H),2.39(s,1H),2.23(d,J=3.8Hz, 2H),1.89(s,1H),1.76(d,J=3.8Hz,2H),1.24(s,6H).MS(ESI,m / z):1062(M + +1).
[0824] Example 204: Synthesis of Compound S176
[0825]
[0826] According to the synthesis of compound S71, compound S176 was obtained by replacing the corresponding intermediate. 1H NMR (500MHz, DMSO-d6) δ11.02(s,1H),8.57(s,1H),8.11(d,J=4.9Hz,1H),7.86(d,J=7.5Hz,1H),7.59(d,J=2.0Hz,1H),7.42(dd,J=7.5,2.0Hz,1 H),7.33(s,1H),7.28(s,1H),7.02(t,J=3.7Hz,1H),6.62(d,J=4.9Hz,1 H),5.01(s,1H),4.92(s,1H),4.11(d,J=14.5Hz,2H),3.96(s,1H),3.70( s,4H),3.63(s,3H),3.57(d,J=17.2Hz,2H),3.51(s,2H),3.49–3.38(m, 9H),3.29(s,1H),3.16(s,1H),3.09(s,2H),3.02(s,1H),2.92(d,J=10.3 Hz,4H),2.87(s,2H),2.83–2.66(m,8H),2.65–2.57(m,7H),2.39(s,1H), 2.25–2.19(m,4H),1.91–1.81(m,5H),1.24(s,6H).MS(ESI,m / z):1157(M + +1).
[0827] Example 205: Synthesis of Compound S177
[0828]
[0829] According to the synthesis of compound S71, compound S177 was obtained by replacing the corresponding intermediate. 1H NMR (500MHz, DMSO-d6) δ11.02(s,1H),8.57(s,1H),8.11(d,J=4.9Hz,1H),7.83(d,J= 7.5Hz,1H),7.60(d,J=2.0Hz,1H),7.41(dd,J=7.4,1.9Hz,1H),7.33(s,1H),7.08(s,1 H),7.02(t,J=3.7Hz,1H),6.62(d,J=4.9Hz,1H),5.01(s,1H),4.92(s,1H),4.15(s,1 H),4.10(s,1H),3.96(s,1H),3.71(d,J=13.2Hz,4H),3.64(d,J=14.8Hz,5H),3.57(d, J=17.2Hz,2H),3.47(s,2H),3.40(s,3H),3.28(s,2H),3.22(s,2H),3.11(d,J=2.9Hz ,3H),3.00(s,1H),2.98–2.88(m,7H),2.88–2.79(m,5H),2.75(d,J=8.8Hz,3H),2.65– 2.56(m,7H),2.39(s,1H),2.23(d,J=3.8Hz,2H),1.95(s,1H),1.89(s,1H),1.71(d,J =13.0Hz,2H),1.64(d,J=13.0Hz,2H),1.45(s,1H),1.29(s,6H).MS(ESI,m / z):1157(M + +1).
[0830] Example 206: Synthesis of Compound S178
[0831]
[0832] Pd2(dba)3 (45.6 mg, 0.05 mmol), CuI (19 mg, 0.1 mmol) and Cs2CO3 (977 mg, 3.0 mmol) were added to a solution of two equivalent raw materials (1.0 mmol) in 1,4-dioxane (5 mL). The mixture was heated to 100°C for 4 hours until the reaction was complete. After cooling to room temperature, the mixture was extracted three times with EA. The organic phases were combined, dried over anhydrous sodium sulfate, filtered, concentrated and separated by column chromatography to obtain compound S178. 1H NMR (500MHz, DMSO-d6) δ11.02(s,1H),8.34(s,1H),8.11(d,J=4.9Hz,1H),7.92–7.86(m,1H),7.39–7.31(m,4H),7. 02(t,J=3.7Hz,1H),6.80(s,1H),6.62(d,J=4.9Hz,1H),6.55(s,1H),4.92(s,1H),4.51(s,1H),4.11(d,J=14.5Hz, 2H),3.96(s,1H),3.72(s,2H),3.69–3.61(m,4H),3.59(s,1H),3.46(d,J=7.7Hz,4H),3.40(d,J=5.5Hz,5H),2.93( s,3H),2.74(d,J=0.9Hz,4H),2.61(s,1H),2.39(s,1H),2.20(s,2H),1.89(s,1H),1.29(s,6H).MS(ESI,m / z):871(M + +1).
[0833] Example 207: Synthesis of Compound S179
[0834]
[0835] According to the synthesis of compound S178, compound S179 was obtained by replacing the corresponding intermediate. 1 H NMR (500MHz, DMSO-d6) δ11.02(s,1H),8.57(s,1H),8.11(d,J=4.9Hz,1H),7.89(dd,J=7.4,2.1Hz,1H),7.41–7.28(m,4H ),7.02(t,J=3.7Hz,1H),6.74(s,1H),6.65–6.60(m,2H),4.92(s,1H),4.43(s,1H),4.11(d,J=14.5Hz,2H),3.96(s,1H) ,3.73(s,2H),3.69–3.61(m,4H),3.59(s,1H),3.47(d,J=4.0Hz,4H),3.41(d,J=6.0Hz,5H),2.93(s,3H),2.74(d,J=0.9 Hz,4H),2.61(s,1H),2.39(s,1H),1.89(s,1H),1.67(s,2H),1.62(s,2H),1.38(s,2H),1.29(s,6H).MS(ESI,m / z):899(M + +1).
[0836] Example 208: Synthesis of Compound S180
[0837]
[0838] According to the synthesis of compound S178, compound S180 was obtained by replacing the corresponding intermediate. 1 H NMR (500MHz, DMSO-d6) δ11.02(s,1H),8.34(s,1H),8.11(d,J=4.9Hz,1H),7.89(dd,J=7.4,2.1Hz,1H),7.40–7.26(m,4 H),7.02(t,J=3.7Hz,1H),6.88(s,1H),6.62(d,J=4.9Hz,1H),4.92(s,1H),4.35(s,1H),4.11(d,J=14.5Hz,2H),3.96( s,1H),3.72(s,2H),3.69–3.61(m,4H),3.59(s,1H),3.54(s,2H),3.46(d,J=12.8Hz,4H),3.40(s,3H),2.99(d,J=9.9H z,5H),2.93(s,3H),2.61(s,1H),2.50(s,2H),2.39(s,1H),2.02(s,2H),1.89(s,1H),1.29(s,6H).MS(ESI,m / z):885(M + +1).
[0839] Example 209: Synthesis of Compound S181
[0840]
[0841] According to the synthesis of compound S178, compound S181 was obtained by replacing the corresponding intermediate. 1H NMR(500MHz,DMSO-d6)δ11.02(s,1H),8.57(s,1H),8.11(d,J=4.9Hz,1H),7.89(dd,J=7.2,2.3Hz,1H), 7.39–7.28(m,4H),7.02(t,J=3.7Hz,1H),6.75(s,1H),6.65–6.57(m,2H),4.92(s,1H),4.50(s,1H),4.1 5–4.05(m,3H),3.96(s,1H),3.85(s,1H),3.66–3.38(m,13H),2.93(s,3H),2.83–2.72(m,7H),2.67(s, 2H),2.39(s,1H),2.29(s,3H),1.89(s,1H),1.32(s,3H),1.27(s,3H),1.22(s,3H).MS(ESI,m / z):928(M + +1).
[0842] Example 210: Synthesis of Compound S182
[0843]
[0844] According to the synthesis of compound S4, compound S182 was obtained by replacing the corresponding intermediate. 1 HNMR(500MHz,DMSO-d6)δ11.02(s,1H),8.57(s,1H),8.11(d,J=4.9Hz,1H),7.89(dd,J=5.6,3.9Hz,1H),7.74(s,1H),7.37–7.30(m ,3H),7.27(s,1H),7.02(t,J=3.7Hz,1H),6.62(d,J=4.9Hz,1H),6.54(s,1H),6.39(s,1H),4.92(s,1H),4.69(d,J=12.5Hz,1H),4. 54–4.47(m,2H),4.11(d,J=14.5Hz,2H),3.96(s,1H),3.87(s,2H),3.65(d,J=19.1Hz,3H),3.61–3.53(m,4H),3.49–3.42(m,3H),3 .42–3.32(m,4H),3.00(s,2H),2.93(s,3H),2.61(s,1H),2.50(s,2H),2.39(s,1H),1.89(s,1H),1.24(s,6H).MS(ESI,m / z):914(M + +1).
[0845] Example 211: Synthesis of Compound S183
[0846]
[0847] According to the synthesis of compound S178, compound S1883 was obtained by replacing the corresponding intermediate. 1 H NMR(500MHz,DMSO-d6)δ11.02(s,1H),8.57(s,1H),8.11(d,J=4.9Hz,1H),7.89(dd,J=7.2,2.3Hz,1H),7.41–7.31(m,4H) ,7.02(t,J=3.7Hz,1H),6.65–6.60(m,2H),4.92(s,1H),4.35(s,1H),4.11(d,J=14.5Hz,2H),3.96(s,1H),3.87(s,2H),3. 67(s,2H),3.63(s,1H),3.61–3.53(m,5H),3.53–3.45(m,3H),3.40(s,3H),3.15(d,J=0.7Hz,1H),2.99(d,J=9.9Hz,5H), 2.93(d,J=0.8Hz,5H),2.68(s,2H),2.61(s,1H),2.50(s,2H),2.39(s,1H),1.89(s,1H),1.24(s,6H).MS(ESI,m / z):914(M + +1)
[0848] Example 212: Synthesis of Compound S184
[0849]
[0850] According to the synthesis of compound S178, compound S184 was obtained by replacing the corresponding intermediate. 1H NMR (500MHz, DMSO-d6) δ11.03(s,1H),8.57(s,1H),8.11(d,J=4.9Hz,1H),7.94(dd,J=7.5,2.0Hz,1H),7.39(t,J=7.5Hz,1H),7.33(s ,1H),7.26–7.19(m,2H),7.02(t,J=3.7Hz,1H),6.76(s,1H),6.62(d,J=4.9Hz,1H),4.92(s,1H),4.33(s,1H),4.15–4.08(m,4H),3.96 (s,1H),3.73(s,2H),3.69–3.61(m,4H),3.59(s,1H),3.47(d,J=4.2Hz,4H),3.40(s,3H),2.93(s,3H),2.75(d,J=0.9Hz,4H),2.61(s, 1H),2.39(s,1H),1.97–1.87(m,2H),1.80(d,J=12.3Hz,1H),1.70(s,2H),1.41(s,2H),1.34(s,2H),1.29(s,6H).MS(ESI,m / z):914(M + +1).
[0851] Example 213: Synthesis of Compound S185
[0852]
[0853] According to the synthesis of compound S178, compound S185 was obtained by replacing the corresponding intermediate. 1H NMR (500MHz, DMSO-d6) δ11.03(s,1H),8.34(s,1H),8.11(d,J=4.9Hz,1H),7.89(dd,J=7.4,2.1Hz,1H),7.71(s,1H),7.43–7 .32(m,3H),7.12(s,1H),7.07(s,1H),7.02(t,J=3.7Hz,1H),6.62(d,J=4.9Hz,1H),6.34(s,1H),4.92(s,1H),4.50(s,1H), 4.11(d,J=14.5Hz,2H),3.96(s,1H),3.72(s,2H),3.69–3.61(m,4H),3.58(d,J=6.4Hz,3H),3.47(s,2H),3.42–3.34(m,7H) ,2.93(s,3H),2.74(d,J=0.9Hz,4H),2.61(s,1H),2.57(s,2H),2.39(s,1H),1.89(s,1H),1.29(s,6H).MS(ESI,m / z):928(M + +1).
[0854] Example 214: Synthesis of Compound S186
[0855]
[0856] According to the synthesis of compound S178, compound S186 was obtained by replacing the corresponding intermediate. 1 H NMR(500MHz,DMSO-d6)δ11.03(s,1H),8.60(s,1H),8.11(d,J=4.9Hz,1H),7.90(dd,J=6.7,2.8Hz,1H),7.50–7.41(m,3H), 7.26(s,1H),7.02(t,J=3.7Hz,1H),6.88(s,1H),6.62(d,J=4.9Hz,1H),5.12(s,1H),4.92(s,1H),4.11(d,J=14.5Hz,2H), 3.96(s,1H),3.70(s,2H),3.63(s,3H),3.57(d,J=17.2Hz,2H),3.50–3.37(m,7H),2.93(d,J=3.7Hz,4H),2.66(s,1H),2.6 2–2.47(m,9H),2.39(s,1H),1.99(s,1H),1.88(d,J=4.6Hz,3H),1.75(d,J=11.9Hz,4H),1.29(s,6H).MS(ESI,m / z):963(M+ +1).
[0857] Example 215: Anti-cell proliferation activity of the compounds of the present invention
[0858] The anti-cell proliferation activity of the compounds of the present invention was detected by CTG luminescence method. Tumor cell lines (H1975-L858R / T790M / C797S, PC-9Del19 / T790M / C797S, A431-WT) were cultured in a specified culture medium at 37°C, 5% CO2 in an incubator. Cells in the logarithmic growth phase were plated with a cell density of 2000-4000 cells / well and cultured overnight. The next day, the compounds of the present invention were serially diluted and added to a 96-well plate, DMSO was used as a negative control, and the blank control was a culture solution without cells, and culture was continued in an incubator at 37°C, 5% CO2 for 72 hours. After drug treatment for 72 hours, 50 μL of CTG solution pre-melted and equilibrated to room temperature was added to each well, mixed with a microplate oscillator for 2 minutes, and the fluorescence signal value was detected with an enzyme marker after being placed at room temperature for 10 minutes. The effect of the compounds of the present invention on cell growth was fitted by Prism GraphPad and the IC of the compounds of the present invention was calculated. 50 The research results are shown in Table 1. The compounds of the present invention have significant anti-cell proliferation activity against cell lines H1975 (L858R / T790M / C797S) and PC-9 (Del19 / T790M / C797S) carrying EGFR mutations. 50 The values reached nanomolar concentration levels, with the optimum being below 10 nM; however, the anti-cell proliferation activity against EGFR wild-type A431 was relatively poor, which indicates that the compounds of the present invention have good selectivity and low toxicity.
[0859] Table 1. Antiproliferative activity of target compounds of the present invention (IC 50 , nM)
[0860]
[0861]
[0862]
[0863] A: IC 50 ≤10nM; B:10nM<IC 50 ≤30nM; C: 30nM<IC 50 ≤50nM.
[0864] Example 216: Degradation activity test of some compounds of the present invention on EGFR mutant protein
[0865] Protein sample preparation: Ba / F3 (L858R / T790M / C797S, LTC), Ba / F3 (Del19 / T790M / C797S, DTC), Ba / F3 (Del19 / C797S, DC), A431 (WT) were cultured in a designated culture medium at 37°C, 5% CO2 in an incubator. Cells in the logarithmic growth phase were plated at a cell density of 20,000 cells / well and cultured overnight. The next day, the compounds of the present invention were serially diluted and added to a 6-well plate, DMSO was used as a negative control, and the cells were cultured in an incubator at 37°C, 5% CO2 for 24 hours. The original culture medium was discarded, the cells were washed three times with pre-cooled PBS, an appropriate amount of lysis buffer was added, the mixture was evenly mixed and placed on ice for 30 minutes, centrifuged at 12,000 rpm at 4°C for 5 minutes, the protein supernatant sample was collected, the protein was quantified by the BCA method, and the WB detection sample was prepared. The samples were electrophoresed by polyacrylamide gel and transferred to NC membrane, and incubated in blocking buffer at room temperature for 60 minutes. The primary antibodies used were anti-EGFR and anti-GAPDH antibodies and incubated overnight at 4°C. Washed 3 times with PBST at room temperature, 10 minutes each time. Then, incubated in blocking buffer containing secondary antibodies at room temperature for 60 minutes. Washed 3 times with PBST at room temperature, 10 minutes each time. ECL luminescent solution was added, and the results were observed by a developer. The Western results were quantified using Image J software, and the degradation rate was calculated by comparing with the control group without the addition of the compound. Prism GraphPad was used to fit the dose-effect curve and calculate the DC of the compound of the present invention. 50 The experimental results are shown in Table 2. The compounds of the present invention have significant degradation activity on EGFR mutant proteins EGFR-L858R / T790M / C797S, EGFR-Del19 / T790M / C797S and EGFR-Del19 / C797S. 50 The values reached nanomolar concentration levels, with the optimum being below 10 nM; and there was no obvious degradation activity on wild-type EGFR, indicating that the compounds of the present invention have higher selectivity and lower toxicity.
[0866] Table 2. Degradation activity of some compounds of the present invention on EGFR mutant proteins (DC 50 , nM)
[0867]
[0868]
[0869]
[0870] A: DC 50 ≤10 nM; B: 10 nM<DC 50≤50 nM;C:DC 50 >50 nM。
Claims
1. A compound of formula I or its enantiomer, diastereomer, racemate, cis-trans isomer, deuterated product, metabolite, prodrug, solvate, hydrate, pharmaceutically acceptable salt or cocrystal, B-L-E I, In the structure: B is Z is selected from C 1-4 Alkyl, deuterated (C 1-4 Alkyl) or halogenated (C 1-4 alkyl); R1 is selected from hydrogen, halogen, C 1-4 Alkyl, deuterated (C 1-4 Alkyl) or halo (C 1-4 alkyl); R2 is selected from C 1-6 Alkyl, deuterated (C 1-6 Alkyl) or halo (C 1-6 alkyl); X is selected from a single bond, C 1-4 Alkylene, C 2-4 Alkyne or C 2-4 alkenylene; V is selected from -NR x1 (C 1-10 Alkylene)R x2 -, a 4-10 membered monocyclic heterocycloalkylene containing 1 or 2 N atoms, a 6-11 membered spirocyclic heterocycloalkylene containing 1 or 2 N atoms, a 6-10 membered cyclic heterocycloalkylene containing 1 or 2 N atoms, or a 7-10 membered bridged heterocycloalkylene containing 1 or 2 N atoms; and -NR x1 (C 1-10 Alkylene)R x2 -The left end is connected to X and the right end is connected to L; R x1 Selected from hydrogen or C 1-3 alkyl; R x2 Selected from -O-, -N(C 1-3 -alkyl)- or -NH-; R4 is selected from deuterium, halogen, C 1-6 Alkyl, halogenated (C 1-6 Alkyl), C 1-6 Alkoxy, halogenated (C 1-6 Alkoxy) or deuterated (C 1-6 Alkoxy); a is selected from 0, 1, 2, 3 or 4; E is R5 is selected from the group consisting of deuterium, halogen, cyano, C 1-3 Alkyl, halogenated (C 1-3 alkyl) or deuterated (C 1-3 alkyl); b is selected from 0, 1, 2 or 3; W is selected from -C(=O)- or -CH2-; L is L1 is connected to E, L4 is connected to B; L1 is selected from a single bond, -O-, -NR g -, -NH(C=O)-, -C≡C-, 4-10 membered monocyclic heterocycloalkylene containing 1 or 2 N atoms, 6-20 membered spirocyclic heterocycloalkylene containing 1 or 2 N atoms, 6-18 membered cyclic heterocycloalkylene containing 1 or 2 N atoms, or 7-10 membered bridged heterocycloalkylene containing 1 or 2 N atoms; L2 is selected from a single bond, -(CH2) r2 -、-(CH2) r2 -(C=O)-, -(CH2) r2 -NRg-, 4-10 membered monocyclic heterocycloalkylene containing 1 or 2 N atoms, 6-20 membered spirocyclic heterocycloalkylene containing 1 or 2 N atoms, 6-18 membered cycloheterocycloalkylene containing 1 or 2 N atoms, or 7-10 membered bridged heterocycloalkylene containing 1 or 2 N atoms; -(CH2) r2 -(C=O)-, -(CH2) r2 The left end of -NRg- is connected to L1, and the right end is connected to L3; L3 is a single bond, -(CH2) r3 -, a 4-10 membered monocyclic heterocycloalkylene containing 1 or 2 N atoms, a 6-20 membered spirocyclic heterocycloalkylene containing 1 or 2 N atoms, a 6-18 membered cyclic heterocycloalkylene containing 1 or 2 N atoms, or a 7-10 membered bridged heterocycloalkylene containing 1 or 2 N atoms; L4 is selected from a single bond, -(CH2) r4 -, a 4-10 membered monocyclic heterocycloalkylene containing 1 or 2 N atoms, a 6-20 membered spirocyclic heterocycloalkylene containing 1 or 2 N atoms, a 6-18 membered cyclic heterocycloalkylene containing 1 or 2 N atoms, or a 7-10 membered bridged heterocycloalkylene containing 1 or 2 N atoms; R g Selected from hydrogen or C 1-3 alkyl; r2 is selected from 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12; r3 is selected from 1, 2, 3, 4, 5, 6 or 8; r4 is selected from 1, 2, 3, 4, 5, 6 or 8.
2. The compound according to claim 1 or its enantiomer, diastereomer, racemate, cis-trans isomer, deuterated product, metabolite, prodrug, solvate, hydrate, pharmaceutically acceptable salt or cocrystal, characterized in that: Z is selected from methyl, ethyl, propyl, isopropyl, -CD3 or trifluoromethyl; R1 is selected from hydrogen, methyl, ethyl, propyl, -CD3 or trifluoromethyl; R2 is selected from methyl, ethyl, propyl, isopropyl, isobutyl or sec-butyl; X is selected from a single bond, -CH2-, -CH2CH2- or -C≡C-; V is selected from -NR x1 (C 1-8 Alkylene)R x2 -, a 4-6 membered monocyclic heterocycloalkylene group containing 1 or 2 N atoms, a 6-11 membered spirocyclic heterocycloalkylene group containing 1 or 2 N atoms, a 6-10 membered cyclic heterocycloalkylene group containing 1 or 2 N atoms, or a 7-8 membered bridged heterocycloalkylene group containing 1 or 2 N atoms; -NR x1 (C 1-8 Alkylene)R x2 -'s left end is connected to X, and its right end is connected to L; R x1 is selected from hydrogen or methyl; R x2 Selected from -O-, -NCH3- or -NH-; R4 is selected from deuterium, fluorine, chlorine, bromine, -CF3, methyl, methoxy, ethoxy, propoxy, isopropoxy, trifluoromethoxy or -OCD3; a is selected from 0, 1, 2 or 3.
3. The compound according to claim 1 or its enantiomer, diastereomer, racemate, cis-trans isomer, deuterated product, metabolite, prodrug, solvate, hydrate, pharmaceutically acceptable salt or cocrystal, characterized in that: R1 is selected from hydrogen, methyl or -CD3; R2 is selected from isopropyl, isobutyl or sec-butyl; X is selected from a single bond, -CH2- or -C≡C-; V is selected from -NR x1 (C 1-6 Alkylene)R x2 -, aziridinyl, tetrahydropyrrolidinyl, piperazinyl, piperidinyl, cyclopropylidene azetidinyl, cyclopropylidene azetidine, cyclopropylidene azetidine, cyclopropylidene azetidine, cyclobutylidene azetidine, cyclobutylidene azetidine, cyclobutylidene azetidine, cyclobutylidene azetidine, cyclobutylidene azetidine, cyclopentylidene azetidine, cyclopentylidene azetidine, cyclopentylidene azetidine, cyclopentylidene azetidine, cyclohexylidene azetidine, cyclohexylidene azetidine, cyclohexylidene azetidine, azetidinyl, azetidine, azetidine, azetidine, azetidine, azetidine, azetidine, azetidine, azetidine, azetidine, azetidine, azetidine, azetidine, azetidine, azetidine, azetidine, azetidine, azetidine, azetidine, azetidine, azetidine, azetidine Cyclobutyl, cyclohexylidene azetyl, cyclohexylidene azetyl, cyclobutylidene spiroazetyl, cyclobutylidene spiroazetyl, cyclobutylidene spiroazetyl, cyclobutylidene spiroazetyl, cyclopentylidene spiroazetyl, cyclopentylidene spiroazetyl, cyclopentylidene spiroazetyl, cyclopentylidene spiroazetyl, cyclohexylidene spiroazetyl, cyclohexylidene spiroazetyl azetidinyl, azetidinyl spiroazetidinyl, azetidinyl spiroazepentyl, azetidinyl spiroazetidinyl, azetidinyl spiroazetidinyl, azetidinyl spiroazetidinyl, azetidinyl spiroazetidinyl, azetidinyl spiroazetidinyl, azetidinyl spiroazetidinyl, azetidinyl spiroazetidinyl, azetidinyl spiroazetidinyl; R x1 is selected from hydrogen or methyl; R x2 Selected from -O-, -NCH3- or -NH-; R4 is selected from fluorine, methoxy, trifluoromethoxy or -OCD3; R5 is selected from fluoro, cyano, methyl, trifluoromethyl or -CD3; b is selected from 0, 1 or 2; W is selected from -C(=O)- or -CH2-.
4. The compound according to claim 1 or its enantiomer, diastereomer, racemate, cis-trans isomer, deuterated product, metabolite, prodrug, solvate, hydrate, pharmaceutically acceptable salt or cocrystal, characterized in that: V is selected from -N(CH3)-(C 1-6 Alkylene)-NH-, -NH-(C 1-6 Alkylene)-NH-, -NH-(C 1-6 Alkylene)-N(CH3)-, -NH-(C 1-6 Alkylene)-C(=O)-, -NH-(C 1-6 Alkylene)-O-, The left side of the V structure fragment is connected to X, and the right side is connected to L; E is selected from R5 is selected from fluorine, methyl, trifluoromethyl or -CD3; b is selected from 0 or 1.
5. The compound according to claim 1 or its enantiomer, diastereomer, racemate, cis-trans isomer, deuterated product, metabolite, prodrug, solvate, hydrate, pharmaceutically acceptable salt or cocrystal, characterized in that: B is selected from R1 is selected from hydrogen or methyl; R2 is selected from isopropyl, sec-butyl or isobutyl; R 41 is selected from methoxy, deuterated methoxy or trifluoromethoxy; Z is selected from methyl, ethyl, propyl or isopropyl; c is selected from 0, 1, 2, 3, 4, 5 or 6; E is selected from 6. The compound according to claim 1 or its enantiomer, diastereomer, racemate, cis-trans isomer, deuterated product, metabolite, prodrug, solvate, hydrate, pharmaceutically acceptable salt or cocrystal, characterized in that: L1 is selected from a single bond, -O-, -NH, -N(CH3)-, and The left side is connected to E, and the right side is connected to L2; L2 is selected from a single bond, -(CH2)r2-, -(CH2) r2 -(C=O)-, -(CH2) r2 -NH-, -(CH2) r2 -N(CH3)-, And -(CH2) r2 -(C=O)-, -(CH2) r2 -NH-, -(CH2) r2 -N(CH3)-, The left side is connected to L1, and the right side is connected to L3; L3 is selected from a single bond, -(CH2) r3 -、 The left side is connected to L2, and the right side is connected to L4; L4 is selected from a single bond, -(CH2) r4 -、 and The left side is connected to L3, and the right side is connected to B; n1 is 1, 2, 3 or 4; n2 is 1, 2, 3 or 4; n3 is 1, 2, 3 or 4; n4 is 1, 2, 3 or 4; n5 is 1, 2, 3 or 4; n6 is 1, 2 or 3; n7 is 0, 1, 2 or 3; n8 is 0, 1, 2, or 3; n9 is 0, 1, 2 or 3; n10 is 0, 1, 2 or 3; Q 1 is CH or N; Q 2 is CH or N; Q 3 is CH or N; Y is hydrogen, halogen, -(C=O) or C 1-3 alkyl; n11 is 1, 2, 3 or 4; r2 is selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10; r3 is selected from 1, 2, 3, 4, 5 or 6; r4 is selected from 1, 2, 3, 4, 5 or 6.
7. The compound according to claim 1 or its enantiomer, diastereomer, racemate, cis-trans isomer, deuterated product, metabolite, prodrug, solvate, hydrate, pharmaceutically acceptable salt or cocrystal, characterized in that: L1 is selected from a single bond, -O-, -NH, -N(CH3)-, and The left side is connected to E, and the right side is connected to L2; L2 is selected from a single bond, -(CH2) r2 -、-(CH2) r2 -(C=O)-, -(CH2) r2 -NH-, -(CH2) r2 -N(CH3)-, And -(CH2) r2 -(C=O)-, -(CH2) r2 -NH-, -(CH2) r2 -N(CH3)-, The left side is connected to L1, and the right side is connected to L3; L3 is selected from a single bond, -(CH2) r3 -、 and The left side is connected to L2, and the right side is connected to L4; L4 is selected from a single bond, -(CH2) r4 -、 and The left side is connected to L3, and the right side is connected to B; n1 is 1, 2 or 3; n2 is 1, 2 or 3; n3 is 1 or 2; n4 is 1 or 2; n5 is 1 or 2; n6 is 1 or 2; n7 is 1 or 2; n8 is 1 or 2; n9 is 0, 1 or 2; n10 is 0, 1 or 2; Q 1 is CH or N; Q 2 For CH, Q 3 is N; Or, Q 2 N, Q 3 for CH; Y is hydrogen; r2 is selected from 1, 2, 3, 4, 5, 6, 7, 8, or 9; r3 is selected from 1, 2, 3 or 4; r4 is selected from 1, 2, 3 or 4.
8. The compound according to claim 1 or its enantiomer, diastereomer, racemate, cis-trans isomer, deuterated product, metabolite, prodrug, solvate, hydrate, pharmaceutically acceptable salt or cocrystal, characterized in that: L1 is selected from a single bond, -O-, -NH, -N(CH3)-, -(C=O)NH-, -NH(C=O)-, -C≡C-, The left side of the L1 structural fragment is connected to E, and the right side is connected to L2; L2 is selected from a single bond, -(CH2) r2 -、-(CH2) r2 -(C=O)-, -(CH2) r2 -NH-, -(CH2) r 2-N(CH3)-, The left side of the L2 structural fragment is connected to L1, and the right side is connected to L3; L3 is selected from a single bond, -(CH2) r3 -、 The left side of the L3 structural fragment is connected to L2, and the right side is connected to L4; L4 is selected from a single bond, -(CH2) r4 -、 The left side of the L4 structural fragment is connected to L3, and the right side is connected to v; r2 is selected from 1, 2, 3, 4, 5, 6, 7 or 8; r3 is selected from 1 or 2; r4 is selected from 1 or 2.
9. The compound according to claim 1 or its enantiomer, diastereomer, racemate, cis-trans isomer, deuterated product, metabolite, prodrug, solvate, hydrate, pharmaceutically acceptable salt or cocrystal, characterized in that: L is selected from a single bond, The left side of the L structural fragment is connected to E, and the right side is connected to B; d is selected from 0, 1, 2, 3, 4, 5, 6, 7 or 8; t is selected from 0, 1, 2, 3, 4, 5, 6, 7 or 8; n is selected from 1, 2 or 3; q is selected from 1, 2 or 3; m is selected from 0, 1, 2, 3 or 4.
10. The compound according to claim 1 or its enantiomer, diastereomer, racemate, cis-trans isomer, deuterated product, metabolite, prodrug, solvate, hydrate, pharmaceutically acceptable salt or cocrystal, characterized in that: Select any of the following compounds:
11. A pharmaceutical composition, characterized in that Containing a therapeutically effective amount of the compound described in any one of claims 1 to 10 or its enantiomer, diastereomer, racemate, cis-trans isomer, deuterated product, metabolite, prodrug, solvate, hydrate, pharmaceutically acceptable salt or cocrystal and a pharmaceutically acceptable carrier or excipient.
12. Use of a compound according to any one of claims 1 to 10 or its enantiomer, diastereomer, racemate, cis-trans isomer, deuterated product, metabolite, prodrug, solvate, hydrate, pharmaceutically acceptable salt or cocrystal, or the pharmaceutical composition according to claim 11 in the preparation of an EGFR degrader drug.
13. Use of a compound according to any one of claims 1 to 10 or its enantiomer, diastereomer, racemate, cis-trans isomer, deuterated product, metabolite, prodrug, solvate, hydrate, pharmaceutically acceptable salt or cocrystal, or the pharmaceutical composition according to claim 11 in the preparation of a drug for treating and / or preventing cancer.
